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 Abstract 
 
The adenomatous polyposis coli (APC) gene encodes a multifunctional tumour suppressor protein 
that is essential for normal development. The most characterised role of APC is its ability to mediate 
the Wnt signaling pathway, a pathway disrupted in the majority of human cancers. The identification 
of a second adenomatous polyposis coli gene (APC2) which possesses many shared structural 
characteristics with APC and potentially comparable functions raises the possibility that APC2 also 
functions both in development and in tumour suppression, and that some redundancy may exist 
between the two proteins. Analysis of these proteins in the mouse has been hampered due to the 
lethality of the Apc mutation and the lack of a suitable Apc2 mutation. However, to circumvent the 
first of these difficulties, Cre-lox technology was employed to conditionally delete Apc in adult 
mouse tissues and so study its function in vivo. To circumvent the second difficulty, a novel Apc2 null 
allele had become available from the laboratory of Professor Hans Clevers. Remarkably, constitutive 
deletion of Apc2 does not lead to embryonic lethality, permitting study of the effects of Apc2 
deficiency within adult tissues. In this thesis I aimed to characterise the consequences of Apc2 loss 
alone, and in the context of tissue specific Apc loss, in a range of tissues. Apc2 deficiency led to 
subtle changes in Wnt signaling in the intestines and liver however, no detectable differences of this 
pathway were apparent within the mammary gland. Phenotypically, altered homeostasis was only 
observed within the intestines. Apc2 deficiency led to an increase in epithelial cell division, an 
increase in markers of intestinal stemness and increases in intestinal cell migration. However, loss of 
Apc2 failed to induce tumourigenesis in the intestines or indeed any other tissue. In the context of 
Apc loss, the effect was dependent upon the tissue. Within the intestines, additional loss of Apc2 
altered the immediate phenotype of Apc loss but failed to modify Apc induced tumourigenesis. 
Within the mammary gland, whilst either Apc protein alone was dispensable, combined loss 
synergised to disrupt homeostasis and drive tumourigenesis. Contrary to this, in the liver the 
additional loss of Apc2 attenuated tumourigenesis induced by reduced levels of Apc. Together, these 
studies highlight the importance of these proteins and their interactions and redundancies in 
homeostasis and tumourigenesis.  
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Chapter 1  
General introduction  
 
1.1 Cancer 
1.1.1 Cancer statistics  
 
It was estimated by the World Health Organisation that in 2008 cancer was the cause of 7.9 
million deaths worldwide, accounting for 13% of the recorded deaths (Ferlay et al., 2008). In 
2010, it was responsible for 28% of recorded UK deaths (Figure 1.1, Cancer Research UK). 
People living within developed countries are 1.7 times more likely to develop cancer than 
 
 
Figure 1.1 In 2010, 28% of all UK deaths were attributed to cancer. Males represented a slightly 
higher percentage (31%) than females (26%) (Cancer Research UK). 
 
those living in developing countries. Certain cancers such as melanoma of the skin, kidney 
cancer and multiple myeloma display rates more than three times higher in developed 
countries.  Regardless of geographic location, cancer rates also display sexual dimorphism. 
Males have both a higher occurrence and a higher rate of cancer related death (Ferlay et al., 
 2 
 
2008). Discrepancies in cancer rates between different populations and genders may be 
influenced by a range of environmental, racial, cultural and socioeconomic factors. 
However, the underlying molecular mechanisms which lead to cancer development remain 
constant.  
 
The recorded incidence of cancer has been on the increase within the UK (Figure 1.2, Cancer 
Research UK). Whilst many factors have contributed to this increase in a negative way, such 
as lifestyle or environmental changes, better awareness, screening and diagnosis may 
positively contribute. For example, advances in screening methods and technology have led 
to earlier tumour detection and treatment, an important factor in positively influencing  
 
 
Figure 1.2 Incidence of cancer has increased with time. European age-standardised incidence rates 
have increased for all cancers in the UK by 22% in males and by 42% in females (Cancer Research 
UK).  
 
prognosis. Although an increase in cancer incidence has occurred with time, so has the 
understanding of the disease. Increased understanding has directly led to better treatment 
strategies and improved 10 year survival rates in a range of cancers (Figure 1.3, Cancer 
Research UK). However, it is important to stress that although we are getting better at  
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Figure 1.3 Shows the increase in ten-year survival rates from the 1970s to the present for some 
common cancers. Whilst there has been improvement in survival for most cancers, some display 
very little change and survival remains low (Cancer Research UK). 
 
treating some cancers such as colon, breast and melanoma, other cancers such as lung and 
pancreatic cancer have displayed minimal increases in patient survival. Earlier detection and 
better treatment strategies have helped reduce the sum of all UK cancer related deaths for 
both genders since the 1990s. (Figure 1.4, Cancer Research UK).  Continuing advancement in 
the understanding of the biological and molecular mechanisms responsible for tumour 
initiation and progression is key in further increasing the survival of patients and improving 
overall quality of life.  
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Figure 1.4 In the UK mortality for all cancers combined started to fall in the early 1990s. European 
age-standardised mortality rates decreased by 26% in males and 20% in females during the 1989-
2010 period (Cancer Research UK). 
 
1.1.2 Definition of cancer 
 
Cancer is the collective term for over 100 diseases. It is the endpoint of a process whereby 
normal human cells have transformed into malignant tumours (Figure 1.5). Cumulative 
genetic changes initiate and contribute to this transition in a stepwise manner. Whilst 
different tumours may follow unique pathways of progression, key alterations in regulation 
of a number of biological processes are required for all cancers (reviewed in Hanahan & 
Weinberg, 2000; Hanahan & Weinberg, 2011).  Regardless of cellular origin, control of 
proliferation and/or apoptosis must be bypassed in the early stages, whilst in the later 
stages cells must acquire invasive and metastatic abilities.  In cancer patients with advanced 
disease, deaths usually occur due to organ or tissue failure. Invading cancer cells possess the 
ability to outcompete normal physiologically relevant cells, disrupting vital body functions. 
90% of all cancer related deaths are attributed to the ability of cancer cells to invade and 
metastasise (Chaffer & Weinberg, 2011). 
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Figure 1.5 Diagram depicting cancer progression.  Most cancers are thought to arise due to 
accumulative mutations in key genes which control a number of regulatory possesses.  Hyperplasia is 
an early step where cells acquire the ability to increase proliferation and/or reduce apoptosis.  
Subsequent alterations in other genes and regulatory possesses allow these cells to progress into 
invasive carcinomas through a stepwise progression. In most patients, cancer related death is due to 
the acquired invasive capability of cancer cells. Cells can ‘break off’ from the original primary 
tumour, travel though the lymphatic and/or blood circulatory systems, attach and form secondary 
tumours in various locations (adapted from www.ndhealthfacts.org/wiki/oncology). 
 
 
 
1.1.3 “The hallmarks of cancer”  
 
It was proposed by Hanahan & Weinberg (2000) that six essential alterations in cell 
physiology could cooperatively dictate malignant growth, coined “the hallmarks of cancer”. 
Following more than a decade of research, four new “hallmarks” have emerged and 
together these highlight the barriers that cells need to circumvent to develop into cancer 
(Figure 1.6, discussed in Hanahan & Weinberg, 2011). Some criticisms have been made of 
these hallmarks, as benign tumours also possess a majority of these features, thus the only 
true requisite for “cancer” classification  are invasive and metastatic capabilities (Lazebnik, 
2010). However, regardless of differences in definition, these acquired capabilities are vital 
components of most cancers and are central to the understanding of the disease. These 
‘hallmarks’ will briefly be discussed. 
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Figure 1.6 “The hallmarks of cancer”. Ten traits govern the transformation of cells from normalcy to 
cancer (Hanahan & Weinberg, 2011). 
 
 
Sustaining proliferative signaling 
The ability to continually proliferate is one of the most fundamental traits of cancer cells. 
This is achieved through disruption in the regulation of growth signals and/or transduction 
of these signals.  
 
Enabling replicative immortality  
Most normal cell lineages in the body pass through a limited number of successive growth 
and division cycles. Cancer cell have the ability to circumvent this limitation. 
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Deregulating cellular energetics 
Cancer cells acquire the ability to alter their energy metabolism in order to fuel cell growth 
and division. This is achieved through reprograming various metabolic pathways.  
 
Inducing angiogenesis 
For tumours to progress, neoplastic cells, like normal cells, require nutrients and oxygen and 
to get rid of waste materials such as carbon dioxide. Increases in tumour mass require 
increased vasculature. This is achieved through the process of angiogenesis, a process 
usually quiescent in adult tissues. 
 
Tumour-promoting inflammation 
It is known that tumour progression can be influenced by the micro-environment. 
Inflammation has been shown to help tumour progression. Tumour cells can induce an 
inflammatory response which subsequently helps neoplastic cells acquire further hallmark 
capabilities which aid progression. 
 
Evading growth suppressors 
In a normal setting, many tumour suppressors operate in various ways to negatively 
regulate cell proliferation. Tumour cells acquire the ability to circumvent the mechanisms in 
place that control growth and proliferation.  
 
Resisting cell death 
‘Programed cell death’ serves as a natural barrier to cancer. Neoplastic cell acquire the 
ability to circumvent control mechanisms which normally impose apoptosis in response to a 
range of cellular stresses.  
 
Avoiding immune destruction 
In a normal setting, the immune system is constantly monitoring and destroying cells that 
display abnormalities. Neoplastic cells either avoid detection or limit the extent of 
immunological killing, thus evading eradication.  
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Activating invasion & metastasis  
This is the most advanced stage of cancer, responsible for 90% of related deaths (Chaffer & 
Weinberg, 2011) and some deem the only true requisite for cancer (Lazebnik, 2010). For 
invasion and metastasis to occur, cancer cells must acquire the ability to alter cell-cell 
interactions, cell-extracellular matrix interactions and cellular shape and motility. Cancer 
cells can now spread within tissues and migrate from the site of origin to new locations in 
the body forming secondary tumours. 
 
 
Genome instability & Mutation 
Genomic instability is a characteristic of most cancers. Defects in genome maintenance 
allow and accelerate the necessary genetic changes that are needed for tumourigenesis. It is 
known that tumourigenesis is a multistep process and each step can be implemented 
through subsequent accumulation of genetic alterations (Foulds, 1958; Bodmer, 1996; 
Kinzler & Vogelstein, 1996). How these genetic alterations impact upon each of the 
necessary cancer hallmarks has been the basis of a broad array of cancer research. 
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1.1.4 Cancer syndromes 
 
An insight into the genetic alterations that contribute to cancer has come from the study of 
cancer syndromes.  A cancer syndrome is a hereditary genetic disorder that predisposes 
affected individuals to the development of cancer. It is estimated that 5-10% of all cancers 
are hereditary (Nagy et al., 2004). Cancer syndromes are caused by the inheritance of 
genetic mutations in one or more genes, usually tumour suppressor, oncogenes and/or DNA 
repair genes. Numerous syndromes have been identified and a full list can be found at 
www.facd.info. Some of the most characterised cancer syndromes will briefly be discussed. 
 
Hereditary breast and ovarian cancer (HBOC) 
Patients with HBOC have a 65-85% risk of developing breast cancer (Thompson & Easton, 
2002; Brose et al., 2002), ~35% risk of developing ovarian cancer (Easton et al., 1995; Ford 
et al., 1994; Easton et al., 1993) and a higher risk of developing other cancers in their 
lifetime. Inherited mutations in BRCA1 & BRCA2 genes were identified as responsible for this 
cancer syndrome (Miki et al., 1994; Wooster et al., 1995). The gene products are responsible 
for repairing DNA or destroying cells if DNA cannot be repaired (reviewed in Venkitaraman, 
2002). When mutated, these functions are lost introducing genomic instability (one of the 
‘hallmarks’ of cancer). Cells can now accumulate further genetic alterations that are 
required for cancer progression. 
 
Cowden syndrome 
Patients with Cowden disease develop hamartomas (Eng et al., 1994) in multiple organs and 
have an increased risk of breast, thyroid and skin cancer (Lloyd & Dennis, 1963; Carlson et 
al., 1986; Mallory, 1995). Inherited mutations in the PTEN gene was identified as responsible 
for the majority of cases of this syndrome (Liaw et al., 1997). PTEN is a tumour suppressor 
gene, its most recognised role is regulating the oncogenic pro-survival PI3K/AKT signaling  
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pathway. Loss of this function through PTEN mutation leads to increased growth and 
proliferation of cells through increased ribosomal and protein translation (reviewed in 
Salmena et al., 2008). These attributes would contribute to sustained proliferative signaling, 
another of the ‘hallmarks’ of cancer. 
 
Li-Fraumeni syndrome 
Patients with Li-Fraumeni syndrome have an 85% risk of developing cancer in their lifetime. 
These include leukemia, soft tissue & bone sarcomas, breast and brain cancers (Ramzi et al., 
2010). Inherited mutations in the p53 gene were identified as responsible for the majority of 
cases of this syndrome (Malkin et al., 1990). p53 is a tumour suppressor gene, it regulates 
the cell cycle and allows for repair and survival or apoptosis following DNA damage or cell 
cycle abnormalities. Loss of this function through mutation leads to genomic instability and 
accumulation of genetic alterations needed for tumourigenesis (reviewed in Levine, 1997). 
 
Von hippel-lindau disease 
Von hippel-lindau disease is a cancer syndrome that is associated with a germline mutation 
in the VHL tumour suppressor gene. Affected individuals are at an increased risk of 
developing benign and malignant tumours typically in the central nervous system but also in 
other locations (Lonser et al., 2003).  The VHL protein is a tumour suppressor involved with 
regulation of genes specific for metabolic and angiogenic changes in response to hypoxia 
through binding HIF-1 (reviewed in Pugh & Ratcliffe, 1997). Loss of this function of VHL leads 
to inappropriate levels of HIF-1 and thus transcription of genes allowing necessary 
metabolic and angiogentic changes essential for tumour progression (Maxwell et al., 1999; 
Forsythe et al., 1996). Dysregulated cellular energetics and induced angiogenesis are two 
further ‘hallmarks’ of cancer. 
 
Hereditary non-polyposis colon cancer (HNPCC) 
Patients with HNPCC have a 60% risk of developing colorectal cancer in their lifetime 
(Hampel et al., 2005) and HNPCC accounts for 2.5-5% of all colorectal cancers (Chapelle,  
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2004). The majority of inherited mutations which cause HNPCC are within mis-match repair 
(MMR) genes (mutation in MLH1 & MSH2 account for 90% of cases, other mutated genes 
can include MSH6, PMS1 and PMS2) (Lui et al., 1996; Wheeler et al., 2000). MMR genes 
recognise and help repair abnormalities that arise following DNA replication, recombination 
and some forms of DNA damage (reviewed in Kolodner, 1996). Disruption of this function 
through mutation of one or more of the various MMR genes, can lead to tumourigenesis 
through increased genomic instability (Thibodeau et al., 1996). 
 
 
The cancer syndromes detailed above clearly show that genetic mutations that predispose 
to cancer have the potential to induce ‘hallmarks’ essential for tumourigenesis. These genes 
are also often found mutated in sporadic tumours. Together, this demonstrates the clear 
association of genetic abnormalities with tumourigenesis. This is perhaps most elegantly 
shown in the case of familial adenomatous polyposis, where we are beginning to 
understand the true molecular basis of this predisposition, as outlined in detail below. 
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1.2 Adenomatous polyposis coli (APC) 
 
1.2.1 Familial adenomatous polyposis (FAP) 
 
The Adenomatous polyposis coli (APC) gene was initially identified due to its association 
with colorectal cancer. It is highly evolutionally conserved (Aoki & Taketo, 2007) and in 
humans, located on chromosome 5q21 encoding a 2843aa protein contained in 15 exons 
(AGCOH). Germline mutation in one copy of the APC gene is responsible for the inherited 
disease familial adenomatous polyposis (FAP) (Kinzler et al., 1991; Groden et al., 1991). This 
disease is characterised by the development of hundreds to thousands of adenomatous 
polyps in the colorectum, some of which inevitably progress to carcinoma. Initial 
development of the polyps usually arises due to somatic mutation of the normal remaining 
APC allele.  This demonstrates the importance of APC in preventing the early stages of a 
progression towards cancer.  Once APC is lost, subsequent accumulation of mutations in 
other genes, such as KRAS and P53, assist the development of polyps in a stepwise 
progression towards carcinoma (Vogelstein and Kinzler, 1996). APC is also mutated in up to 
80% of sporadic colorectal cancers (Powell et al., 1992; Nagase & Nakamura, 1993; Ilyas et 
al., 1996). This demonstrates its importance as a “gatekeeper” of intestinal tumourigenesis.  
 
 
1.2.2 APC’s role in tumour suppression 
 
Along with APC’s role in intestinal tumourigenesis, loss of APC has been implicated in a 
range of other cancers (Damjanov et al., 1996; Virmani et al., 2001; Furuuchi et al., 2000; 
Kashiwaba et al., 1994; Giardiello et al 1996; Hirschman et al 2005; Gruner et al., 1998; 
Toiyama et al., 2011). Significant effort has been placed into studying the functions of APC 
and how loss of these functions leads to tumour initiation and progression (reviewed by 
Aoki and Taketo, 2007; Senda et al., 2007; Hanson et al., 2005; Nathke, 2005; Polakis, 2000; 
McCartney & Nathke, 2008; Prosperi & Goss, 2011).   
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Figure 1.7 Multifunctional roles of the APC protein.  APC’s most influential role is its ability to 
mediate Wnt signaling though inhibition of β-catenin/TCF transcription. However, many other 
interactions are lost following disruption of APC which also contribute to tumourigenesis (Aoki & 
Taketo, 2007). 
 
APC is a large protein and its role is multifunctional (Figure 1.7). Previous studies suggest its 
most influential role in tumourigenesis is loss of its ability to regulate Wnt signaling (Hanson 
et al., 2005; Nathke, 2005; Polakis, 2000). However, other regulatory abilities beyond Wnt 
control such as those in migration, polarity, adhesion, cell cycle progression, cell death and 
chromosome instability also contribute to tumorigenesis. 
 
 
1.2.3 APC and its role in the canonical Wnt signaling pathway 
 
The Wnt signaling pathway is a highly evolutionally conserved signaling pathway, activated 
by secreted Wnt proteins. It controls many biological events from early embryonic 
development, right through to adult tissues (for review see Clevers, 2006). The secreted 
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Wnt ligands are cell signaling glycoproteins which bind to the Frizzled and LRP family 
member receptors. This is a complex relationship with an abundance of both Wnt ligands, 
receptors and repressors (Polakis, 2000). However, once the pathway is activated, various 
factors can be altered at the cellular level such as proliferation, morphology, motility and 
fate (Polakis, 2000; Oving & Clevers, 2002).  Although three separate pathways are believed 
to be activated upon Wnt ligand/ receptor binding; the Wnt/Ca2+, the planar cell polarity 
and the canonical pathways (Clevers, 2006), APC’s influence is mostly associated with the 
canonical (Reya & Clevers, 2005). The first connection between APC and the Wnt signaling 
pathway was made when APC was found to interact with β-catenin, an intracellular signal 
transducer (Rubinfeld et al., 1993; Su et al., 1993). Now, it is recognised as a vital 
component of the β-catenin destruction complex assisting in mediation of the Wnt signal 
(Figure 1.8).  
 
 
 
Figure 1.8 The canonical Wnt signaling pathway (this diagram depicts a simplified version). (A) In the 
absence of Wnt signals, APC forms a multi-protein destruction complex that phosphorylates β-
catenin thus labelling it for destruction by the proteasome. In this case, β-catenin is unable to 
translocate to the nucleus and Wnt gene transcription is repressed. (B) In the presence of a Wnt 
signal, the destruction complex is disrupted. This prevents β-catenin from being targeted for 
degradation. β-catenin then translocates to the nucleus where it acts as a co-activator of 
transcription with the  TCF/LEF family of transcription factors. Wnt target genes are subsequently 
expressed altering cell fate (adapted from Perez-Plasencia, 2008). 
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In response to a Wnt signal, activation of Wnt gene expression occurs through a 
multifaceted transduction cascade (Bienz & Clevers, 2000; Fodde, 2002; Polakis, 2000; Reya 
& Clevers, 2005; Clevers, 2006). Ultimately, β-catenin is freed from destruction and can 
translocate to the nucleus, upon binding to the N-terminus of LEF/TCF (lymphoid enhancer 
factor/T cell factor) it activates transcription of a number of Wnt target genes (Molenaar et 
al., 1996; van de Wetering et al., 1997; Polakis, 2000; Sansom et al., 2004). Wnt target genes 
are continuing to be identified and a full list can be found on the Wnt homepage 
(http://www.stanford.edu/~rnusse/wntwindow.html). Wnt activation may promote a range 
of biological events ranging from cell proliferation and tissue expansion to fate 
determination and terminal differentiation. Importantly, the cellular action taken upon Wnt 
activation is determined by distinct transcriptional outputs. This is mostly determined by the 
developmental identity of the responding cell as oppose to the nature of the signal (Clevers, 
2006). However, evidence does suggest that varying levels of β-catenin activation can 
induce differential profiles of Wnt gene transcription (Kielman et al., 2002). 
 
The Wnt pathway is one of the most commonly dysregulated signaling pathway in human 
cancers (Reya et al., 2001). Aberrations in this pathway, such as loss of APC, can cause 
inappropriate nuclear accumulation of β-catenin leading to transcription of a range of β-
catenin/TCF gene targets. Some of these include renowned oncogenes:  cMyc, Cyclin D1, 
AP1, Wisp1 (He et al., 1998; Mann et al., 1999; Testu and McCormick, 1999; Shtutman et al., 
1999; Xu et al., 2000). Together, inapt expression of β-catenin/TCF gene targets can cause 
various unprompted cellular changes such as induced cell division, leading cells down a 
cascade towards cancer.  
 
 
1.2.4 The “just right” hypothesis  
 
The APC protein contains three 15aa repeats and seven 20aa repeats (Figure 1.7), both of 
which are known to bind β-catenin (Rubinfeld et al., 1993; Su et al., 1993). In both 
hereditary and sporadic colorectal cancers, mutations of the APC gene result in truncation  
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Figure 1.9 APC truncations and Wnt transduction.  A range of APC mutations have been identified 
which result in varying degrees of protein truncation. Increased disruption of the β-catenin binding 
sites inversely correlates with the level of active β-catenin and thus Wnt target gene expression.  In 
human colorectal cancer, mutations usually occur in a specific region (MCR) where some residual β-
catenin regulation is retained (marked by asterisk) (adapted from Aoki & Taketo, 2007). 
 
 
of the APC protein with varying degrees of disruption of these binding sites. Different 
severities of APC mutation can result in different levels of ability to mediate Wnt signaling 
(Figure 1.9) (Gaspar & Fodde, 2004). A large spectrum of APC mutations have been 
characterised in colorectal cancer and the majority occur within a region known as the 
mutational cluster region (MCR) (Miyoshi et al., 1992; Ichii et al., 1993). Mutations in this 
region do not completely abolish APC’s ability to regulate β-catenin and analyses of human 
tumour samples reveal a certain degree of pathway regulation is usually retained (Le et al., 
2008; Vermeulen et al., 2010; Sousa et al., 2011). Interestingly, in FAP patients, the position 
of the germline mutation in APC influences the nature of the second mutation in the normal 
residing allele (Lamlun et al., 1999) and this never results in complete loss of function of the 
APC protein (Albuquerque et al., 2002). Together, these findings propose a ‘just right’ level 
of Wnt activation required for tumour growth (Figure 1.10).   
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Figure 1.10 The ‘just right’ hypothesis. Mediocre levels of Wnt activation are optimal for tumour 
growth whilst levels too high are selected against. 
 
 
The ‘Just right’ hypothesis has been demonstrated elegantly in colorectal cancer cell lines. 
Moderate levels of Wnt activation incur a growth advantage (Lamlum et al., 1999; 
Albuquerque et al., 2002; Lucero et al., 2010) whilst higher levels induce cell death (Lazarova 
et al., 2004; Bordonaro et al., 2008). Further, it was shown by Chandra et al. (2012) that 
down-regulation of truncated APC found in human colorectal cell lines increased β-catenin 
signaling but inhibited cell expansion ‘in vitro’ and tumour outgrowth ‘in vivo’ . Human ‘In 
vivo’ data further supports this hypothesis. Mutations in the second half of the last APC 
exon result in typical FAP, whereas mutations earlier in the gene which allow less β-catenin 
interaction, manifest as attenuated FAP (AFAP) characterised by fewer adenomas as well as 
delayed adenoma formation (reviewed in Sancho et al., 2004). Together, these studies 
suggest a fine-tuned balance of Wnt activity is needed and optimal for cell transformation. 
 
Although APC mutation and perturbations in the Wnt signaling pathway are well recognised 
in intestinal tumourigenesis, the importance of APC and ‘Just right’ levels of Wnt signaling 
are beginning to be exposed in tumourigenesis in a range of tissues. It is known that 
patients with FAP can develop a range of tumours outside of the intestinal tract (Gardener, 
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1951). However, the true consequence of reduced levels of APC in other tissues may be 
‘masked’ by the predisposition to rapid intestinal tumourigenesis. Gaspar et al. (2009) 
created a mouse model with mild levels of Wnt activation through disrupted Apc and these 
mice were predisposed to mammary tumourigenesis as oppose to intestinal. This study 
highlights two important actualities: that increased Wnt activation through Apc loss can lead 
to tumourigenesis in other tissues, and that different tissues may have different thresholds 
levels needed for Wnt activated tumourigenesis. A further study by Buchert et al. (2010) 
reiterated these findings by analysing the phenotypes of a range of transgenic mice with 
truncating or hypomorphic mutations in the Apc gene. Each mutant displayed a different 
level of Wnt regulatory ability. Different permissive Wnt signaling thresholds appeared to be 
required for embryonic development of the head, Hepatocellular carcinoma, liver zonation 
and adult intestinal polyposis. Together these experiments demonstrate that Wnt signal 
regulation through Apc is essential in a range of tissues, and that these tissues require 
different levels of Wnt activation to induce pathophysiological/ tumorigenic phenotypes.   
 
 
 
1.2.5 Non-canonical roles of APC 
 
As mentioned previously, the Apc protein is a large protein with many interaction sites. 
Although its role in controlling Wnt signaling is well known, this may overshadow other 
interactions vital for homeostasis and tumour suppressor function. It is undeniable that 
APC’s role in tumour suppression is multifunctional (reviewed by Aoki and Taketo, 2007; 
Senda et al., 2007; Hanson et al., 2005; Nathke, 2005; Polakis, 2000; McCartney & Nathke, 
2008; Prosperi & Goss, 2011) and evidence towards the significance of Wnt independent 
roles is mounting. Interestingly, introduction of exogenous APC into colorectal cancer cells 
‘in vitro’ induces a G1/S-phase cycle arrest which can only partially be rescued by a non-
degradable mutant form of β-catenin (Heinen et al., 2002). Also, some mutant Apc alleles 
which cause profound tumourigenesis do not display vigorous levels of β-catenin  
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Figure 1.11 Non-canonical functions of APC. This image depicts some of the Wnt independent 
interactions of the APC Protein. APC has the Ability to interact with the cytoskeleton, junctional and 
polarity complexes, nuclear proteins and apoptotic factors. Loss of these interactions indubitably 
contributes to tumourigenesis (Prosperi & Goss, 2011). 
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stabilization (Pollard et al., 2009; Gaspar et al., 2009). Together, these experiments highlight 
that some effects of APC loss in tumourigenesis may not solely be explained through Wnt 
transcriptional control. Wnt independent functions of APC are continuing to be exposed and 
include interactions with the cytoskeleton, junctional and polarity complexes, nuclear 
proteins and apoptotic factors.  Studies have shown that through these interactions, APC 
has influences in a variety of cellular functions which include: Polarity, adhesion, migration, 
genomic stability, cell cycle progression, apoptosis, DNA replication and DNA repair (Figure 
1.11). APC’s involvement with these functions and how loss contributes to tumourigenesis 
will each be discussed in turn.  
 
APC’s role in Polarity & adhesion 
Most epithelium consists of a polarised layer of cells. APC has been shown to localise to the 
membrane of these cells in a variety of tissues (Reinacher-Schick & Gumbiner, 2001; Rosin-
Ardesfeld et al., 2001; Townsley & Bienz, 2000; Prosperi et al., 2009). In a colorectal cancer 
cell line with mutated APC (SW480), introduction of exogenous full length APC induced 
tighter cell-cells contacts, altered morphology and increased adhesion concomitant with 
reduced tumorigenic potential (Faux et al., 2004). In mice with heterozygous Apc mutation 
(Apcmin), although the most characterised phenotype is an induction of intestinal 
tumourigenesis (Moser et al., 1993), loss of mammary epithelial integrity and occasional 
mammary tumorigenesis is manifest. This is purportedly through junctional protein and 
polarity disruption (Prosperi et al., 2009). These studies suggest a tumour suppressor 
function of APC in controlling adhesion and polarity.  
 
APC’s role in cell-cell contacts and adhesion is unclear but may lie with the fact it localises 
with both adherens junctions and tight junctions (Reichert et al., 2000; Bienz and Hamada, 
2004). These junctions are crucial in establishing and maintaining polarity and adhesion 
(Ando-Akatsuka et al., 1999). APC may be a direct component of these junctions or may 
directly regulate them. The exact mechanisms linking junctional disruption and APC loss 
remain to be elucidated. 
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APC’s role in polarity is somewhat clearer through its ability to interact with both 
components of polarity complexes and microtubules. Polarity complexes confer the identity 
of the apical and basolateral membrane domain in polarised epithelial cells (for review see 
Bryant & Mostev, 2008). APC has been shown to bind both Scribble (Scrib) (Takizawa et al., 
2006) and Discs large (Dlg) (Matsumine et al., 1996). Together Scrib and Dlg form a polarity 
complex with Lethal giant larvae (Lgl). All are required for adherens junction formation, all 
are required for polarity and all are tumour suppressors (reviewed in Humburt et al., 2008). 
This fortifies the concept that loss of polarity is important for tumourigenesis. As APC 
directly binds these proteins, its loss may directly interfere with their polarity function 
and/or tumour suppressor function, however, the exact relationship remains to be defined.  
 
APC has the ability to interact with microtubules (Nathke et al., 1996; Collin et al., 2008 
Dikovskaya et al., 2001). This can occur through both a direct interaction (Munemitsu et al., 
1994) and indirect through its binding partner end-binding protein 1 (EB1) (Nakamura et al., 
2001). Microtubules are vital in inducing and maintaining polarity in a range of tissues 
(reviewed in Siegrist & Doe, 2007). Lack of APC correlates with disrupted microtubule 
stability (Dikovskaya et al., 2001; Kroboth et al., 2006) and studies have shown that APC is 
essential for the polarity function of microtubules (Dikovskaya et al., 2001; Etienne-
Manneville & Hall, 2003; Watanabe et al., 2004).  
 
Polarity and adhesion defects are found in almost all human cancers (Rothenburg et al., 
2010; Huang & Muthuswamy, 2010; Schmalhofer et al., 2009). It is proposed that polarity 
and adhesion can directly enforce tumour suppression through maintaining tissue 
structurality (Lee & Vasioukhin, 2008). Loss of these features has been shown to contribute 
to tumourigenesis in both the early and advanced stages of progression (Figure 1.12) 
(reviewed in Wodarz & Nathke, 2007; Schmalhofer et al., 2009). As APC has the ability to 
influence these functions through a range of different mechanisms, reduced adhesion and 
polarity through APC loss highlight a Wnt independent contribution to tumourigenesis. 
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Figure 1.12 Adhesion & polarity in tumourigenesis.  Reduced adhesion and polarity marked by loss of 
tight junctions and adhesion junctions can assist in early and advanced stages of tumour 
progression.  Maintained adhesion & polarity can prevent the formation of tumours by maintaining 
structure. Loss of this function is needed to permit abnormal growth. In the advanced stages of 
cancer progression cells acquire the ability to completely detach and invade/metastasise. This is 
characterised by a complete loss of contact with neighbouring cells and severely altered polarity.   
 
 
  
APC’s role in migration 
Cytoskeletal dynamics dictate cell shape and motility. Given APC possesses the ability to 
interact with both microtubules (Munemitsu et al., 1994; Nathke et al., 1996; Zumbrunn et 
al., 2001; Collin et al., 2006) and actin filaments (Dikovskaya et al., 2001; Watanabe et al., 
2004; Breitsprecher et al., 2012), the major components of the cytoskeleton, it is 
unsurprising that its loss affects cellular migration.  
 
Dysregulated levels of APC have been associated with the migratory ability of intestinal 
epithelial cells ‘in vivo’. Immediate intestinal Apc loss in a murine model abrogated epithelial 
cell migration (Sansom et al., 2004; Andreu et al., 2005). Reduced levels of full length Apc 
expression in the Apcmin mouse, along with pre-disposing mice to intestinal tumourigenesis 
(Moser et al., 1993), attenuated overall intestinal epithelial migration (Oshima et al., 1995; 
Mahmoud et al., 1997). Conversely, forced overexpression of APC in mice resulted in 
disorganised intestinal epithelial migration (Wong et al., 1996).  
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Interestingly, concurrent deletion of both Apc and cMyc from the murine intestinal 
epithelium rescued epithelial migratory defects (Sansom et al., 2007). As cMyc is a direct 
transcriptional target of β-catenin/TCF and activated upon Apc loss, this suggests migratory 
defects following disrupted Apc may be Wnt dependent. However, numerous studies have 
proposed that APC’s role in migration is Wnt independent (reviewed in Barth et al., 2008; 
Etienne-Manneville, 2009; Prospery & Goss, 2011). Although cMyc’s most characterised role 
is as part of the Wnt signaling pathway and a global regulator of transcription (Dang et al., 
2006), it does have other roles (Cole & Cowling, 2008). For example, it has been shown to 
directly bind microtubules both ‘in vivo’ and ‘in vitro’ (Alexandrova et al., 1995; Niklinski et 
al., 2000) which are known to be a vital structural necessity for migration. Perhaps a novel, 
Wnt independent mechanism may account for this ability to rescue migration whilst being 
concomitantly deleted with Apc, which may be associated with its ability to interact with 
microtubules.  
 
APC’s translocation from cell-cell contacts to membrane clusters at cell protrusions 
promoted cell migration and this was found to be independent from its role in β-catenin 
transcriptional activity (Harris & Nelson, 2010). This, together with numerous other studies 
in various cell types have linked APC with migration, and suggest that control of this 
function is both imperative in tumour suppression and independent from Wnt signal 
mediation (reviewed in Barth et al., 2008; Etienne-Manneville, 2009). 
 
Important insights into why migration is important in tumour suppression have come from 
studying the intestines. Intestinal epithelial cells are ‘born’ in a region called the crypt of 
lieberkuhn (crypt) which is located at the base of the intestinal gland structure. Most of 
these cells then migrate upwards along a structure called the villus and are ‘shed off’ into 
the intestinal lumen (see Chapter 3.1). Loss of migratory ability can aid tumour initiation and 
progression a number of ways. Foremost, independent of proliferation changes, cells being 
born that remaining ‘in situ’ as oppose to following a designated migratory path will lead to 
an accumulation of cells (Figure 1.13). This accumulation of cells could be classified as the 
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Figure 1.13 Loss of migratory ability can lead to an accumulation of cells that remain ‘in situ’ and can 
represent the earliest stages of tumour formation.   
 
 
earliest stage of tumour formation.  Loss of migratory ability may aid tumourigenesis further 
by allowing accumulation of genetic alterations. Cells that do not migrate remain ‘in situ’ 
and in contact with ingested material which can be carcinogenic. This prolonged time in 
contact with ingested material within the gut can lead to an accumulation of genetic 
changes which assist in tumour progression.  
 
If the non-steroidal anti-inflammatory sulindac is placed in the diet of Apcmin mice, tumour 
number is reduced concurrent with restored epithelial migration (Mahmoud et al., 1997). 
This provides some evidence that cellular migration is associated with tumourigenesis. Also, 
it was suggested by Oshima et al. (1997) that micro-adenomas, the earliest stage of tumour 
formation in Apcmin mice are initiated by lack of directed cell migration. Further, human 
adenomatous polyps, which are abnormal growths found in the intestinal tract also display 
and could have been initiated by disorganised migration (Moss et al., 1996). These are a pre-
cancerous lesion thus linking migration defects with the early stages of tumourigenesis in 
humans.   
 
Conversely, in the advanced stages of disease progression, cancer cells must acquire the 
ability to ‘migrate’ from their site of origin and metastasise. As APC loss is associated with 
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migratory disruption, this creates a paradox. Perhaps, tumour cells still retain some 
migratory ability which is sufficient for their ability to metastasise. Equally, loss of APC may 
only be sufficient to disrupt migration in particular cell types or settings, once this is altered 
through tumour progression, migratory ability may be governed by APC independent 
means. A more plausible explanation may lay with the actualities of the disruption caused 
by APC loss. It is uncertain whether APC deficient cells lack the cellular capability to migrate 
or lose the ability to know where to migrate. Cells at any stage of tumourigenesis may still 
be ‘moving’ but may just lose their directionality. This may be associated with APC’s role in 
polarity (see above). 
 
To summarise, APC has been implicated in the control of cellular migration and this role is 
most likely Wnt independent, and disrupted migration through APC Loss may contribute to 
tumour initiation and progression. 
 
 
APC’s role in genomic stability 
Loss of genomic stability is one of the ‘hallmarks’ of cancer (Hanahan & Weinberg, 2011). 
The lack of ability to control genomic integrity can allow the necessary genetic alterations 
needed for tumorigenesis. It is unknown whether genomic instability is a cause or 
consequence of tumour formation. However, it is known that it accelerates genetic change 
(Chandhok & Pellman, 2009; Hahn & Weinberg, 2002). Genomic instability can manifest at 
both the nucleotide and chromosome level. Genetic mutation, chromosome rearrangement 
and aneuploidy are all characteristics of genomic instability and all are frequently observed 
in human cancer (Negrini et al., 2010; Salk et al., 2010; Mitelman et al., 1997; Chandhok & 
Pellman, 2009; Weaver & Cleveland, 2006). How APC loss affects genomic stability at the 
nucleotide and chromosome level will be addressed. 
 
Genomic stability can be controlled at the nucleotide level through effective DNA repair. 
DNA is universally being damaged through a range of insults and can lead to mutation. 
However, mechanisms of repair are constantly in place correcting this damage thus 
preventing genetic abnormalities which can lead to tumour initiation and progression 
(reviewed in Hoeijmakers, 2001). Although APC is mostly cytoplasmic and/or membrane  
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associated, it can also be found within the nucleus (Henderson, 2000; Neufeid & White, 
1997) and can directly interact with chromatin (Sierra et al., 2006; Dikovskaya et al., 2012). 
APC has been implicated in DNA repair through several protein interactions (reviewed in 
Jaiswal & Narayan, 2008). Further, it was shown by Kouzmenko et al., (2008) that induction 
of DNA damage stimulated the accumulation of APC at sites of damaged DNA and its 
knockdown using siRNA reduced the rate of DNA repair. This provides a substantial Wnt 
independent link whereby APC loss can assist tumourigenesis through disrupting DNA 
repair.   
 
Genomic instability can also be manifest at a more global level. Chromosome 
rearrangement and aneuploidy are indicative of genomic instability and are usually 
implemented through defective mitosis. For these defects to occur, the correct process of 
chromosome segregation is disrupted along with circumvention of the usual failsafe 
mechanisms which prevent manifestation of these abnormalities. 
 
Aneuploidy and chromosome rearrangement have been observed in both human and 
mouse tissues with APC deficiency (Frodde et al., 2001; Su et al., 1995; Miki et al., 1992; 
Dikovskaya et al., 2007; Caldwell et al., 2007). As mentioned previously, APC has the ability 
to interact with microtubules both directly and indirectly through EB1 (Nakamura et al., 
2001; Nathke et al., 1996; Collin et al., 2006; Munemitsu et al., 1994). Loss of this function 
may disrupt the microtubules ability to mechanically align and separate paired 
chromosomes during mitosis. Defects in these processes are commonly found in human 
cancers displaying genomic instability (reviewed in Pease et al., 2011).   
 
During mitosis, APC is known to localise near the centrosomes and associate with the 
microtubule-organising centre to maintain chromosome structure (Olmeda et al., 2003) and 
its loss has been associated with reduced fidelity of chromosome segregation (Fodde et al., 
2001; Kaplan et al., 2001). This may be through loss of its role either alone or with EB1 in 
regulating spindle dynamics and chromosome alignment (Green et al., 2005; Draviam et al., 
2006; Green et al., 2003; Dikovskaya et al., 2007) or disruption of its ability to anchor the 
spindle to the cell cortex during mitosis (Beamish et al., 2009). 
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Various studies have shown loss of APC leads to the mis-orientation of mitotic spindles 
which affect proper chromosome segregation (Caldwell et al., 2007; Dikovskaya et al., 2007; 
Fleming et al., 2009). This may be influenced though loss of direct interaction with 
microtubules, through a loss of polarity (see above) or a combination of the two. 
Interestingly, defective regulation of spindle orientation due to APC loss has been reported 
in intestinal stem cells (Quyn et al., 2010). Spindle orientation can influence the generation 
of symmetric or asymmetric cell fates (reviewed in Siller & Doe, 2009). The importance of 
stem cells in cancer and how Wnt Signaling affects these cells is well documented (reviewed 
in Reya & Clevers, 2005). However, how defective spindle orientation directly contributes to 
stem cell aberrations in cancer remains to be fully elucidated. 
 
Along with defects in the mechanics of proper chromosome segregation, for genetic 
abnormalities to persist, failsafe mechanisms which regulate this process must be 
circumvented. One of these mechanisms is the spindle checkpoint which in normal cells, 
delays mitotic progression until defects can be corrected (reviewed in Musacchio & 
Hardwick, 2002). Studies have shown loss or truncation of APC can lead to defects in this 
checkpoint (Radulescu et al., 2010; Tighe et al., 2004). Further, it was shown by Zhang et al. 
(2009) that truncated APC interacts with Mad2, an essential mitotic checkpoint protein. This 
interaction decreases the soluble pool of Mad2 inducing premature anaphase onset 
inducing mis-segregation of chromosomes.  
 
To summarise, genomic instability is frequently found in human cancer. Loss of APC can lead 
to genomic instability at both the nucleotide and chromosome level through various 
mechanisms. This highlights a further Wnt independent mechanism whereby APC loss may 
influence tumourigenesis. 
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Other non-canonical roles for APC in tumour suppression 
Numerous other roles for APC have been identified and can include a wide array of cellular 
functions, ranging from control of cell cycle progression and DNA replication to influences in 
cell death (reviewed in Prosperi & Goss, 2011). New roles of the APC protein are constantly 
being discovered and how these contribute to tumourigenesis independent of Wnt 
signalling will continue to be defined.  
 
 
To summarise, APC is a potent tumour suppressor. Although it is a “gatekeeper” of intestinal 
tumourigenesis, its loss is associated with a wide range of human cancers. The most 
influential role of APC lies with its ability to mediate the Wnt signaling pathway, a pathway 
dysregulated in the majority of human cancers. The degree of APC mutation and thus the 
level of Wnt regulatory ability is important in creating a “just right” level of Wnt signaling 
optimum for tumour growth. Although Wnt regulation is the most characterised function of 
APC, its role is multi-functional and its loss can influence tumourigenesis in an increasing 
number of ways. 
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1.3 Adenomatous polyposis coli 2(APC2) 
 
1.3.1 Discovery of APC2 
 
Embryonic expression of Apc-like (Apc), which is the Drosophila homolog of the APC gene, is 
largely confined to the central nervous system (Hayashi et al., 1997). This observation, along 
with the fact Apc null mutants are viable with defects only observable in the larval 
photoreceptors (Ahmed et al., 1998), suggested the existence of another Drosophila Apc-
like protein. In a yeast two-hybrid screen for proteins that bind to the Drosophila β-catenin 
homologue, Apc2 was identified (Yu, et al., 1999). Further, McCartney et al. (1999) 
confirmed the existence of this second homologue and demonstrated that its gene 
sequence displayed striking similarities to both Drosophila Apc and human APC. 
 
APC2 has now been identified in a range of other species including:  Zebrafish (Faro et al., 
2010), chick (Shintani et al., 2009), mouse (Yamanaka et al., 2002; Shintani et al., 2012) and 
human (Nakagawa et al., 1998; Van Es et al., 1999; Jarrett et al., 2001). An evolutionary tree 
of fly, mouse and human APC and APC2 proteins was constructed by Aoki & Takoto (2007) 
which demonstrates evolutionarily conservation (Figure 1.14). The conservation and protein 
similarities suggest both APC proteins may have important and redundant roles. 
 
 
 
 
Figure 1.14 Both APC proteins are evolutionarily conserved. However, it is important to note that the 
two fly APC genes are not direct orthologues of the two mammalian genes (Aoki and Taketo, 2007). 
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In humans, APC2 is located on chromosome 19p13.3 and encodes a 2274aa protein 
contained in 14 exons (slightly shorter than the 2843aa coded in 15 exons of APC) 
(Nakagawa et al., 1998; Van Es et al., 1999; Jarrett et al., 2001). It was shown by Van Es et al. 
(1999) that the highest detected expression of APC2 mRNA was found in Foetal brain, 
followed by adult brain.  APC also displayed this trend although expression levels were 
lower. Importantly, both APC’s were shown to be expressed in the majority of tissues 
analysed (Figure 1.5). It was also shown by Jarrett et al. (2001) that APC2 was expressed in a 
wide range of human tissues and cell lines. 
 
 
 
Figure 1.15 Both APC proteins are expressed in a range of tissues. mRNA for both APC and APC2 was 
detected in a wide range of tissues. High levels of expression for both genes were observed 
throughout the central nervous system (Van Es et al., 1999). 
 
APC2 displays similarities in protein structure to APC (Figure 1.16). The most similarity is 
apparent in the N-terminus, the homology then drops steeply towards the C-terminus end. 
Both proteins are predicted to contain the heptad repeat domains, suggesting both are 
likely to form homo- or heterodimers. The armadillo domain is also conserved, suggesting 
both may be involved in cellular adhesion and/or migration. Importantly, although APC2 
lacked the three 15aa repeats that can bind β-catenin, both APC proteins contained SAMP 
domains and 20aa repeats that bind axin and β-catenin respectively. Towards the C- 
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terminus where the similarity dropped, APC2 is predicted to lack domains that interact with 
microtubules, mDia, EB1 and Dlg (Nakagawa et al., 1998; Van Es et al., 1999; McCartney et 
al., 1999). This suggests that APC2 may lack certain functions in comparison to APC relating 
to microtubules, cytoskeletal organisation, polarity, etc. However, APC2’s interactions and 
binding partners may yet remain to be fully discovered. Indeed, in Drosophila, APC2 has 
been reported to be cytoskeletally-associated (McCartney et al., 1999) and important for 
spindle orientation (Yamashita et al., 2003). In vertebrates, APC2 has been shown to directly 
interact with microtubules and F-actin (Shintani et al., 2009; Shintani et al., 2012). It has also 
been associated with regulation of microtubules through interaction with EB3, a homolog of 
EB1 (Nakagawa et al., 2000) and DDA3, a downstream target of p53 (Hsieh et al., 2007). 
Together these studies suggest that APC2 is also a multifunctional protein although these 
functions remain to fully defined.  
 
 
 
Figure 1.16 APC2 is similar in structure to APC so may have comparable functions. Although APC2 
lacks the three 15aa repeats that can bind β-catenin, it contains both SAMP domain and 20aa 
repeats which bind axin and β-catenin respectively. Homology decreases towards the C-terminus 
end (McCartney et al., 2006). 
 
 
1.3.2 APC2’s role in the canonical Wnt signaling pathway 
 
Due to the ability of both APC proteins to bind β-catenin and axin, APC2 was also predicted 
to have a role in negative regulation of the Wnt signaling pathway. Indeed, this was found to 
be the case (McCartney et al., 1999). In Drosophila, Apc2 forms a destruction complex with  
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homologs of the mammalian GSK-3 and axin (Yu et al., 1999). Apc and Apc2 are partially 
redundant in Wnt signaling and both may regulate signal transduction throughout all 
Drosophila development, in the majority of tissues (Ahmed et al., 2002; Akong et al., 2002a; 
Akong et al., 2002b). There appears to be an absolute requirement of an Apc protein in 
order for β -catenin degradation and shuttling out of the nucleus to occur, and the 
combined activity of Apc and Apc2 within the same cell may allow for tight regulation of 
these processes (Ahmed et al., 2002). Functional redundancies have also been exposed 
through complementary Wnt gene transcription rescue, further highlighting the interplay 
between these proteins in Wnt signaling (Kunttas-Tatli et al., 2011; Roberts et al., 2012). 
APC2 has also been shown to deplete cytoplasmic β-catenin via direct interaction in human 
tissue and cell lines (Nakagawa et al., 1998; Van Es et al., 1999; Roberts et al., 2012). 
However, its ability to rescue Wnt target gene expression in a Wnt activated colorectal cell 
line is somewhat reduced in comparison to APC (Nakagawa et al., 1998). This suggests APC2 
may have a reduced ability to degrade β-catenin. This may be through a reduced binding 
affinity, APC2 does lack the 15aa repeats that also bind β-catenin found in APC (Nakagawa 
et al., 1998; Van Es et al., 1999; McCartney et al., 1999) or through reduced β-catenin 
availability. Indeed, β-catenin phosphorylation is performed by APC2 in a destruction 
complex spatially and functionally isolated from the APC associated destruction complex 
(Maher et al., 2009). 
In human colorectal cell lines with reduced APC, transfection with APC2 can rescue β-
catenin destruction and reduce Wnt-responsive gene transcription (Nakagawa et al., 1998; 
Van Es et al., 1999; Roberts et al., 2012). This, together with complimentary rescue in 
Drosophila suggests that functional redundancies in regulating Wnt transduction may be 
evolutionarily conserved.  
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1.3.3 Non-canonical roles of APC2 
 
Drosophila 
Like APC, APC2 has also been implicated in functions beyond regulation of Wnt signaling. In 
Drosophila, Apc2 has been reported to localise to the apical membrane of polarised 
epithelial cells (McCartney et al., 1999). Yu et al. (1999) found Apc2 to be concentrated in 
the apicolateral adhesive zones of these cells, along with the Drosophila homologs of β-
catenin and E-Cadherin, both of which are integral components of adherens junctions. Loss 
of function of Apc2 leads to dissociation of these junctions and defects in adhesion 
(McCartney et al., 1999; Hamada & Bienz, 2002). The mechanisms behind these defects 
remain to be fully defined. 
Studies in Drosophila also revealed a role for Apc2 in cell division (McCartney et al., 2001). 
Apc2 is shown to localise to both spindle poles and the cell cortex where astral microtubules 
are thought to contact cortical actin. This suggests a role in anchoring the spindle to the cell 
cortex. Mutants of Apc2 display defects in syncytial development consistent with anchoring 
defects (McCartney et al., 2001).  A further role for Apc2 is apparent in ensuring asymmetric 
division of Drosophila male germline stem cells (Yamashita et al., 2003). Apc2 helps establish 
polarity to correctly orientate the mitotic spindle. As mentioned previously, spindle 
orientation can govern between symmetric and asymmetric cell division (reviewed in Siller 
& Doe, 2009). Loss of this ability through Apc2 loss may be direct or indirect through 
dissociation of adherens junctions. Adherens junctions are known to provide polarity clues 
for spindle orientation (Song et al., 2002).  
Together these results indicate Apc2 is involved in adhesion, polarity and cell division in 
Drosophila tissue. However, more studies are needed to define these roles and to elucidate 
if these roles are evolutionarily conserved.  
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Vertebrates  
To date, only two studies have been published analysing loss of function of Apc2 in 
vertebrate tissue, both studies focused on loss within neural tissue. It is known Apc2 is 
expressed at its highest levels in the central nervous system (Nakagawa et al., 1998; 
Yamanaka et al., 2002), with peak levels detected during foetal brain development (Van Es 
et al., 1999). Shintani et al. (2009) demonstrated that Apc2 is important in the formation of 
neural projections and that Apc2 associates with microtubules and stabilises them in 
growing axons. Upon suppression of Apc2 expression, axonal behaviour became abnormal 
in a dose dependent manner. This implies Apc2 level plays a critical function in the 
development of neural circuits. Further, Shintani et al. (2012) created a constitutive mouse 
model disrupting Apc2. Again, these mice displayed neural defects. Apc2 co-localised to 
both microtubules and F-actin and loss of function resulted in laminary and migratory 
defects.  
Importantly, β-catenin remained unaltered in either study thus implicating a Wnt 
independent role of Apc2 in neuronal development. However, it is unclear whether Wnt 
signaling differences are subtle or Apc compensates for Apc2’s loss. Defects in both studies 
were attributed to microtubule and F-actin regulatory defects.  Interestingly, Apc2 lacks 
both a basic domain and an EB1 binding domain. So, it is predicted that Apc2 cannot bind to 
microtubules. However, Shintani et al. (2012) have identified a direct microtubule binding 
site within the unique C-terminus of Apc2. Also, APC2 has been shown to interact with EB3 
and DDA3 which are microtubule binding proteins highly expressed in the brain (Nakagawa 
et al., 2000; Hsieh et al., 2007).  
Together, studies from Drosophila, chick, mice and human suggest that like APC, APC2 has 
both Wnt dependent and independent functions. Due to the similarities in functions 
between APC proteins, it is predicted that APC2 may also have a role in tumourigenesis. If 
this is the case and how APC2 loss contributes to tumourigenesis remains to be elucidated. 
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APC2 in cancer 
APC2 is located at chromosome 19p13.3 a region lost with Peutz-Jeghers syndrome (JPS) 
and patients with PJS are more susceptible to breast, testis, gastrointestinal, and ovarian 
cancers (Mehenni et al., 1998; Bignell et al., 1998). Although loss of the LKB1 gene is 
responsible for most of the symptoms of PJS, this gene is not mutated in sporadic cancers 
thus suggesting the existence of another tumour suppressor within this region of 
chromosome. Loss of 19p13.3 occurs in many sporadic cancers, including those of the 
breast, and is remarkably common in sporadic ovarian carcinomas (Wang et al., 1999; Jarrett 
et al., 2001). Also, 100% loss of heterozygosity (LOH) is found at this site in adenoma 
malignum of the uterine cervix (Lee et al., 1998). APC2 expression was found to be 
significantly reduced in most gliomas however single-strand conformation polymorphism 
(SSCP) analysis revealed no mutations suggesting that some epigenetic mechanism is 
responsible for this decrease in expression (Nakagawa et al., 1999). 
Although known mutations in APC2 are rare, epigenetic silencing and reduction in 
expression is now recognised in a variety of cancers through hypermethylation (reviewed in 
Herman & Baylin, 2003; Jones & Baylin, 2007). Epigenetic abnormalities can cooperate with 
genetic alterations to effect aberrant gene function that results in cancer (Jones & Baylin, 
2002). It is known that levels of promoter methylation correlate with levels of protein 
expression (Suzuki & Bird, 2008) and this is indeed the case with APC2 (Figure 1.17). It was 
demonstrated by Chan et al. (2008) that increased methylation status of APC2 led to a 
decrease in protein expression and that hypermethylation occurred in 100% of primary 
colon tumours and 77% of primary breast tumours. In this study hypermethylation also was 
noticed in 9 out of 11 breast cancer cell lines analysed. Studies by Mokarram et al. (2009) 
and Kumar et al. (2009) have confirmed hypermethylation of APC2 in 90-98% of colorectal 
tumour samples compared to control tissue in a variety of human populations. 
Hypermethylation of APC2 was also associated with progression from inflammatory bowel 
disease (IBD) to IBD associated neoplasia (Dhir et al., 2008). Interestingly, APC also  
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Figure 1.17 APC2 gene silencing through promoter hypermethylation. Increased methylation status 
of the CpG islands in the promoter region of APC2 decreases the affinity for transcription factors (TF) 
and decreases gene expression.  Decreased expression of APC2 is predicted to increase the amount 
of active β-catenin and Wnt target gene expression. APC has also been shown to display promoter 
hypermethylation in human tumours. 
  
displays hypermethylation in a wide range of human cancers (Deng et al., 2004; Hsieh et al., 
2007; Zare et al., 2009; Jin et al., 2001; Ho et al., 1999; Schlosshauer et al., 2000; Sarrio et 
al., 2003; Van der Auwera et al., 2008).  Given APC mutation was the only factor searched 
for in a range of historic studies, it would be of great interest to re-analyse tumour data to 
inspect for both mutation and hypermethylation. One could speculate APC loss achieved 
through a combination of these events may be higher than previously thought in a range of 
human cancers. 
From these studies it is clear that loss of APC2 is associated with human cancer. However it 
is unknown if APC2 loss has the ability to initiate tumour formation, is associated with 
tumour progression or is just a passive event. Intriguingly, no studies to date have 
concurrently analysed both APC proteins in human tumourigenesis. 
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1.4 Aims 
APC’s role in human cancer is undeniable. It acts as a “gatekeeper” of intestinal 
tumourigenesis and is also associated with a wide range of other tumours. APC is 
multifunctional and its loss induces and promotes tumourigenesis a number of ways. The 
most influential contribution is loss of its ability to mediate the Wnt signaling pathway, a 
pathway dysregulated in almost all human cancer. Loss of APC’s other functions also 
contribute to tumourigenesis. Although a vast amount of effort has been placed into 
studying APC, it has a second family member which possesses similar structural 
characteristics, functions and is also lost in a range of human cancer.  Work in Drosophila 
suggests function redundancies exist between these two homologs and studies in human 
cancer cell lines demonstrate APC2 can rescue some attributes of APC loss. A lack of 
published studies highlights a gap in the understanding of the roles of APC2 in mammalian 
development, homeostasis and/or contribution to tumourigenesis. 
We have acquired a mouse model with loss of Apc2 function. The main aims of this thesis 
are: 
 To characterise the consequences of mammalian Apc2 loss. Analysis will focus on a 
range of tissues including: the intestines, mammary gland and liver. 
 
 To elucidate if Apc2 loss has the potential to induce tumourigenesis in these tissues. 
 
 To analyse Apc2 loss  in the context of targeted Apc loss. This will help reveal if any 
functional redundancies exist within mammalian tissue. 
 
 To delineate any additional contribution of Apc2 to tumourigenesis following 
altered Apc expression.  
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Chapter 2 
Materials and Methods 
*Some protocols in this section were either directly transcribed or adapted from Holisk 
(2012) or generic protocols within the ARC laboratory.    
 
2.1 Experimental animals  
All experiments were conducted in accordance with the UK Animals (Scientific Procedures) 
Act, 1986 and all other Home Office Guidelines, under valid personal and project licenses. 
 
2.1.1 Transgenic constructs and animals used in the project 
A number of genetically modified mice were used in this project. An Apc2 mutant mouse 
was kindly gifted from Prof. Clevers laboratory (Van der Meer et al., 2001). This was 
generated containing a constitutive truncating mutation (termed Apc2-/). For targeted Apc 
loss, mice were used containing an Apc transgene containing loxP sites positioned in the 
introns surrounding exon 14 (Shibata et al., 1997). Tissue-specific transgenes included; The 
Villin-CreER transgene, which expresses Cre recombinase specifically in the intestinal 
epithelium following a Tamoxifen induction regime (Colnot et al., 2004), the Ah-Cre 
transgene, which expresses Cre recombinase in the intestinal epithelium and liver cells 
among other tissues following a β-naphthoflavone induction regime (Ireland et al., 2004) 
and the Blg-Cre+ transgene, which expressed Cre recombinase specifically in the mammary 
epithelium, constitutively (Selbert et al., 1998).  A Cre ROSA26 reporter strain was also used 
to detect recombination events (Soriano et al., 1999) 
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2.1.2 Animal husbandry 
Colony maintenance 
Mice were housed in a standard facility that meets all home office standards and had access 
to the Harlan standard diet (Scientific Diet Services, RM3(E)) and water ad libitum. 
  
Breeding 
All mice were maintained on a mixed background. Adult animals (6 weeks and older) of 
known genotype were mainly bred in trios (one male with two females). Pups were left 
with their mothers until capable of feeding independently. They were weaned on average 
at four weeks of age. 
 
Identification, ear and tail biopsies 
At the time of weaning animals were sexed and separated. Ear clipping was employed 
for animal identification. The resulting ear pinna was used for DNA extraction and 
genotyping (described below).  
 
2.1.3 Experimental Procedures  
Unless otherwise specified, animals were aged to at least 10 weeks before being subjected 
to any experimental procedures. Intraperitoneal injections were performed using a 1 ml 
syringe (BD Plastipak) and 25G needle (BD Microlance 3).  
 
β-naphthoflavone induction 
Expression of the Ah-Cre recombinase was induced by administration of β-naphthoflavone 
(bNF, Sigma) in corn oil (Sigma). Powdered bNF to a concentration of 10 mg/ml was added 
to corn oil in an amber bottle in order to protect bNF from light exposure. The solution was 
heated to 80 ◦C and stirred vigorously to aid complete dissolution of bNF. Aliquots of bNF 
solution were frozen and stored at −20 ◦C until required. Prior to injection, aliquots were 
thawed, heated to 80 ◦C and kept at that temperature until immediately before injection to 
prevent bNF precipitation out of the solution. bNF was injected intraperitoneally at a dose 
of 80 mg of bNF per kg of body weight. This dose was repeated thrice with 8 hour interval 
 40 
 
between injections (4 injections in total). During a single course of injections solution was 
kept in darkness at 4 ◦C and then any remaining solution was discarded. 
 
Tamoxifen induction 
Animals expressing the Villin-CreER transgene were induced by administration 
of Tamoxifen (Sigma) in corn oil. Powdered Tamoxifen was added to corn oil in an amber 
bottle to final concentration of 10 mg/ml. The solution was heated to 80 ◦C with regular 
shaking to aid Tamoxifen dissolution. Once completely dissolved, the Tamoxifen 
solution was aliquoted and stored at −20 ◦C. Prior to injection the solution was thawed, 
heated to 80 ◦C and kept at this temperature until immediately before injection. Tamoxifen 
was injected intraperitoneally at a dose of 80 mg of Tamoxifen per kg of body weight. This 
dose was repeated twice with 4 hour interval between injections (3 injections in total). 
During a single course of injections solution was kept in darkness at 4 ◦C and then any 
remaining solution was discarded.  
 
 
2.1.4 PCR Genotyping 
Mice were genotyped by PCR using DNA extracted from ear or tail biopsies at weaning age 
(four weeks) and confirmed at death. Unless provided by earlier publications, all primers 
used were designed using Primer3 software at http://fokker.wi.mit.edu/primer3/input.htm, 
checked for specificity using BLAST engine against Ensembl database (http://www.ensembl.- 
org/Multi/blastview) and synthesised by Sigma Genosys. 
 
 
DNA purification (Puregene method) 
Ear biopsy was placed in a 1.5 ml eppendorf tube and stored at −20 ◦C until 
analysis. For DNA isolation 250 μl of Cell Lysis Solution (Gentra) and 5 μl of 20 mg/ml 
Proteinase K (Roche) were added to the tissue and incubated overnight at 37 ◦C with 
agitation. The next day the contents of the tubes were cooled to room temperature, 
mixed with 100 μl of Protein Precipitation Solution (Gentra) and centrifuged at 13000 
rpm in a microcentrifuge for 10 min. The supernatant was recovered and mixed with 250 
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μl of isopropanol in a fresh 1.5 ml eppendorf tube and centrifuged at 13000 rpm for 15 
min. The supernatant was carefully discarded, and the tubes were left to air-dry for 1 
hour. The DNA was then dissolved in 250 μl of PCR-grade water (Sigma) and 2.5 μl of 
the resulting solution was used in PCR reactions. 
 
Generic protocol for PCR genotyping 
PCR reactions were carried out in thin-wall 96-well plates or in thin-wall 0.2 ml strip tubes 
(Greiner Bio-One) and run using either PTC-100 Peltier (MJ Research), Techne Flexigene 
(Krackeler Scientific) or GS1 (G-Storm) thermal cycler. Pipetting of the reagents 
and DNA samples was carried out using filtered pipette tips to avoid aerosol contamination. 
2.5 μl of crude genomic DNA extract was loaded into wells using multi-channel 
pipette. The master-mix containing the remaining components of the reaction (distilled 
water, GOTaq 5X PCR buffer (Promega), 25 mM Magnesium Chloride (Promega), 25 
mM dNTPs (Bioline), Primers (Sigma-Genosys) and GOTaq (Promega)) was prepared 
according to Table 2.1. 47.5 μl of the appropriate master-mix were added to each well. 96-
well plates were sealed with aluminiumfoil tape, while strip-tubes were closed with 
appropriate caps (Greiner Bio-One). The tubes were gently tapped to dislodge air bubbles 
and ensure the mixture was at the bottom of the well. Reactions were run using cycle 
conditions outlined in Table 2.1. The primer sequences used for genotyping of the particular 
transgenes and the size of respective products are provided in Table 2.2. 
 
Visualisation of PCR products 
After completion of PCR reactions the products were visualised by agarose gel 
electrophoresis. The reactions using colourless 5X PCR buffer (Promega) were mixed with 
5μl of DNA loading dye (50% Glycerol (Sigma), 50% distilled water, 0.1% (w/v) Bromophenol 
Blue (Sigma)). All samples and an appropriate marker (e.g. 100 bp ladder 
(Promega)) were loaded onto 2% agarose gel (4 g agarose (Eurogentech), 200 ml 1X Tris- 
Borate-EDTA (TBE) buffer (Sigma), 10 μl of 10 mg/ml ethidium bromide (Sigma) or 
10μl Safeview (NBS Biologicals)). The products of Ah-Responder PCR were analysed 
using 4% agarose gel. Gels were run in 1X TBE buffer at 120 V for 30 minutes. Products 
were visualised in UV light using GelDoc apparatus (BioRad). 
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Table 2.1: Genotyping PCR reaction conditions 
PCR Reaction Components: 
DNA extract (See section 2.1.4)                          2.5 μl  
Master Mix: 
PCR-grade H2o (Sigma)                                       31.7 μl 
GOTaq PCR Buffer (5X, Promega)                        10 μl 
Magnesium Cloride (25 mM, Promega)               5 μl 
dNTPs (25 mM, Bioline)                                       0.4 μl 
Forward Primer (100 mM, Sigma Genosys)     0.1 μl 
Reverse Primer (100 mM, Sigma Genosys)      0.1 μl 
Taq Polymerase(GOTaq)                                      0.2 μl 
Total Reaction Volume:                                         50 μl 
 
 
Table 2.1(cont.) 
Cycling conditions (Time; Temperature) 
Initial denaturation                                                                2.5 min; 94 ◦C  
Cycle number                                                                                    30  
Step 1 (Denaturation)                                                              30 sec; 95 ◦C 
Step 2 (Annealing)                                                                    30 sec; 55 ◦C  
Step 3 (Elongation)                                                                    1 min; 72 ◦C  
Final Extension                                                                           5 min; 72 ◦C  
Hold                                                                                                 15◦C ∞ 
 
 
Table 2.2: Primer sequences used for PCR genotyping 
 
ApcLoxP 
Gene Forward Primer Sequence (5-3)                              GTTCTGTATCATGGAAAGATAGGTGGTC 
Reverse Primer Sequence (5-3)                                          CACTCAAAACGCTTTTGAGGGTTGATTC 
Product Size                                                                             WT: 226bp     ApcLoxP: 314 
 
Apc2-   
Gene Forward Primer Sequence (5-3)                                ATTGTATCATGGAAAGATAGGTCGTC 
Reverse Primer Sequence (5-3)                                           CTCACTCAAAACGCTTTTGAGGGTTGA 
Product Size                                                                             WT: 450bp     Apc2-: 400bp 
 
LacZ 
Gene Forward Primer Sequence (5-3)                                 CTGGCGTTACCCAACTTAAT 
Reverse Primer Sequence (5-3)                                            ATAACTGCCGTCACTCCAAC 
Product Size                                                                             WT: 0bp      LacZ: 500 
 
Villin-CreER 
Gene Forward Primer Sequence (5-3)                                CAA GCC TGG CTC GAC GGC C 
Reverse Primer Sequence (5-3)                                            CGC GAA CAT CTT CAG GTT CT 
Product Size                                                                             WT: 0bp   Villin-CreER+: 1000bp 
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Ah-Cre 
Gene Forward Primer Sequence (5-3)                                ATT GCC CCT GTT TCA CTA TC 
Reverse Primer Sequence (5-3)                                           CCT GAC TAG CAT GGC GAT AC 
Product Size                                                                             WT: 0bp     Ah-Cre+: 1000bp 
 
Blg-Cre  
Gene Forward Primer Sequence (5-3)                                TGACCGTACACCAAAATTTG 
Reverse Primer Sequence (5-3)                                            ATTGCCCCTGTTTCACTATC 
Product Size                                                                             WT: 0bp     Blg-Cre+: 1000bp 
 
 
 
 
2.2 Tissue harvesting and processing  
 
2.2.1 Tissue harvesting  
Mammary Glands 
Following a schedule 1 approved method of culling (cervical dislocation), animals were 
dissected using a micro-dissection kit. The fur was sprayed with 70% ethanol and an 
incision made along the mid-line of the abdomen, through just the skin leaving the  
peritoneal wall intact. Incisions through the skin were then made transversely along the 
neck and groin regions. The skin was ‘peeled’ back from the peritoneal wall and mammary 
glands dissected, placed into small cassettes and ‘stretched out’ for fixing. 
 
Other tissues 
An incision was made along the mid-line of the abdomen, through both, skin and peritoneal 
wall. Liver, kidney, spleen, pancreas, lung, stomach, appendix and any abnormal tissue was 
collected and fixed. The small intestine between stomach and caecum and large intestine 
between the appendix and anus was isolated and flushed with ice cold 1X PBS (Invitrogen) 
using a 60 ml syringe (BD Plastipak). Intestines were then opened longitudinally on blotting 
paper and either fixed overnight in methacarn (methanol, chloroform and acetic acid; 4:2:1) 
for tumour scoring or processed as follows. The first 10cm were opened up and a 2-4mm 
longitudinal section dissected for RNA (see section 2.2.4). The reminding tissue from the 
first 10cm’s is then ‘swiss-rolled’. The following 8 cm were cut into four 2 cm pieces and 
bundled together with surgical microtape. The large intestine between the caecum and 
the rectum was also ’swiss-rolled’ if not fixed for tumour scoring. 
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2.2.2 Tissue fixation  
Once collected, tissue samples were immersed in ice cold formalin (4% neutral buffered 
formaldehyde in saline, Sigma) and incubated for 24 hours at 4 ◦C. Mammary glands were 
fixed for 2 hours in 4% paraformaldehyde. After initial fixation, samples were either 
processed straight away as described below or transferred into ice cold 70% ethanol and 
stored at 4 ◦C until processing. Fixation method used for whole mount and β-galactosidase 
staining is described in section 2.2.5. 
 
 
2.2.3 Tissue processing for lightmicroscopy  
Tissue dehydration 
Tissue samples were arranged in histocasettes and processed using an automatic processor 
(Leica TP1050). Samples were dehydrated in increasing concentrations of ethanol (70% 
for 1 hour, 95% for 1 hour, 100% 2 x 1 hour 30 min, 100% for 2 hours), Xylene 2 x 1 hour 
and paraffin 1 x 1 hour and 2 x 2 hours. After dehydration, samples were embedded in 
paraffin wax. 
 
Tissue sectioning 
A microtome (Leica RM2135) was used to cut 5 μm thick sections from paraffin blocks. 
Sections were then floated onto slides coated with poly-L-lysine (PLL) and baked at 58 ◦C 
for 24 hours. 
 
2.2.4 Tissue preservation for RNA 
Tissues intended for RNA extraction were removed and frozen as quickly as 
possible to avoid RNA and protein degradation, respectively. Liver samples were frozen 
using liquid nitrogen or dry ice and stored at -80. Intestinal tissue intended for RNA 
extraction was processed using Weiser solution (section 2.2.6).  
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2.2.5 Staining of tissue whole mounts  
Carmine alum staining of mammary whole mount tissue 
Whole mammary glands were washed 3 times with 1XPBS following fixation, then left in 
carmine alum solution (1g carmine, 2.5g aluminum in 500ml distilled water) on rocker 
overnight.  Glands were then washed again 3 times with 1XPBS, dehydrated in increasing 
concentrations of ethanol and placed in xylene for 2 hours to clear fat. Glands were then 
mounted on slide using glycerol. Stained wholemounts were illuminated with Leica CLS50X 
light source and visually analysed under Olympus SZX12 low-magnification stereo 
microscope. Where needed, pictures were taken with Olympus C4040ZOOM 4.1 Megapixel 
digital camera. 
 
LacZ staining of whole mount tissue  
Mammary or liver whole mounts were fixed then stained using X-Gal staining solution: 1 
mM MgCl2 (Sigma), 3 mM potassium ferricyanide (Sigma),3 mM potassium ferrocyanide 
(Sigma) in 1X PBS. The solution was stored in a tin foilwrapped bottle at −20 ◦C and stock X-
Gal solution (5% in DMF, Promega) 0.02% was added immediately prior to staining. The 
tissue was incubated with the staining solution overnight or until the sufficient level of 
staining was achieved at 37 ◦C. Once stained, tissues were washed with 1X PBS and fixed 
with formalin to avoid further staining. Stained whole mounts were illuminated with Leica 
CLS50X light source and visually analysed under Olympus SZX12 low-magnification stereo 
microscope. Where needed, pictures were taken with Olympus C4040ZOOM 4.1 Megapixel 
digital camera. 
 
2.2.6 Isolation of epithelium enriched cell populations  
Isolation of the intestinal epithelial cells using Weiser solution 
The protocol was adapted from (Flint et al., 1991). The first 10 cm of the small intestine 
from the stomach was flushed with ice cold 1X PBS (Invitrogen), opened longitudinally 
and a 2-4mm longitudinal section placed in 50 ml falcon tube (Greiner Bio-One) containing 
15 ml of freshly prepared ice cold modified Weiser chelating solution (5.56 mM disodium 
hydrogen orthophosphate (Sigma), 8 mM potassium dihydrogen orthophosphate (Sigma), 
96 mM sodium chloride (Sigma), 1.5 mM potassium chloride (Sigma), 27 mM tri-Sodium 
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citrate (Sigma), 0.5mM dithiothreitol (DTT, Sigma), 1.5% sucrose (Sigma), 1% D-sorbitol 
(Sigma), 6.07 mM EDTA (Sigma), 4 mM EGTA (Sigma), pH 7.3). The intestine was washed in 
three changes of ice cold Weiser solution by gentle shaking. After the washes, the tube 
containing 15 ml of Weiser solution was attached to the vortex mixer and shaken at the 
lowest setting for 15 min. The tube was then shaken vigorously by hand and the solution 
was transferred into a fresh tube. Fresh 15 ml of Weiser solution was added to the tube 
containing the intestine and the shaking steps were repeated. Two 15 ml fractions were 
joined together and the intestine was discarded. 30 ml of Weiser solution containing the 
epithelial cells were centrifuged at 1500-2000 rpm for 5 min. The resulting pellet was 
resuspended in 20 ml of ice cold 1X PBS and centrifuged. The wash in 1X PBS was repeated 
twice, the pellet was resuspended in 3 ml of 1X PBS and aliquoted into three 1.5 ml 
eppendorf tubes. The tubes were centrifuged using a mini-centrifuge for 1 minute. The 
supernatant was removed, the pellet was snap-frozen in LN2 and stored at −80 ◦C until 
needed. 
 
2.2.7 Isolation, culture and infection of mammary epithelium 
Isolation of mammary epithelium 
The fourth mammary fat pads were harvested (mice were culled in batches of three per 
genotype) for mammary epithelum. This was done in a sterile hood, the mice were culled, 
immersed in 70% ethanol, and then mammary glands accessed as before. Lymph nodes were 
removed then the remaining gland was placed in L15/10% FCS + P/S (Leibowitz L15 medium 
(L15) with L-Glutamine (Invitrogen, Paisley, UK) plus 10% v/v Heat Inactivated Foetal Calf 
Serum (FCS) (Invitrogen), Penicillin at 100 IU ml-1 and Streptomycin at 100 µg ml-1 
(Invitrogen)) on ice until all glands were harvested. Fat pads were quickly dipped 3 times in 
70% ethanol and then transferred to fresh L15 /10% FCS+P/S. Fat pads (from 3 mice) were 
finely minced three times on the McIlwain Tissue Chopper (tissues were stirred and then 
collected back in the middle of the cutting disc with a sterile Pasteur pipette between each 
chop). The minced tissue was transferred to a 50 ml Falcon tube (Tube A) containing 10mls 
collagenase /trypsin digestion mix (30mg of collagenase/15mg tripsine) (4oC) using cell 
scrapers. The tube was then placed horizontally on a shaker platform and incubated for one 
hour at 37oC (75rev/min). The digested mixture was then transferred into a 15ml Falcon tube and 
centrifuged at 1500rpm for 5 minutes. The fat layer and supernatant was poured off into a fresh 
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15 ml Falcon tube (Tube B) (leaving the tube A laid on its side). The pellet of tube A was then 
immediately transferred to a fresh 15 ml Falcon in 5 ml L15/10% FCS. Tube B was spun 
1500rpm for 5 minutes. The fat layer and supernatant was then discarded and the pellet was 
taken up in in 5 ml L15/10% FCS and then pooled with the one from Tube A and centrifuged at 
250 x g for 5 minutes. The new pellet was resuspended in 5mls Sigma Red Blood Cell Lysis 
Buffer and incubated for 5 minutes at RT. The sample was then centrifuged at 1500rpm for 5 
minutes and resuspended in a fresh in 10 ml L15/10%FCS without P/S and pelleted at 
1500rpm for 5 minutes.  
To remove most of the mammary fibroblasts from the sample, it was resuspended in 15 ml of 
DMEM/10% FCS (Dulbecco’s Modified Eagle’s Medium (DMEM) with L-Glutamine 
(Invitrogen) with 10% v/v FCS, Penicillin at 100 IU ml-1 and Streptomycin at 100 ug ml-1) and 
transferred to a T-80 tissue culture flask. The flask was then incubated for one hour at 37oC 
5%CO2 5%O2. The majority of fibroblasts attach to the tissue culture plastic in this time 
whilst most of the organoids do not. After the incubation, the flask was shaken in a horizontal 
plane with moderate vigour to ensure the organoids are in suspension and they were 
pipetted off. The flask was rinsed with 10 ml L15/10% FCS+P/S, shaken as before and then this 
wash was pipetted off. The organoid suspension and the wash were then spun at 1500rpm 
for 5 minutes. The supernatants were then poured off and the pellets resuspended in 1 ml 
L15/10% FCS (sample composed of mammary epithelial organoids, tissue lymphocytes and 
some remaining fibroblasts). 
 
Primary mammary epithelial culture 
The epithelial organoids were plated out to generate bulk cell by resuspending them in 
CT:I:EGF medium (1:1 v/v DMEM / Ham’s F12 mix (Invitrogen), 10% v/v FCS, Penicillin at 100 
IU ml-1, Streptomycin at 100 ug ml-1, 4 mM L-glutamine (Invitrogen), 5 ug/ml bovine 
pancreatic insulin (I) (Sigma, cell culture tested solution), 10 ng/ml cholera toxin (CT) (Sigma) 
and 10 ng/ml epidermal growth factor (EGF) (Sigma, murine submaxillary, cell culture 
tested)) and transferred to flasks. Cultures were maintained at 37oC 5% CO2 5% O2. Over a 
period of several days, the epithelial cells mobilise and spread out from the organoids to 
form a monolayer. 
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Adenoviral infection  
All viral work was carried out in accordance with GMO safety regulations and approval. To 
delete Apc from cultured mammary epithelium AD5-CMV-CRE (Vector Labs) was added to 
the culture medium (see above) at a Multiplicity of infection (MOI) of 10, 50 & 100. The 
AD5-CMV-CRE was left in the culture for 12 hours then the cultures were washed and 
maintained in CT:I:EGF medium without AD5-CMV-CRE. An MOI of 50 provided efficient 
recombination in comparison to cell death. Cultures were imaged 36 hours following 
infection. 
 
Visualisation  
Cultures with and without infection were imaged using an Olympus inverted IX71 
microscope. 
 
2.3 Histological analysis  
 
2.3.1 Haematoxylin and Eosin (H&E staining of tissue sections)  
Slides containing tissue sections were dewaxed and rehydrated as described in section 2.4. 
Slides were stained for 5 min in Mayer’s Haemalum (R. A. Lamb), washed in running 
tap water for further 5 min followed by 5 min staining in 1% aqueous Eosin (R.A. Lamb) 
solution. Eosin was washed off by two 15 second washes in water. Stained sections were 
dehydrated and mounted as described in section 2.4. 
 
2.3.2 Quantitative histological analysis of H&E stained sections  
Histological quantification of the tissue sections was carried out using an Olympus BX41 
light microscope. Where appropriate, microphotographs were taken with a Colorview III 
camera (5 megapixel, Soft Imaging Systems) aided with AnalySIS software (v3.2, Build 
831, Soft Imaging Systems) or Moticam 5000 camera (5 megpixel, Motic Instruments) 
aided with Motic Images Advanced software (v.3.2, Motic China Group). Quantitative 
and statistical analysis of histological parameters was carried out as described in section 
2.6. 
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Scoring of crypt length 
Crypt length was scored by counting the number of cells from the base of the crypt to the 
crypt-villus junction. Scoring was carried out for 50 half-crypts per section and average 
of 50 crypts were scored per mouse. 
 
Scoring of villus length 
To score villus length, the total number of cells from the crypt bottom to the villus tip was 
counted on 50 half crypt-villus axes per slide. The average villus length was calculated as 
average total crypt-villus length minus average crypt length for each mouse. 
 
Scoring of Mitotic index 
Mitotic figures were scored on H&E stained sections based on their morphological 
appearance. Cells were included if chromosome alignment/segregation was microscopically 
visable (metaphase, anaphase and telophase). Number of mitotic figures was counted in at 
least 1000 cells. Mitotic index was calculated as average number of mitotic figures per total 
cells counted. 
 
Scoring of Apoptotic index 
Apoptotic cells were scored based on their characteristic appearance on H&E stained 
sections. Cells were characterised as apoptotic by the microscopic presence of apoptotic 
bodies, nuclear fragments and/or membrane detachment from neighbouring cells. The 
number of apoptotic bodies was counted in at least 1000 cells. Apoptotic index was 
calculated as average number of apoptotic cells per total cells counted. 
 
 
2.3.3 Use of specific stains for quantification of histological traits  
Staining with Alcian Blue 
Alcian Blue staining was used to identify mucin-containing goblet cells. Tissue sections 
were dewaxed and rehydrated as described in section 2.4. Slides were immersed in Alcian 
Blue staining solution (1% (w/v) Alcian Blue (Sigma), in 3% (v/v) acetic acid (Fisher 
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Scientific)) for 30 seconds followed by washing in running water for 5 minutes. Slides were 
washed in running water for 5 min and then dehydrated and mounted as described in 
section 2.4. Stained sections were examined and the number and position of goblet cells 
was scored in 50 half crypt-villus axes per mouse. The average number of goblet cells per 
half crypt-villus axis was calculated and position of these cells was calculated and analysed 
for each mouse as described in section 2.6. 
 
Lysozyme staining 
Immunohistochemistry with an anti-lysozyme antibody (see section 2.4) was used to 
identify Paneth cells. Both Paneth cell number and position was scored. Paneth cell quantity 
was scored as the number of lysozyme positive cells in 50 half-crypts per section. The 
average number of Paneth cells per half-crypt was calculated for each mouse and analysed 
as described in section 2.6. Paneth cell position was counted from the bottom of the 
crypt, the bottom-most cell being #1. Paneth cell positions from all the mice of the same 
genotype were pooled together and analysed as described in section 2.6. 
 
β-catenin staining 
Immunohistochemistry with an anti-β-catenin antibody (see section 2.4) was used to assess 
its protein location. Within the intestines cells containing nuclear localised β-catenin were 
scored. The average number of displayed cells nuclear localised β-catenin per crypt was 
calculated from 50 crypts per mouse and analysed as described in section 2.6. 
 
Ki67 staining 
Immunohistochemistry with an anti-Ki67 antibody (see section 2.4) was used to identify 
proliferating cells. The number of proliferating cells was scored as a percent of total cells 
counted. At least 1000 cells were analysed per tissue per mouse. Data was then analysed as 
described in section 2.6.  
 
Cleaved Caspase-3 staining 
Immunostaining with cleaved caspase-3 antibody (see section 2.4) was used to confirm the 
morphology-based apoptotic index. The number of Caspase-3 positive cells was scored 
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as a percent of total cells counted. At least 1000 cells were counted per tissue per mouse. 
Data was then analysed as described in section 2.6.  
 
BrdU staining 
Tissue samples harvested from mice injected with BrdU at 2 or 24 hours prior to dissection 
were stained with a BrdU antibody as described in section 2.4. The number and position 
of BrdU positive cells at 2 and 24 hours post labelling were used to assess proliferation 
activity and cell migration respectively. The number of BrdU positive cells was scored in 
50 half-crypts per slide. The average number of BrdU positive cells per half-crypt was 
calculated for each mouse and analysed as described in section 2.6. The position of BrdU 
labelled cells was counted from the bottom of the crypt, the bottom-most cell being #1. 
Cell positions from all the mice of the same genotype were pooled together and analysed 
as described in section 2.6. 
 
 
2.4 Immunohistochemistry (IHC)  
 
All standard IHC was carried out according to the generic protocol outlined below. Specific 
conditions and modifications for particular antibodies are provided in Table 2.3. Unless 
otherwise specified, all incubation steps were carried out at room temperature 
(approximately 22 ◦C) in humidified chamber to avoid drying out of the sections or if left 
overnight at 4◦C. To contain the applied solutions to the tissue, slides were gently dried 
around the tissue section with tissue paper and the area surrounding the tissue was circled 
with a water-resistant ImmEdge pen (Vector Labs) typically before endogenous peroxidase 
block or serum block stage. 
 
 
2.4.1 Generic immunohistochemistry protocol  
Dewaxing and rehydration of tissue sections 
Tissue sections were dewaxed by two 5 min washes in xylene (Fisher Scientific) followed 
by rehydration washes in decreasing concentrations of ethanol (Fisher Scientific): two 2 
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min washes in 100%, one 2 min wash in 95% and one 2 min wash in 70% ethanol. Slides 
were then transferred into dH2O and washed for 5 min. 
 
 
 
Antigen retrieval 
Antigen retrieval was achieved by heating slides in a microwave in 1X citrate buffer 
(LabVision) for 2 x 7 min (850 W). Slides were then left to cool in the solution for 30-60 min. 
Slides were then washed in dH2O for 5 mins followed by 2 X 5 min washes in washing buffer 
(1X TBS (Sigma) in dH2O with 0.1% (v/v) TWEEN-20 (Sigma)). 
 
 
Endogenous peroxidase activity block 
Activity of endogenous peroxidases was blocked by incubating tissue sections with hydrogen 
peroxide. Either 30% hydrogen peroxide (Sigma) diluted in dH2O to appropriate 
concentration or a commercial peroxidase blocking solution (Envision+ Kit, DAKO) were 
used. The appropriate hydrogen peroxide concentrations and incubation times for specific 
antibodies are provided in Table 2.3. When using commercial peroxidase block, the tissue 
was circled with water-resistant pen, placed in a slide chamber and enough solution was 
applied to cover the tissue. When using hydrogen peroxide from the stock solution, slides 
were placed in a Coplin jar containing enough solution to cover the tissue. After incubation 
with the peroxidase blocking solution, slides were briefly rinsed in dH2O and washed 3 x 5 
min in washing buffer. 
 
Non-specific antibody binding block 
To diminish non-specific antibody binding, tissue sections were treated either with normal 
serum (DAKO) or BSA (Sigma) diluted to an appropriate concentration in washing buffer. 
The specific blocking agent, concentrations and incubation times for particular antibodies 
are outlined in Table 2.3. Typically, the serum used for blocking was derived from the 
species, in which the secondary antibody was raised (i.e. if a secondary antibody was 
raised in rabbit, normal rabbit serum was used to block non-specific binding). If not 
already done, the tissue containing area was circled with a water-resistant pen, slides 
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were overlaid with 200 μl of blocking solution and incubated for the time specified. 
 
Primary antibody treatment 
Following incubation, blocking solution was removed and 200 μl of primary antibody 
diluted in blocking solution was applied without washing of sides. The dilutions  
used with specific antibodies are outlined in Table 2.3. All slides were left in the cold room 
(4◦C ) overnight  for incubation, following this the slides were washed 3 x 5 min in washing 
buffer. 
 
Secondary antibody treatment 
The slides were incubated with an appropriate secondary antibody; either an appropriate 
Horseradish peroxidase (HRP) conjugated secondary antibody (Envision+ Kit, DAKO) used 
undiluted or if signal amplification was required, a suitable biotinylated secondary antibody 
(DAKO) was diluted 1:200 in blocking and applied following signal amplification (see table 
for details 2.3). After incubation, slides were washed 3 x 5 min in washing buffer. 
 
Signal amplification 
In instances, when anti-mouse or anti-rabbit Envision+ kits (DAKO) could not be used, a 
signal amplification step was introduced into the protocol. Avidin-Biotin Complex reagent 
(Vectastain ABC kit, Vector labs) was prepared according to manufacturer’s instructions 
30 min prior to use and stored at room temperature. Tissue sections were covered with 
200 μl of ABC reagent and incubated for 30 min at room temperature, followed by 3 x 5 
min washes in washing buffer. 
 
Signal visualisation with 3.3’-diaminobenzidine (DAB) 
Antibody binding was visualised by colourimetric detection with 3,3’-diaminobenzidine 
(DAB). Tissue sections were covered with 200 μl of DAB solution (2 drops of DAB chromogen 
mixed with 1 ml of DAB substrate (Envision+ Kit, DAKO)). Slides were incubated 
for 5–10 min or until a sufficient level of staining was attained followed by a 5 min wash 
in dH2O. 
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Counterstaining, dehydration and mounting 
Tissue sections were counterstained in Mayers Haemalum (R. A. Lamb) for 30 sec and 
washed in running tap water for 5 min. Slides were then dehydrated by consecutive washes 
in increasing concentrations of ethanol (1 x 3 min 70%, 1 x 3 min in 95%, 2 x 3 min in 
100%) and 2 x 5 min washes in xylene. Coverslips were mounted over dehydrated sections 
using DPX mounting medium (R. A. Lamb). 
 
 
 
Table 2.3: Antibody specific conditions for IHC 
 
Lysosome IHC 
Primary Antibody                                           Peroxidase block                                     Blocking solution 
Neomarkers (RB-372-A), 1:100              1.5% H2O2, 15min                              10% NGS, 30 min  
 
Signal amplification                                      Secondary Antibody  
          No                                                     Envision+ HRP conjugated anti-rabbit, 30min 
                                           
 
BrdU IHC 
Primary Antibody                                           Peroxidase block                                     Blocking solution 
BD biosciences (347580), 1:150               DAKO, 5min                                      1% BSA, 30 min  
 
Signal amplification                                      Secondary Antibody  
          No                                                     Envision+ HRP conjugated anti-mouse, 30min 
 
 
β-catenin IHC 
Primary Antibody                                           Peroxidase block                                     Blocking solution 
BD transduction labs (610154) 1:300      DAKO, 5min                                     10% NRS, 30 min  
 
Signal amplification                                      Secondary Antibody  
          No                                                     Envision+ HRP conjugated anti-mouse, 30min 
 
 
Ki-67 IHC 
Primary Antibody                                           Peroxidase block                                     Blocking solution 
Vector labs (VPK452) 1:20                      0.5% H2O2, 30min                              20% NRS, 30 min  
 
Signal amplification                                      Secondary Antibody  
 ABC kit (Vector labs)                               Biotinylated anti-mouse (DAKO), 30min 
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Table 2.3 (cont.) 
 
Cleaved caspase-3 IHC 
Primary Antibody                                           Peroxidase block                                     Blocking solution 
Cell signaling (9661), 1:200                     3% H2O2, 10min                                 5% NGS, 30 min  
 
Signal amplification                                      Secondary Antibody  
ABC kit (Vector labs)                                Biotinylated anti-mouse (DAKO), 30min 
 
 
cMyc IHC 
Primary Antibody                                           Peroxidase block                                     Blocking solution 
Santa Cruz (sc-788), 1:200                      1.5% H2O2, 15min                               5% NGS, 30 min  
 
Signal amplification                                      Secondary Antibody  
          No                                                     Envision+ HRP conjugated anti-rabbit, 30min 
 
 
CD44 IHC 
Primary Antibody                                           Peroxidase block                                     Blocking solution 
BD Pharmigen (550638), 1:50                1.5% H2O2, 15min                              10% NRS, 30 min  
 
Signal amplification                                      Secondary Antibody  
ABC kit (Vector labs)                                Biotinylated anti-rat (DAKO), 30min 
 
 
*NRS: normal rabbit serum, NGS: normal goat serum, BSA: bovine serum albumin. 
 
 
 
2.4.2 Fluorescent immunohistochemistry protocol  
 
For fluorescent immunohistochemistry, slides were processed as above (section 2.4.1) up 
until the endogenous peroxidase activity block stage. This step was excluded as antibodies 
were visualised using fluorescently conjugated secondary antibodies. The serum block used 
was dependent upon the antibodies used (detailed in Table 2.4) but constant with an 
incubation time of 30 min.  Some slides were double labelled using two primary antibodies 
and two corresponding fluorescently labelled secondary antibodies. Care was taken when 
selecting antibodies to avoid cross-reactivity. The protocol remains similar to the generic 
IHC protocol until addition of the secondary antibodies. All secondary antibodies were used  
at a concentration of 1:200 diluted in blocking serum however, exposure to daylight of the 
secondary antibody solution and stained sections was kept to a minimum to avoid photo-
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bleaching. The slides were incubated with secondary antibodies for 1-2 hours. Following the 
final Wash with wash buffer after incubation with the secondary antibodies, slides were 
wahed in 1 X PBS (Invitrogen) and mounted without dehydration using Vectashield hardset 
mounting medium with DAPI (DAPI labels nuclear material blue) (Vector Labs). Slides were 
kept in the dark at 4◦C and imaged within 2 weeks. Images were taken using an Olympus 
BX61 with correct filters and lamp for detecting fluorescent probes. 
 
 
  
Table 2.4: Antibody specific conditions for fluorescent IHC 
 
CK5 & CK8 
Primary antibodies                                            Secondary antibodies                       
CK5, Abcam (ad24647), 1:200                          anti-rabbit Alexafluor 594, Invitrogen (A11037) 
CK8, Abcam (ab14053), 1:250                          anti-chicken Alexafluor 488, Invitrogen (A11039)  
 
Blocking serum 
5% NGS 
 
Apc 
Primary antibodies                                             Secondary antibodies                       
APC, Santa Cruz (ad24647), 1:50                      anti-rabbit Alexafluor 488, Invitrogen (A11008) 
                                                                                anti-rabbit Alexafluor 594, Invitrogen (A11037)   
Blocking serum 
5% BSA 
 
Apc2 
Primary antibodies                                             Secondary antibodies                       
APC2, Zymed (384000), 1:100                           anti-rabbit Alexafluor 594, Invitrogen (A11037) 
                                                                                anti-rabbit Alexafluor 488, Invitrogen (A11008) 
Blocking serum 
10% NGS 
 
β-galactosidase 
Primary antibodies                                             Secondary antibodies                       
Β-galactosidase,  
Millipore (Ab1211), 1:10,000                            anti-rabbit Alexafluor 594, Invitrogen (A11037) 
                                                  
Blocking serum 
5% NGS 
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Table 2.4 (cont.) 
β-catenin 
Primary antibodies                                             Secondary antibodies                       
β-catenin, BD transduction 
Labs (610154), 1:200                                           anti-mouse Alexafluor 594, Invitrogen (A11005) 
                                                  
Blocking serum 
10% NGS 
 
Zo-1 & E-cadherin 
Primary antibodies                                             Secondary antibodies                       
Zo-1, Zymed (402300), 1:400                            anti-rabbit Alexafluor 594, Invitrogen (A11037) 
E-cadherin, BD transduction 
Labs (610182), 1:200                                          anti-mouse Alexafluor 488, Invitrogen (A11001) 
                                                  
Blocking serum 
20% NGS 
 
Vimentin & E-cadherin 
Primary antibodies                                             Secondary antibodies                       
Vimentin, Santa Cruz (sc7557), 1:300              anti-rabbit Alexafluor 488, Invitrogen (A11008) 
E-cadherin, BD transduction 
Labs (610182), 1:200                                           anti-mouse Alexafluor 594, Invitrogen (A11005) 
                                                  
Blocking serum 
20% NGS 
 
α-tubulin 
Primary antibodies                                             Secondary antibodies                       
α-tubulin,  
Invitrogen (A11126), 1:400                                anti-mouse Alexafluor 488, Invitrogen (A11001) 
                                                  
Blocking serum 
2.5% BSA 
 
β-catenin & Lec2 
Primary antibodies                                             Secondary antibodies                       
β-catenin, BD transduction 
Labs (610154), 1:200                                           anti-mouse Alexafluor 594, Invitrogen (A11005) 
Lect 2, (Gift from Satoshi 
Yamagoe), 1:500                                                  anti-rabbit Alexafluor 488, Invitrogen (A11008)                                                 
                                                       
Blocking serum 
5% NGS 
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Table 2.4 (cont.) 
 
GS & CPS 
Primary antibodies                                             Secondary antibodies                       
GS, BD Transduction 
Labs (ALX803055), 1:400                                   anti-mouse Alexafluor 594, Invitrogen (A11005) 
CPS, Santa Cruz (sc30060), 1:600                    anti-rabbit Alexafluor 488, Invitrogen (A11008) 
                                                  
Blocking serum 
10% NGS 
 
*NGS: normal goat serum, BSA: bovine serum albumin. 
 
 
2.5 Gene Expression Analysis  
 
2.5.1 RNA extraction from tissue samples  
Homogenisation of tissue samples 
Tissue samples were removed from -80 storage and placed in screw-cap tubes containing 
1 ml Trizol reagent (Invitrogen) and 1.4 mm ceramic beads (Lysing matrix D tubes, 
MP Biomedical), Samples were then homogenised using Precellys24 homogeniser (Bertin 
Technologies) at 6500 RPM for 2 x 45 second cycles. Tubes were centrifuged at 11000 x g for 
10 min at 4 ◦C to pellet the beads and tissue debris. 
 
RNA extraction 
Supernatant was transferred into fresh 1.5 ml eppendorf tubes containing 200 μl of 
chloroform (Fisher Scientific). Tubes were then shaken vigorously by hand for 30 seconds 
and allowed to stand at room temperature for 3 min. Tubes were centrifuged at 11000 x g 
for 15 min at 4 ◦C. The top, aqueous, phase (approximately 400 μl) containing RNA was 
removed and transferred into fresh 1.5 ml eppendorf tubes containing 400 μl of 
isopropanol. Tubes were gently inverted until well mixed. 
 
RNA purification and DNAse treatment 
RNA purification was performed using the RNeasy mini kit (Qiagen) according to the 
manufacturer’s instructions. All centrifugation steps were performed at 11000 x g in a 
refrigerated bench top centrifuge cooled to 4 ◦C. The mix from the previous step was 
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transferred into purification columns placed in a collection tubes. Columns were centrifuged 
for 30 seconds and the flow-through was discarded. Columns were washed by 
adding 500 μl of RPE wash buffer (RNeasy kit, Qiagen) and centrifuging for 30 seconds. 
The flow-through was discarded and the wash was repeated, followed by 2 min 
centrifugation. The flow-through was discarded and columns were centrifuged once again 
for 1 min to remove the remnants of the buffer from columns. To elute RNA, columns were 
placed into fresh 1.5 ml eppendorf tubes, 100 μl of RNAse-free dH2O was pipetted onto 
columns and allowed to stand for 3 min at 4 ◦C. Eluate containing RNA was collected 
by centrifuging columns for 1 min and immediately placed on ice. RNA was then DNAse 
treated using the DNA-free Kit (Ambion) following manufacturer’s instructions. 
 
The concentration and purity of RNA was assessed using NanoDrop 1000 (Thermo 
Scientific). RNA samples were stored at −80 ◦C until needed. 
 
Determination of RNA quality 
The quality of the extracted RNA was analysed using denaturing agarose gel electrophoresis 
as described in Qiagen Bench Guide (Qiagen). RNA samples containing 2 μg of RNA 
were mixed with the appropriate amount of RNA 5X loading buffer (0.25% Bromophenol 
blue (Sigma), 4 mM EDTA (Sigma), 0.9 M formaldehyde (Sigma), 20% glycerol (Sigma), 
30.1 % formamide (Sigma), 4X FA gel buffer (see below)), incubated at 65 ◦C for 3–5 min 
and quenched on ice. Samples were then loaded onto a denaturing gel (1% agarose 
(Eurogentech), in 1X FA gel buffer (20 mM 3-(N-Morpholino)propanesulfonic acid (MOPS, 
Sigma), 5 mM sodium acetate (Sigma), 1 mM EDTA (Sigma), 0.22 M formaldehyde 
(Sigma), 0.1 μg/ml Ethidium bromide (Sigma) in dH2O)). The gel was run in FA gel running 
buffer (20 mM 3-(N-Morpholino)propanesulfonic acid (MOPS, Sigma), 5 mM sodium 
acetate (Sigma), 1 mM EDTA (Sigma), 0.25 M formaldehyde (Sigma) in dH2O) at 50 V 
for 1 hour. RNA was then visualised under UV light on a GelDoc (BioRad). Assessment 
of RNA quality was based on the sharpness of 18S and 28S ribosomal RNA bands. 
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2.5.2 Preparation of cDNA for quantitative analysis  
cDNA synthesis was performed as described by Untergasser A. 
(http://www.untergasser.de/lab/protocols/cdna synthesis superscript ii v1 0. 
Htm) using Superscript II RNAse H reverse transcriptase kit (Invitrogen). 1 μg of RNA 
was mixed with 5 μl of 100 ng/μl random hexamers (Promega), and made up to 20 μl 
with DNAse free dH2O (Sigma). The mix was then incubated at 70 ◦C for 10 min, 25 ◦C 
for 10 min and held at 4 ◦C long enough to add 20 μl of enzyme mix (8 μl 5X First Strand 
Buffer, 4 μl 0.1 M DTT, 0.8 μl 25 mM dNTPs (Bioline), 1 μl Superscript II enzyme, 6.2 
μl RNAse-free dH2O) per reaction. The reaction mix was then incubated at 25 ◦C for 10 
min, 37 ◦C for 45 min, 42 ◦C for 45 min, 70 ◦C for 15 and stored at 4 ◦C. 160 μl of DNAse 
free dH2O was added to 40 μl of reaction mix and 1 μl of the resulting cDNA was used 
per reaction in quantitative RT-PCR. Negative control cDNA samples were synthesised 
in the same manner but without addition of Superscript II enzyme to the enzyme mix. 
 
2.5.3 Quantitative real-time PCR analysis  
Primer design for qRT-PCR 
Primers for qRT-PCR analysis (unless previously published) were designed using Primer3 
software at http://fokker.wi.mit.edu/primer3/input.htm, checked for mispriming using 
BLAST engine against Ensembl database (http://www.ensembl.org/Multi/blastview) and 
synthesised by Sigma Genosys. A number of conditions were considered when designing 
primers. Primers were designed to reside across exon boundaries to avoid amplification of 
genomic DNA. Primers were to yield a PCR product of 100–200 bp in size and to have an 
annealing temperature close to 60 ◦C. The primer sequences used are specified in Table 2.5.  
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Table 2.5: Primer sequences used for qRT-PCR  
 
Gene                                     Forward primer                                            Reverse Primer 
β-actin                       TGTTACCAACTGGGACGACA                    GGGGTGTTGAAGGTCTCAAA 
β-catenin                AGTCCTTTATGAATGGGAGCAA                TCTGAGCCCTAGTCATTGCATA 
cMyc                      CTAGTGCTGCATGAGGAGACAC                GTAGTTGTGCTGGTGAGTGGAG 
Cyclin D1                 ACGATTTCATCGAACACTTCCT                GGTCACACTTGATGACTCTGGA 
Axin 2                      GCAGCTCAGCAAAAAGGGAAAT              TACATGGGGAGCACTGTCTCGT 
CD44                     ATCGCGGTCAATAGTAGGAGAA                 AAATGCACCATTTCCTGAGACT 
MIF                        GGTATTGCGTGGTACACTGCT                      TGTAGGTTTCCAGCATCACATC 
WIF1                     AACAAGTGCCAGTGTCGAGAGG                  GCCTTTTTAAGTGAAGGCGTGTG 
Ephrin B2              AAACCCTGATGGACTCTACGAC                   TTGTTCTGGCTTGACTCAAAGA 
Ephrin B3              TAACGCTGTGGAGGTCTCTGTA                   CCTTGCTTTGCTTTGTAACTCC 
Ascl2                      CAGGAGCTGCTTGACTTTTCCA                   GGGCTAGAAGCAGGTAGGTCCA 
Lgr5                         TGCTCGGACCTGGGGCTCTC                        GCCCGTGAACGCTCCCTTGG 
Bmi 1                    AAGCTTGTCTATTGAGTTCTTTGA                  TCTCAAGTGCATCACAGTCATT 
Groucho               GGAGAGAGCTCCTGAAGTTTCC                    TTCTCTTTGTTCCTCTTCAATGG 
Dickkopf 2            TCACTATTCCAACCATGACCTG                      CTTCTTGCGTTGTTTGGTACAG 
 
 
 
qRT-PCR reaction set-up 
All reactions were run on StepOnePlus real-time PCR system supplemented with StepOne 
software v2.1 (Applied Biosystems). All reactions were run in a minimum of three technical 
and three biological replicates. Samples devoid of cDNA served as negative controls 
to test for contamination with genomic DNA. A housekeeping gene (typically β-actin) 
was used in each run as a reference gene. Reactions were run using DyNAmo HS SYBR Green 
qPCR kit (Finnzymes) according to the manufacturer’s instructions. qRT-PCR reactions for 
the intestinal stem cell markers (Lgr5 and Ascl2) were confirmed using TaqMan assay 
(Applied Biosystems) following the manufacturer’s instructions and using custom designed 
TaqMan probes (Applied Biosystems).  
 
Forward and reverse primers (100 mM) were mixed in equal quantities and diluted to 10 
mM concentration. 0.4 μl of the resulting 10 mM primer mix was then used per reaction. 
For all reactions 1 μl of cDNA was loaded into a thin wall 96-well PCR plate (Applied 
Biosystems). 19 μl of Master Mix containing appropriate primers or TaqMan probes were 
added to cDNA samples and plates were sealed with optically clear sealing film (Applied 
Biosystems). All SYBR Green reactions were run using the same cycling conditions: 95 ◦C 
for 10 min followed by 40 cycles (95 ◦C for 15 seconds, 60 ◦C for 30 seconds, 72 ◦C for 30 
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seconds), To ensure that a single product was amplified by the primer set, a melting curve 
was run after cycling from 60 ◦C to 95◦C with a 0.5◦C increment. TaqMan reactions were 
run using the following conditions 50 ◦C for 2 min, 95 ◦C for 10 min followed by 40 cycles 
(95 ◦C for 15 seconds, 60 ◦C for 1 min). 
 
 
Analysis of qRT-PCR data 
Data from the samples with reproducible cycle time (Ct) values and a single peak melting 
curve (when applicable) were analysed using the 2ΔΔCt method (Livak and Schmittgen, 
2001). ΔCt values were calculated using Ct value of the reference gene from the same 
sample.Average ΔCt values were calculated for all control samples and ΔΔCt value for each 
individual sample was calculated in reference to the average ‘control’ ΔCt. Average ΔΔCt 
values were calculated for samples from each biological group and the Mann-Whitney U 
test was used to test for significant differences between means. The average ΔΔCt from 
each biological group was transformed into fold change using formula 2ΔΔCt . 
 
2.5.4 In situ hybridisation  
In situ hybridisation was used to examine the expression of the intestinal stem cell markers 
Ascl2 and Olfm4. This technique utilised digoxigenin (DIG) labelled anti-sense RNA probes 
(ribo probes) complementary to Ascl2 and Olfm4 mRNA sequence. Probe binding was 
detected using an anti-digoxigenin alkaline phosphatase-conjugated antibody by 
development of purple staining. The probe for Ascl2 was provided by Dr. Simon Tunster 
(Cardiff university). The probe for Olfm4, cloned in a pBluescript II SK+ vector, was provided 
by Hans Clever’s group (Hubrecht Institute, Netherlands). All glassware used in the protocol 
was heat-treated by baking at 200 ◦C overnight and RNAse-free (Sigma) or DEPC treated 
dH2O was used to prepare all solutions. 
 
 
Probe synthesis 
The probes were synthesised by linearisation of plasmid DNA, RNA polymerase 
reaction from the T7 promoter and DIG labelling. 30 μg of plasmid DNA was linearised 
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by restriction digest with NotI restriction enzyme (NEB) according to manufacturer’s 
instructions. The restriction digest was carried out overnight at the appropriate 
temperature, and 5 μl of reaction was run on an agarose gel alongside undigested vector to 
confirm complete linearisation. Linearised DNA was then purified using DNA purification 
columns (Qiagen). DNA concentration of the purified plasmid was determined using 
NanoDrop 1000 (Thermo Scientific), and adjusted to 1 μg/μl using 10 mM Tris (pH 8.0) 
as required. The linearised plasmid DNA was used as a template for the transcription 
of DIG-labelled riboprobes using T7 RNA polymerase (Roche). The components of the 
riboprobe-labelling reaction are outlined in Table 2.5. 
 
 
Table 2.6: Reaction constituents for DIG labelling  
 
Component                                                                           Volume 
RNase Free H2O                                                                       12 μl 
Transcription Buffer (10X) (Roche)                                         2 μl 
DIG RNA Labelling mix (Roche)                                               2 μl 
RNasin (Promega)                                                                      1 μl 
T7 RNA Polymerase (Roche)                                                    2 μl 
DNA (1 μg/μl)                                                                              1 μl 
 
 
The labelling reaction was carried out for 2 hours at 37 ◦C, followed by DNA template 
digestion by incubation with 20 units of DNase I (Ambion) for 15 minutes at 37 ◦C. 
Riboprobes were purified using the RNeasy Mini kit (Qiagen) according to manufacturer’s 
instructions. Probes were eluted with 100 μl of RNAse-free H2O and divided into 10 μl 
aliquots, which were transferred to storage at -80 ◦C. 
 
Probe hybridisation 
Slides were dewaxed in 2 x 10 min changes of xylene, and rehydrated by 1 min washes in 
ethanol of decreasing concentration: 2 x 100%, 95%, 85%, 75%, 50% and 30%. Slides were 
incubated in 1X saline for 5 min followed by 5 min wash in 1X PBS. Endogenous alkaline 
phosphatase activity was blocked by a 30 min incubation in 6% hydrogen peroxide (in 1X 
PBS) at room temperature. Slides were washed 2 x 5 min in 1X PBS, fixed in ice cold 
4% PFA (Sigma) (in 1X PBS) for 20 minutes followed by 2 x 5 min washes in 1X PBS. 
Slides were incubated in Proteinase K (Roche) (20 μg/ml Proteinase K, 50 mM Tris, 5 
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mM EDTA in dH2O) for 5 min at room temperature, washed for 5 min in 1X PBS, postfixed 
in 4% PFA for 5 minutes followed by 2 min wash in DEPC treated H2O. To reduce 
non-specific probe binding, slides were incubated with acetic anhydride (0.01 M acetic 
anhydride (Sigma), in 0.1 M triethanolamine hydrochloride (Sigma)), for 10 min at room 
temperature. Slides were then consecutively washed in 1X PBS and 1X saline for 5 min at 
room temperature. Slides were rehydrated through 1 min washes in 30%, 50%, 70%, 85%, 
95% and 2 x 100% EtOH solutions (70% ethanol wash was carried out for 5 min to prevent 
salt precipitation). Slides were air dried for 30 minutes and transferred into sealable boxes 
lined with tissue paper saturated in moisture buffer (5X saline sodium citrate (SSC) buffer 
(Sigma), 50% (v/v) formamide (Sigma) in dH2O). The probe was heated at 80 ◦C for 3 
minutes, and quenched on ice, and hybridisation buffer (5X SSC, 50% formamide, 1% 
SDS, 0.05 mg/ml heparin (Sigma), 0.05 mg/ml calf liver tRNA (Merck) in dH2O) was 
thawed at 80 ◦C. Adequate amounts of probe and hybridisation buffer were mixed (1 μl 
probe per 100 μl hybridisation buffer per slide), and applied to slides. A piece of parafilm 
was placed on top of the slide to prevent probe mixture evaporation. The box was sealed 
with electrical tape and incubated at 65 ◦C overnight in a water bath. 
 
Post-hybridisation treatment 
Slides were removed from the box and incubated in pre-warmed 5X SSC buffer at 65 ◦C 
for 30 minutes. Slides were then washed 2 x 30 min in solution I (50% formamide, 5X 
SSC, 1% (v/v) SDS (Sigma)) pre-warmed to 65 ◦C followed by 3 x 10 min washes in 
solution II (0.5 M NaCl (Sigma), 0.01 Tris pH 7.5 (Sigma), 0.1% TWEEN-20 (Sigma)) 
at room temperature. Unhybridised probe was digested by a 45 min incubation with 
RNase A (Roche) (0.02 mg/ml in solution II) at 37 ◦C, followed by a 10 min wash in 
solution II at room temperature. Slides were washed 2 x 30 min in solution III (50% 
formamide, 5X SSC) preheated to 65 ◦C. Slides were washed 2 x 10 min in PBS/T (0.1% 
TWEEN-20 in 1X PBS) and pre-blocked in 10% heat-inactivated sheep serum (DAKO) in 
PBS/T for 3 hours, covered with a piece of parafilm to prevent drying up of the solution. 
Anti-DIG alkaline phosphatase conjugated antibody (Roche) was pre-absorbed in 1% heat 
inactivated sheep serum in PBS/T containing 6 mg/ml small intestine tissue powder for 3 
hours at 4 ◦C and diluted to a final concentration of 1:2000 in 1% sheep serum in PBS/T. 
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Slides were washed in PBS/T for 5 min, overlaid with 100 μl of antibody solution, covered 
with a piece of parafilm, and incubated overnight at 4 ◦C. 
 
Signal detection 
Slides were washed in PBS/T for 5 min, followed by 2 x 5 min and subsequent 3 x 
30 min washes in PBS/T. Slides were preconditioned in 3 x 5 min washes of NTMT 
(0.1 M sodium chloride, 0.1 M Tris pH 9.5, 0.05 M magnesium chloride (Sigma), 0.1% 
TWEEN-20) containing 2 mM Levamisole (Sigma). Slides were completely covered with 
BM Purple substrate (Roche), sealed in a dark box and incubated at room temperature 
until the desired level of signal was developed. Slides were then washed in PBS/T for 
10 min, followed by a 30 min wash in dH2O, and counterstained by immersion in Eosin 
Y Solution (Sigma) for up to 10 seconds. Excess eosin was washed off under running 
tap water and slides were air dried for 30 min. Slides were washed briefly in xylene and 
mounted in DPX mounting media (R. A. Lamb). 
 
 
2.6 Quantitative and statistical analysis of data  
 
2.6.1 Quantitative analysis of histological parameters  
Quantitative analysis of tissue sections was carried out using an Olympus BX41 light 
microscope. Sample IDs were covered on all slides before scoring to avoid possible bias. 
Areas to be quantified were carefully selected to ensure that they belong to approximately 
the same region of the tissue and are free of sectioning artefacts. Quantifiable traits, such as 
crypt and villus length (within the intestine), mitosis and apoptosis levels, number of 
differentiated cells of particular types, etc. were scored on appropriately stained tissue 
sections. A minimum of 50 half-crypt or half-crypt-villus axes were stained per mouse in 
intestinal studies or at least 1000 cells in other tissues. At least 3 different animals per 
genotype were examined to allow for statistical analysis. Scores from mice of the same 
genotype were used to calculate average ‘group’ value as well as standard deviation. 
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Average ‘group’ values were plotted as histograms with error bars representing standard 
deviation within each group. MS Excel 2010 was primarily used for graphical representation 
of the data. Individual ‘mouse’ values were also used to test for significant difference 
between means as described below. For all tests, the use of one- or two-tailed test was 
decided on a case-by-case basis, depending on the appropriate null hypothesis. 
 
2.6.2 Comparison of means  
Quantitative data was first tested for normal distribution using normal plot of residuals 
and Anderson-Darling test in Minitab statistical analysis software (version 15.1.30.0). 
Normally distributed data (Anderson-Darling test p≥0.05) was then tested for significant 
difference between means using One-Way ANOVA using SPSS software (version 17.0.2). 
If data from more than two groups were compared, One-Way ANOVA test was used to 
establish the difference across all the groups and Post-Hoc Tukey’s test was subsequently 
employed to perform pair-wise comparisons between groups. These tests were carried out 
using SPSS software. A significant difference between means was accepted, when p value 
was equal or less than 0.05. Non-normally distributed data (Anderson-Darling test p≤0.05) 
was tested for significant difference between means using Mann-Whitney U test. The test 
was performed in SPSS software. A significant difference between means was accepted, 
when p value was equal or less than 0.05. 
 
 
2.6.3 Kolmogorov-Smirnov Z test  
Kolmogorov-Smirnov Z test was used to test for the significant difference in distribution 
between two data sets. To assess the distribution of specific cells (i.e. BrdU positive, Goblet 
or Paneth cells) the positions of positive cells were recorded using a following method. Each 
half-crypt was represented as a column of numbers in a spreadsheet with positive cells 
recorded as 1 and negative cells recorded as 0. Counting was started from the crypt-base so 
that the row in the column corresponded to cell position on the crypt-villus axis. This was 
repeated for 50 half-crypts per mouse. The sum of all 1 and 0 in any given row (at any given  
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position) in every mouse was calculated and sums of all the mice of the same genotype 
were pooled together. These intermediate data sets were used to build graphs of 
cumulative frequency of positive cells manually using MS excel. To test for the difference in 
distribution between the biological groups a K-S statistic was calculated and significance 
tested using formulas: see http://www.physics.csbsju.edu/stats/KS-test.html. Statistically 
significant difference between distributions was accepted, when p value was less or equal 
0.05. 
 
2.6.4 Kaplan-Meier survival analysis  
Survival analysis and generation of survival curves was performed using the Kaplan-Meier 
method with the aid of SPSS software . Statistical significance between survival time of 
different experimental cohorts was assessed using the Log-Rank method. Differences in 
survival probability were accepted as significant, when p value was less or equal 0.05. 
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Chapter 3 
Investigating the effects of Apc2 loss in the small intestinal 
epithelium 
 
3.1 Introduction 
APC has been extensively studied in both development and tumorigenesis.  Initially 
identified as the defective gene responsible for inherited FAP, it is characterized by 
numerous adenomas polyps in the intestines of which some inevitably progress to 
carcinoma (Kinzler et al., 1991; Groden et al., 1991; Nishisho et al., 1991). Patients carry one 
mutated copy of APC and a ‘second hit’ (mutation of the normal residing APC allele) initiates 
polyp formation. Tumour progression through to carcinoma occurs due to subsequent 
mutations in other oncogenic genes. Loss of function mutations of APC were also found in 
the majority of sporadic colorectal cancers (Powell et al., 1992; Nagase & Nakamura, 1993). 
Mutations in APC are recognised as an early event in colorectal tumourigenesis (Powell et 
al., 1992) and although its role in tumour suppression is multifunctional (reviewed by Aoki & 
Taketo, 2007; Senda et al., 2007), previous studies suggest the most influential role lies with 
its ability to mediate Wnt signaling (Hanson et al., 2005; Nathke, 2005; Polakis, 2000).   
Interestingly, APC2 possesses many shared structural characteristics with APC and may 
therefore have comparable functions. It had been shown APC2 can deplete cytoplasmic β –
catenin via direct interaction and can complement APC loss in human colon carcinoma cells 
(Nakagawa et al., 1998; Van Es et al., 1999). This is performed by APC2 in a destruction 
complex spatially and functionally isolated from the APC associated destruction complex 
(Maher et al., 2009). There is now accumulating evidence that APC2 may also act as a 
tumour suppressor in humans. APC2 is located within a chromosome region lost with Peutz-
Jeghers syndrome (PJS). Patients with PJS are more susceptible to certain cancers including 
testis, ovarian, breast and colon (Mehenni et al., 1998; Bignell et al., 1998). However, 
mutations in the PJS gene, LKB1, are not present in most sporadic cases of these cancers, 
suggesting the existence of other tumour suppressor loci in this region of chromosome. It 
was also shown that APC2 displays allelic imbalance in most breast and ovarian tumours 
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(Jarrett et al., 2001) and exhibits significant LOH in certain sporadic cancers (Sobottka et al., 
2000; Yang et al., 2004; Wang et al., 1999).  
Although known mutations in APC2 are rare, epigenetic silencing and reduction in 
expression is now recognised in a variety of cancers through hypermethylation (reviewed in 
Herman & Baylin, 2003; Jones & Baylin, 2007), including; neurological cancer (Nakagawa et 
al., 1999), breast cancer (Chan et al., 2008) and indeed colorectal cancer (Schuebel et al., 
2007; Hsieh et al., 2007; Chan et al., 2008). Epigenetic abnormalities can cooperate with 
genetic alterations to effect aberrant gene function that results in cancer (Jones & Baylin, 
2002). Hypermethylation of APC2 is associated with progression from inflammatory bowel 
disease (IBD) to IBD associated neoplasia (Montgomery et al., 2008). It was demonstrated by 
Chan et al. (2008) that increased methylation status of APC2 led to a decrease in protein 
expression and that hypermethylation occurred in 100% of primary colon tumours 
compared to control tissue. Studies by (Mokarram et al., 2009) and (Kumar et al., 2009) 
have confirmed hypermethylation of APC2 in 90-98% of colorectal tumour samples 
compared to control in a variety of human populations. 
In mice, constitutive Apc loss causes embryonic lethality (Moser et al., 1995) whilst 
heterozygosity leads to intestinal tumour formation (Moser et al., 1990). To circumvent 
embryonic lethality, studies have utilised cre-lox technology to obtain homozygous Apc loss 
within the intestine (Sansom et al., 2004; Andreu et al., 2005). Immediate loss of Apc results 
in changes in proliferation, migration and differentiation, primarily thought to be through 
aberrant Wnt signaling. The importance of normal Wnt signaling in small intestinal epithelial 
maintenance has been known for some time (Korinek et al., 1998). Perturbed Wnt has 
implications for intestinal stem cells and indeed cancer initiation/progression (for review 
see Reya & Clevers, 2005). Studies have shown intestinal stem cell populations depend on 
active Wnt signaling for their self-renewal (Fevr et al., 2007). Inversely, over-activated Wnt 
signaling achieved through Apc loss leads to an increase in stem cell expression markers 
(Jubb et al., 2006; Merlos-Suarez et al., 2011). The intestinal epithelium composes a cellular 
environment which is critically reliant on Wnt signalling for its homeostasis. Furthermore, it 
is a commonly used model to study colorectal cancer (reviewed in Heyer et al., 1999) and 
would therefore represent an excellent tissue to study the consequences of Apc2 loss. 
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In this chapter I wished to characterise Apc2 loss with particular emphasis on the small 
intestine. Parameters analysed were those normally associated with Apc loss with an aim to 
elucidate comparable functions. 
The main functions of the small intestine include digestion, absorption and secretion of 
gastrointestinal hormones. The physiology of the small intestines enables it to maximize 
efficiency in conducting these functions (Figure 3.0). The epithelium of the small intestines 
consists of four main differentiated cell types (enterocytes, goblet, paneth and 
enteroendocrine) of which the majority are replenished every 4 to 5 days (excluding paneth 
cells). Cells are born and divide in a region known as the crypts of lieberkühn (crypts), whilst 
paneth cells differentiate and migrate to the bottom of these crypts, all other differentiated 
cell types migrate towards the lumen of the small intestine along finger like projections 
termed villi.  Once cells reach the tip of the villus they are ‘shed off’ into the lumen. 
 
 
Figure 3.0 Diagram depicts a cross section through the small intestine and a corresponding H&E 
stained section of small intestinal epithelia. The useful surface of the small intestine is vastly 
increased due to the formation of finger-like projections termed villi.  Water, electrolytes and 
nutrients are absorbed from the digested contents within the lumen through the intestinal 
epithelium and into a network of capillaries that run along the villi.  
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3.2 Results 
3.2.1 APC2 is down-regulated in human colorectal cancer 
As previously mentioned, increasing evidence implicates APC2 in tumour suppression. In 
order to assess the potential importance of APC2 in the pathogenesis of human colorectal 
cancer (CRC), we analysed the APC2 gene expression profile in matched normal and tumour 
samples from 18 patients (courtesy of Dr F Song, Liverpool University).  A significant 
reduction of APC2 expression levels in tumour samples was shown (see Figure 3.1, Median 
fold change of -2.754, Wilcoxon Signed Rank Test: Significant with P=0.001).  This 
significance is indicative of a mechanistic link associating APC2 expression levels and 
tumorigenesis. 
 
 
Figure 3.1 APC2 is down regulated in human colorectal cancer.  Quantitative RT-PCR was used to 
compare APC2 expression levels between colorectal tumour samples and corresponding 
macroscopically normal surrounding tissue from 18 patients.  There was a significant reduction of 
APC2 expression in tumour samples (Median fold change of -2.754, Wilcoxon Signed Rank Test, 
P=0.001). 
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3.2.2 Constitutive Apc2 mutation 
Due to a suggested link between APC2 and tumorigenesis and the fact that homology exists 
between APC2 and APC (Apc is indispensable for development and tumour suppression), an 
Apc2 mutant mouse was generated and kindly gifted to us from Prof. Hans Clevers’ 
laboratory (termed Apc2-). Briefly, Van der Meer et al., (2001) generated this mouse using 
genetic engineering to disrupt Apc2 by introducing a stop codon into the open reading 
frame, resulting in a shortened gene product (Figure 3.2A). PCR was used to confirm and 
identify mutated animals (Figure 3.2B). Both Apc and Apc2 share the ability to bind β-
catenin and Axin. However, in Apc2+/- mice (which appear phenotypically indifferent from 
Wt {Apc2+/+}), one copy of Apc2 is constitutively truncated lacking β-catenin and Axin 
binding sites (Figure 3.2C).  
 
Figure 3.2 Global Apc2 loss via a constitutive truncating mutation. (A) Schematic representation of 
targeted Apc2 mutation and primer positions for detection. The Apc2 locus was genetically modified 
by excising a fragment out of the open reading frame, introducing a STOP Codon (Van der Meer et 
al., 2001). Specifically designed primers allow for PCR mediated detection of Apc2 mutation (FPr= 
forward primer, RPr=reverse primer, yellow and red indicate expected PCR product length). (B) PCR 
reaction designed to detect mutant allele (yellow arrowhead=Apc+ PCR fragment, red arrowhead= 
Apc- PCR fragment). (C) Schematic representation of translated Apc, Apc2+ and Apc2- protein. Both 
Apc proteins contain β-catenin and Axin binding sites. Apc2- protein lose these interaction sites and 
mimic truncation usually found in cancer related APC loss (adapted from Webb et al., 2009).  
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In contrast to the embryonic lethality associated with homozygous constitutive Apc 
mutation (Moser et al., 1995; Oshima et al., 1995), Apc2-/- mice were viable. However, a 
substantial proportion of Apc2-/- mice, whilst maintained on a mostly C57BL/6 genetic 
background, developed hydrocephalus shortly after birth. Hydrocephalus in Apc2-/- mice 
usually presents at around 2-5 weeks of age where mice with symptoms become ill and 
were culled.  Apc2-/- mice that survive this time period did not develop hydrocephalus and 
can live healthily beyond 100 days of age.  Macro- and microscopic examination of the gross 
morphology of the intestines from mice with hydrocephalus did not identify any differences 
when compared to age matched Apc2+/+ controls. However, in depth analysis of intestines 
from hydrocephalic mice was avoided to ensure any differences observed in Apc2-/- intestine 
were true consequences of Apc2 loss within the intestines, rather than features resulting 
from hydrocephalic associated brain issues such as altered eating habits or hormone 
regulation. In order to elucidate if any brain defects resided in hydrocephalus-free surviving 
Apc2-/- mice, a small battery of behavioural tests was employed. Locomotor activity, rotarod 
and cylinder test revealed no behavioural differences between Apc2+/+ and Apc2-/- mice 
older than 100 days of age (data not shown). This data, along with the observation that 
surviving Apc2-/- mice appeared healthy, suggests no residing brain defects persist. APC2 has 
been reported to be expressed in a wide range of tissues, including the intestines (Van Es et 
al., 1999). In order to test the significance of Apc2 within the intestines, cohorts of Apc2+/+, 
Apc2+/- and Apc2-/- mice were established and sacrificed at approximately 3 months of age. 
In depth intestinal characterisation was then performed focusing on the small intestines.  
 
3.2.3 Loss of Apc2 does not lead to morphological changes in intestinal crypt-
villus architecture or alter terminal differentiated cell composition/position 
No intestinal lesions were noticed in any genotype at 3 months of age both macro- and/or 
microscopically. Histological analysis of H&E stained intestinal sections revealed no major 
alterations in intestinal crypt or villus morphology between experimental and control tissues 
(Figure 3.3A). Crypt size (Figure 3.3B) or villus length (Figure 3.3C) was measured by cell 
number and displayed no significant differences between experimental and control tissues 
(both Apc2+/- & Apc2-/- vs Apc2+/+ comparisons n≥4, Mann-Whitney U-test p≥0.54). 
 74 
 
 
 
Figure 3.3 Apc2 loss does not lead to alterations in intestinal crypt-villus morphology (A) H&E stained 
intestinal tissue from control and Apc2-/- mice culled at 120 days of age revealed no gross 
microscopic alterations to crypt-villus architecture (Scale bar represents 50μm). Quantitative 
analysis of villus length (B) and crypt size (C) between cohorts of Apc2+/+ (black bar),  Apc2+/-(dark 
gray bar) and  Apc2-/- (light gray bar) mice revealed no significant difference between any genotype 
(error bars represent standard deviation, p˃0.3, Mann-Whitney U-test, n≥5). 
 
Wnt signaling has been closely coupled with intestinal differentiation and Apc deficient 
intestines display perturbed differentiation (Sansom et al., 2004; Andreu et al., 2005).To 
assess differentiated cell types in Apc2 deficient intestines, sections from Apc2+/+ and Apc2-/- 
intestines were co-labelled with cytokeratin 5 and 8 antibodies, using florescent IHC (Figure 
3.4A). Cytokeratin 5 labels the secretory lineages (composed of goblet, enteroendocrine  
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and paneth cells) whilst cytokeratin 8 labels the absorptive lineage (consisting solely of 
enterocytes). Together this double stain can label the majority of terminally differentiated 
intestinal epithelia and the absence of stain can expose the non-terminally differentiated 
cell population.  Indeed this stain can expose differentiation changes in Apc deficient 
intestinal models (unpublished data). No differences were observed between Apc2+/+ and 
Apc2-/- mice, indicating that both genotypes contain comparable undifferentiated, 
absorptive and secretory lineages. Given that Apc deficient intestines display perturbed 
differentiation with alterations in paneth and goblet cell populations (Sansom et al., 2004; 
Andreu et al., 2005), in depth analysis of these cell types was carried out in Apc2-/- 
intestines. Intestinal sections from Apc2+/+ and Apc2-/- were stained with alcian blue (goblet 
cell specific stain) and lysozyme (paneth specific stain) (Figure 3.4B). There was no 
difference between Apc2+/+ and Apc2-/- in total number of paneth cells (2.93±0.18 vs 
3.05±0.21 paneth cells per half crypt respectively, p=0.42, Mann-Whitney U-test, n=5) or 
goblet cells (9.21±1.98 vs 9.51±1.39 goblet cells per half crypt respectively, p=0.56, Mann-
Whitney U-test, n=5). Positional analysis was performed and represented as the percentage 
chance of a cell being positively labelled (X axis) vs position of that cell (Y axis, 0 represents 
base of crypt) (Figure 3.4C). No differences were observed in distributions of paneth or 
goblet cells between Apc2+/+ and Apc2-/- intestines. Kolmogorov-Smirnov Z test proved no 
statistical difference in distribution between Apc2+/+ and Apc2-/- in either paneth (p=0.42, 
n=4) or goblet (p=0.51, n=4) cells. 
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Figure 3.4 Loss of Apc2 does not have an effect on terminally differentiated cell types. (A) Sections of 
aged matched Apc2+/+ and Apc2-/- intestines were stained for differentiated cells using double label 
fluorescent IHC for cytokeratin 8 (CK8) and cytokeratin 5 (CK5) (Scale bar represents 100μm).  No 
differences were noticed between Apc2+/+ and Apc2-/- intestines in absorptive (CK8) or secretory 
(CK5) lineages. (B) Aged matched Apc2+/+ and Apc2-/- intestines were stained for lysozyme (paneth 
cells) and alcian blue (goblet cells). Scale bar represents 100μm. There was no difference in either 
total number (C) (error bars represent standard deviation, p˃0.4, Mann-Whitney U-test, n=5) or 
position (D) (cell position {Y axis} vs percent chance positively labelled {X axis}, for graph description 
see methods, p˃0.25, Kolmogorov-Smirnov Z test, n≥4). 
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3.2.4 Apc2 deficiency does not affect apoptosis however it does cause an 
increase in the number of mitotic figures  
Apc2 has the proven ability to mediate Wnt signaling (Nakagawa et al., 1998; Van Es et al., 
1999). Furthermore, modification of intestinal Wnt signaling as a consequence of Apc 
deletion is known to result in substantial proliferative and apoptotic changes (Sansom et al., 
2004). Thus, intestinal proliferation and apoptosis was analysed in mice deficient for Apc2. 
H&E stained intestinal sections from all genotypes were used to quantify mitotic figures 
(Figure 3.5A) and apoptotic bodies (Figure 3.5B) (for description see methods 2.3.2). Mitotic 
and apoptotic index were defined as a percent of total crypt cells. There was a statistically 
significant increase in mitotic figures in Apc2 deficient intestines (Apc2+/+ 0.80±0.15 vs Apc2-
/- 1.61±0.18 percent of cells displaying mitotic figures, p≤0.05, Mann-Whitney U-test, n=5) 
whilst apoptosis remained unaltered between genotypes (Apc2+/+ 0.26±0.07 vs Apc2+/- 
0.31±0.11 vs Apc2-/- 0.28±0.15 percent of cells displaying apoptotic bodies, for all 
comparisons p˃0.2, Mann-Whitney U-test, n≥4). To confirm increases in mitotic index, mice 
were injected 2 hours before death with bromodeoxyuridine (BrdU). Cells entering S-phase 
incorporate BrdU which can be detected on intestinal sections using an anti-BrdU antibody 
(Figure 3.5C).  Quantitative analysis of BrdU positive cells per half crypt-villus (Figure 3.5D) 
demonstrated that Apc2-/- crypts displayed an increase in proliferation compared to Apc2+/+ 
and this increase was in a gene dose dependent manner (Apc2+/+ 5.29±0.29 vs Apc2-/+ 
6.90±0.66 vs Apc2-/- 8.91±1.41 positive BrdU cells per half crypt-villus, for both Apc2+/+ vs 
Apc2-/+ and Apc2+/+ vs Apc2-/- p≤0.05, Mann-Whitney U-test, n≥4).  Positional analysis of 
BrdU positive cells indicated dividing cells were still confined to the crypt region consistent 
with the location of the usual proliferative compartment. However, there was an increase in 
the likelihood of a cell being positively labelled across all crypt positions again in a gene dose 
dependent manner (Figure 3.5E). 
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Figure 3.5 Loss of Apc2 caused an increase in proliferative index. Sections of aged matched Apc2+/+, 
Apc2+/- and Apc2-/- intestines were stained with H&E and scored for epithelial incidence of mitotic 
figures and apoptotic fragments (see methods). (A) Quantitative analysis between Apc2+/+, Apc2+/- 
and Apc2-/- intestinal sections showed a statistical increase in mitotic index between Apc2+/+ and 
Apc2-/- (error bars represent standard deviation, asterisks mark p≤0.05, Mann-Whitney U-test, n=5). 
(B) Apoptosis was unaltered following Apc2 loss (error bars represent standard deviation, p˃0.2, 
Mann-Whitney U-test, n≥4).  (C) Aged matched cohorts from each genotype were injected 2h before 
death with BrdU then sections stained using an anti-BrdU antibody (scale bar represents 50μm). (D) 
Quantitative analysis between Apc2+/+, Apc2+/- and Apc2-/- sections revealed a statistical increase in 
BrdU positive cells (error bars represent standard deviation, asterisks mark p≤0.05, Mann-Whitney 
U-test, n≥4). (E) Positional analysis suggests an increase in mitosis across all cell positions along the 
crypt axis in a dose dependent manner. 
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3.2.5 Loss of Apc2 leads to an increase in intestinal epithelial migration along 
the crypt-villus axis  
In order to analyse the effects of Apc2 loss on epithelial cell migration a BrdU pulse chase 
experiment was carried out. Cohorts of Apc2+/+, Apc2+/- and Apc2-/- mice were injected with 
BrdU either 2 or 24 h before death (n≥4). BrdU is only bio-available for <2 h but will stay 
incorporated inside dividing cells effectively ‘tagging’ them, this allowed us to determine 
position of labelled cells following 24 h allowed migration and compare them to that of 2 h 
(Figure 3.6A). In order to quantify migratory ability of the epithelial cells in Apc2 deficient 
and Apc2+/+ intestine, positions of BrdU labelled cells (Figure 3.6B) were scored. Intestinal 
epithelial cells migrate further/faster up the crypt-villus axis in Apc2+/- and more so in Apc2-/- 
mice compared to Apc2+/+ mice, again indicating gene dose dependency. Plotting cumulative 
distribution represented graphically (Figure 3.6C) clearly demonstrated that Apc2 deficiency 
effects the normal distribution after 24 h of migration (Kolmogorov-Smirnov Z test p≤0.05 
between Apc2-/- and Apc2-/- intestines). 
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Figure 3.6 Loss of Apc2 led to an increase in cell migration along the crypt-villus axis. (A) Anti-BrdU 
stained intestinal tissue Apc2+/+ vs Apc2-/-,  2h and 24h after BrdU injection (B) Indicates cell position 
on crypt-villus axis vs percent chance BrdU positive, following 24h allowed  migration (Apc2+/+ , 
Apc2+/- and Apc2-/- ). Note that cells deficient in Apc2 migrate further up the crypt-villus axis in a dose 
dependent manner. (C) Cumulative frequency plot of BrdU positive cells again show differences in 
BrdU positive cell distribution following 24h allowed migration (asterisk marks p≤0.05, Kolmogorov-
Smirnov Z test, n≥4). 
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3.2.6 Apc2 loss leads to an increase in the number of crypt cells displaying 
nuclear localised β-catenin  
As β-catenin is a key mediator of Wnt signaling, involved with phenotypes associated with 
intestinal Apc loss and can be negatively regulated by both Apc proteins, β-catenin status 
was assessed in intestines deficient for Apc2.  Analysis of total levels of β-catenin mRNA 
expression using quantitative real-time PCR (qRT-PCR) revealed no global intestinal 
expression differences between any genotypes (Figure 3.7A, for all comparisons p˃0.2, 
Mann-Whitney U-test, n≥4).  Intestinal sections from Apc2+/+ and Apc2-/- mice were stained 
using an anti-β-catenin antibody to assess protein location (Figure 3.7B). β-catenin remained 
exclusively cytoplasmic or membrane associated in villus cells in Apc2-/- intestines. This 
contrasts to the situation observed in Apc deficient intestines (Sansom et al., 2004; Andreu 
et al., 2005), where cells display nuclear β-catenin regardless of crypt or villus position. 
However, a statistically significant increase in the number of cells possessing nuclear 
localised β-catenin did occur in the compartment towards the base of the crypt, in Apc2-/- 
crypts compared to Apc2+/+ (Apc2+/+ 2.32±0.47 and Apc2-/- 4.07±0.62 positive cells per crypt, 
p≤0.03, Mann-Whitney U-test, n≥4 , Figure 3.7C).  
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Figure 3.7 Increased nuclear translocation of the Wnt transduction mediator β-catenin resulting 
from loss of Apc2. (A) Quantitative RT-PCR revealed no difference in total expression levels of β-
catenin between genotypes (p˃0.2, Mann-Whitney U-test, n≥4, error bars represent SEM of Ct 
values). (B) Sections from Apc2+/+ and Apc2-/- intestines were stained with an anti- β-catenin 
antibody. β-catenin remained cytoplasmic/ membrane associated and indifferent from Apc2+/+ 
within the villus region, following Apc2 loss. However, within the crypt region, more cells displayed 
nuclear localisation of β-catenin (black arrowheads indicate nuclear localised β-catenin, scale bar 
represents 50μm). (C)  Quantitative analysis of cells displaying nuclear β-catenin per crypt revealed a 
statistical increase following Apc2 loss (error bars represent standard deviation, asterisk marks 
p≤0.01, Mann-Whitney U-test, n≥4). 
 
3.2.7 Apc2 regulates intestinal Wnt signaling 
To determine if Apc2 loss altered gene expression regulated by Wnt signaling within the 
intestinal epithelium, quantitative analysis of expression levels of a subset of Wnt target 
genes was performed. Total RNA from intestinal epithelial samples was extracted, subjected 
to reverse transcription and then compared using quantitative real-time PCR (qRT-PCR).  
Apc2-/- and Apc2+/- expression levels were directly compared to that of aged matched 
Apc2+/+ samples (Figure 3.8). Cyclin D1, Axin2, MIF and WIF1 displayed a statistical increase 
in expression in Apc2-/- compared to Apc2+/+ control epithelia whilst cMyc and CD44 also 
display a trend towards an increase, while Ephrin B2 and Ephrin B3 remained unaltered. 
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Figure 3.8 Apc2 loss activated Wnt target gene expression. Quantitative RT-PCR was used to 
compare expression levels of a panel of known Wnt target genes between Apc2+/+ (black bars), 
Apc2+/- (dark gray bars) and Apc2-/- (light gray bars) intestinal epithelial extracts.  Most genes showed 
a trend towards an increase in expression in a gene dose dependent manner excluding the Ephrins 
(asterisks mark the comparisons that were found to be significantly different from Apc2+/+, p≤0.05, 
Mann-Whitney U-test, n≥5, error bars represent SEM of Ct values). 
 
3.2.8 Apc2 plays a role in regulating intestinal stem cell populations 
Given Wnt signalling plays a fundamental role in intestinal stem cell regulation (for review 
see Reya & Clevers, 2005) and markers for ’stemness’ are increased following intestinal Apc 
loss (Jubb et al., 2006; Merlos-Suarez et al., 2011), analysis of the stem cell populations in 
intestines deficient for Apc2 was performed. Quantitative analysis examining the levels of 
known intestinal stem cell (ISC) markers; Ascl2, Lgr5 and Bmi1, was performed using qRT-
PCR (Figure 3.9A).  Expression levels of Ascl2 and Lgr5 was elevated in intestines deficient 
for Apc2 (statistically significant between Apc2-/- compared to Apc2+/+ samples, p≤0.05, 
Mann-Whitney U-test, n≥4). Conversely, Bmi1 expression was significantly decreased 
(between Apc2+/- compared to Apc2+/+, p≤0.05, Mann-Whitney U-test, n≥4).  In order to 
assess localisation of ISC populations following loss of Apc2, ‘in situ’ hybridisation analysis of 
Ascl2 and Olfm4 expression was carried out (performed by M. Young). Small intestinal 
sections from Apc2+/+ and Apc2-/- intestines were stained using anti-Ascl2 and anti-Olfm4 
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riboprobes (Figure 3.9B). Although an increase in staining intensity for both probes was 
apparent in Apc2-/- crypts compared to Apc2+/+ controls, labelled cells still resided in the 
usual stem cell compartment towards the crypt base. The increase in staining intensity could 
represent either a higher percentage of positive cells or a comparable ISC number with 
increased ISC marker expression.  
 
Figure 3.9 Apc2 loss modulates intestinal stem cell markers.  (A) Quantitative RT-PCR expression 
analysis revealed a significant up-regulation of the stem cell markers Ascl2 and Lgr5 in the small 
intestinal epithelium of Apc2-/- (light gray bars) compared to Apc2+/+ (black bars). Bmi1 was 
significantly down-regulated in Apc2+/- (dark gray bars) compared to Apc2+/+ (asterisks mark the pair-
wise comparisons that were found to be significantly different, p≤0.05, Mann-Whitney U-test, n≥4, 
error bars represent SEM of Ct values). (B) ‘In situ’ hybridisation analysis of Ascl2 and Olmf4 stem cell 
markers displayed an increase in staining intensity between Apc2-/- compared to Apc2+/+. However, 
positive cells resided in the usual stem cell region towards the base of the crypt (scale bar represents 
50μm). 
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3.2.9 Apc2 is dispensable for tumour suppression 
Alterations in intestinal proliferation, Wnt signalling and ISC populations have been 
implicated with the tumour suppressor function of Apc. Given these features are also 
perturbed in the Apc2-/- intestines, long term survival and intestinal tumour burden of Apc2-
/- was analysed. Cohorts of Apc2+/+ (n=14) and Apc2-/- (n=20) which displayed no signs of 
hydrocephalus or brain trauma (non-existent beyond 100days of age) were established and 
aged until signs of ill health or death (Figure 3.10A).  Survival analysis of the two cohorts 
demonstrated no significant differences between them (p=0.47 Log-Rank test, n≥14).  
 
 
Figure 3.10 Apc2 alone has a limited role in tumour suppression in the murine intestine.  (A)Cohorts 
of Apc2+/+ (black line) and Apc2-/- (light gray line) mice were aged and sacrificed upon signs of ill 
health (survival presented as Kaplan-meier). No significant differences in overall survival were 
observed (Log-rank test, p>0.4, Apc2+/+ n=14, Apc2-/- n=20). Asterisk indicates start of aging cohorts. 
No mice developed hydrocephalus beyond this point. (B) Macroscopic lesions were quantified in the 
small and large intestinal epithelium of Apc2+/+ and Apc2-/- animals at time of death. Data are 
presented as a box plot. Loss of Apc2 did not induce intestinal tumour formation. 
 
 
Notably, mice from both cohorts that were sacrificed due to ill health rarely displayed 
symptoms of intestinal tumorigenesis, such as pale feet or faecal blood. Most included 
symptoms such as piloerection, hunched posture, reduced movement and/or decreased 
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awareness which could be associated with general old age.  Macroscopic tumour scoring 
revealed intestinal tumours were extremely rare in both genotypes (Figure 3.10B). Rare 
macroscopically identified intestinal tumours were usually identified microscopically as 
lymphoma in both cohorts. It was not possible to provide a precise diagnosis for the cause 
of death in the majority of cases, however, occasional non-tissue specific sporadic tumours 
and Lymphoma occurred with equal frequency in both cohorts. This, taken together with no 
overall lifespan changes in Apc2-/- mice, suggests Apc2 alone is dispensable for tumour 
suppressor function. 
 
3.3 Discussion  
Whilst APC’s role as a tumour suppressor is undisputed, evidence implicating APC2 in 
tumourigenesis is mounting. APC2 has been shown to complement APC loss in human colon 
carcinoma cells (Nakagawa et al., 1998; Van Es et al., 1999). Further evidence includes 
epigenetic silencing, allelic imbalance, LOH and/or protein loss of APC2 extensively reported 
in various human cancer cell lines and primary tumours (Jarrett et al., 2001; Sobottka et al., 
2000; Yang et al., 2004; Wang et al., 1999; Nakagawa et al., 1999; Schuebel et al., 2007; 
Hsieh et al., 2007; Chan et al., 2008; Montgomery et al., 2008; Mokarram et al., 2009; Kumar 
et al., 2009).  Our own examination of human CRC samples revealed a reduction in APC2 
expression. However, it is important to note that our study, as is the case in most other 
studies, examined only advanced cancers, within which it is difficult to distinguish the 
importance and contribution of APC2 loss to tumour initiation / progression. As yet, it is 
unclear whether APC2 loss occurs as a passive event contributing little to tumourigenesis, or 
whether it possesses an initiating oncogenic potential or involvement through advancing 
tumour progression.  Further studies to help delineate APC2’s role in tumourigenesis would 
include expression levels correlated with cancer stage.  
Apc has been extensively analysed and studies suggest the majority of its functions lie with 
its ability to regulate Wnt signaling (Hanson et al., 2005; Nathke, 2005; Polakis, 2000). 
Although Apc2 shares this characteristic (Nakagawa et al., 1998; Van Es et al., 1999) its 
importance in mammalian intestinal homeostasis has never been addressed. Apc 
heterozygosity (Apcmin mouse) mimics, to some extent, human mutation where mice are 
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predisposed to intestinal tumours (Moser et al., 1990). Immediate intestinal loss of Apc 
achieved through Cre-lox technology causes lethality within a few days.  Small intestinal 
morphology is altered where villus cells display a ‘crypt like’ phenotype, parameters such as 
cell differentiation, division and migration are perturbed (Sansom et al., 2004; Andreu et al., 
2005) and stem cell populations increased (Jubb et al., 2006; Merlos-Suarez et al., 2011). In 
this chapter I wished to pursue two aims by utilizing a transgenic mouse harbouring an Apc2 
mutation; Foremost, to elucidate Apc2’s role in mammalian intestinal homeostasis focusing 
on above parameters usually altered following Apc loss and secondly to test if Apc2 loss can 
induce tumorigenesis.  
Mice homozygous for constitutive Apc2 mutation, did not die ‘in utero’ and were viable, in 
stark contrast to that observed with Apc homozygous mutation (Moser et al., 1995). This 
demonstrated that fully functional Apc2 containing β-catenin and axin sites is dispensable 
for mouse development. However, a proportion of our Apc2-/- mice did develop 
hydrocephalus (unpublished data). It has been long known that Apc2 is highly expressed in 
the central nervous system (Yamanaka et al., 2002) with highest levels detected during 
foetal brain development (Van Es et al., 1999). Other studies have demonstrated an 
essential role for Apc2 in both foetal chick (Shintani et al., 2009) and mouse brain (Shintani 
et al., 2012). However, these studies utilised models with complete Apc2 loss as opposed to 
a truncation mutation as used in our study. It would be interesting to test the relevance of 
each domain of the Apc2 protein in regards to brain development. Some strained or 
incomplete functional redundancies relating to β-catenin and axin binding may exist 
between Apc homolog’s in brain development, this could account for why only a proportion 
of our Apc2-/- mice developed hydrocephalus. Indeed, Apc is also highly expressed in the 
central nervous system during the embryonic period (Bhat et al., 1994) and deficiency can 
lead to neurological defects (Yokota et al., 2009; Ivaniutsin et al., 2009)  which correlate 
with defects noted in brain specific β-catenin mutations (Chenn and Walsh, 2003; Wrobel et 
al., 2007; Machon et al.,2003). The role Apc proteins play in brain development and if 
functional redundancies exist are currently being pursued in collaboration with others. As 
surviving Apc2-/- mice appear healthy, do not display altered brain morphology, changes in 
behaviour or altered lifespan, we assume minimal brain defects unlikely to alter intestinal 
homeostasis or pathology.  
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Following Apc2 loss, mice did not display alterations in either macroscopic intestinal 
morphology or microscopic crypt-villus architecture and appeared healthy. Composition/ 
position of terminally differentiated cell types remained unaltered as did levels of apoptosis. 
Also, Apc2 loss did not impede intestinal cell migration, surprisingly it was increased in Apc2-
/- mice (discussed in more detail later in discussion). These observations highlight major 
differences between the two Apc homologs in intestinal homeostasis. However, Apc2 loss 
did alter some attributes such as cell division and markers of intestinal stemness suggestive 
of an overlapping role in mediating Wnt signaling. 
Analysis of the small intestinal epithelia between genotypes revealed that Apc2 does play a 
role in Wnt signal transduction. Although villus cells still retained membrane bound/ 
cytoplasmic β-catenin, in contrast to that observed following Apc loss (Sansom et al., 2004; 
Andreu et al., 2005), there was an increase in crypt cells displaying nuclear β-catenin. A 
likely explanation for this may lie with differential affinities for β-catenin destruction 
between Apc homologs (Nakagawa et al., 1998). Whilst Apc loss leads to nuclear 
translocation of β-catenin in both crypt and villus epithelia, villus cells are less sensitive to 
Wnt compared to crypt cells and Apc2 loss may lead to an increase in free β-catenin only 
able to surpass a threshold viable for nuclear translocation within the crypt region. In order 
to further test Apc2’s effect in modulating Wnt signaling, examination of expression levels 
of known downstream gene targets of β-catenin/Wnt activation was carried out. Indeed, a 
subset of Wnt target genes was found to be up-regulated in Apc2 deficient epithelial cell 
extracts. Cyclin D1, Axin2, MIF and WIF1 all displayed a statistical increase in expression, 
along with cMyc and CD44 also displaying this trend. Interestingly, Ephrin B2 and Ephrin B3 
were found to avoid this up-regulation, differing from a pattern normally seen following Apc 
loss (Sansom et al., 2004), the significance of this difference is discussed later.  
Differences in Wnt gene expression could either indicate differential methods of Wnt 
repression between Apc homologs, for instance, Apc has been shown uniquely to directly 
block transcription of some Wnt target genes within the nucleus (Sierra et al., 2006) or that 
different levels of active β-catenin may activate particular Wnt target genes rather than 
homogenously activating the entire Wnt transcriptional program. Evidence towards the 
latter explanation include experiments that conclude that the location of Apc or Apc2 does 
not affect Wnt regulatory ability or rescue (Roberts et al., 2012) and different degrees of β-
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catenin accumulation, achieved either directly (Hirata et al., 2012) or through different 
severities of Apc mutation (Kielman et al., 2002), can induce different patterns of Wnt target 
gene expression. It is important to note that whilst different levels of active β-catenin 
achieved through either Apc or Apc2 loss is a reasonable explanation for differences in Wnt 
target gene expression, we cannot rule out other possibilities, some of which could include; 
increases in expression or sensitivity of Wnt receptors occurring through developmental 
compensation, more effective Wnt repression/repressors or even indirect influences of non-
epithelial tissue also deficient for Apc2. 
 
Loss of Apc2 led to an increase in cell division. This can be explained through increased 
expression of Wnt target genes, some of which are renowned for inducing division. Also, 
coupled with increased Wnt signaling is an intestinal ‘stemness’ signature. Wnt signaling is 
imperative for intestinal stem cell renewal (Fevr et al., 2007) whilst over-activated Wnt, 
through Apc deletion, leads to an increase in stem cell marker expression (Jubb et al., 2006; 
Merlos-Suarez et al., 2011). Apc2 loss demonstrated increased expression of intestinal stem 
cell markers in our study. It came as no surprise that Apc2 had the ability to alter stem cell 
dynamics as previous work on drosophila revealed an intracellular role for Apc2 in stem cell 
renewal (Yamashita et al., 2003), and stable expression of APC2 in a human colon 
adenocarcinoma cell line (HT29) substantially reduced expression of the intestinal stem cell 
marker Ascl2 (Jubb et al., 2006). 
 
Importantly, whilst Ascl2 and Lgr5 expression was increased in Apc2 deficient intestinal 
epithelia, Bmi1 was down-regulated. Whereas Lgr5 marks a crypt base columnar  stem cell 
population (Barker et al., 2007), Bmi1 is thought to label a distinct sub-population of 
intestinal stem cells at the +4 region (Sangiorgi & Capecchi, 2008), although controversy 
exists as to whether these are true distinct populations (Barker et al., 2012; Munoz et al., 
2012).  Recent experiments demonstrate interplay between these two sub-populations 
whereby Lgr5+ indicates a mitotically active population, which upon ablation or damage can 
be replaced by a normally quiescent Bmi1+ population (Tian et al., 2011; Yan et al., 2012). 
Only the Lgr5+ and not the Bmi1+ intestinal stem cell population are sensitive to Wnt 
perturbations (Yan et al., 2012) which may explain why increases are only noticed in Lgr5  
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expression in Apc2 deficient intestines. The noticed decrease in Bmi1 expression may 
specifically reflect a balance between Lgr5+ and Bmi1+ populations. In Apc2-/- intestines, cells 
positive for stem cell markers still resided in the usual crypt base position. Some studies 
suggest paneth cells constitute the important intestinal stem cell niche (Sato et al., 2011; 
Parry et al., 2013), whilst some argue they are dispensable for stem cell function (Kim et al., 
2012). Mislocalisation of paneth cell associated with intestinal Apc loss (Sansom et al., 2004; 
Andreu et al., 2005) could contribute to abnormal stem cell labelling outside the crypt base 
position. Although markers of intestinal stemness increase in Apc2-/- intestines, correct 
location could be attributed to correctly positioned paneth cells.   
 
Interestingly, although Apc2 loss possesses the ability to alter some attributes consistent 
with Apc loss, some parameters remained unaltered.  Small intestinal morphology was 
unaltered as was terminally differentiated cell composition/position. As mentioned 
previously, this highlights major differences between the two Apc homologs in intestinal 
homeostasis. Correct intestinal architecture and number/position of physiologically relevant  
cell types could explain why Apc2-/- mice remain healthy and display no intestinal pathology. 
Mechanistically these differences could be explained a number of ways. Foremost, 
differential affinities for β-catenin destruction between Apc and Apc2 may affect either 
different regions or cells with different required threshold levels needed for Wnt induction 
or these different ‘levels’ may induce differential Wnt target gene programs. Interestingly, 
Ephrin B2 and Ephrin B3 were altered following Apc loss (Sansom et al., 2004) but 
unchanged in Apc2-/- intestines. Disruption of these ephrins has profound effects on cell 
differentiation and sorting/positioning (Batlle et al., 2002) and are proposed as a mechanism 
for some phenotypes associated with intestinal Apc loss (Sansom et al., 2004). Differences in 
gene target expression between the Apc homologs, with the ephrins being one example, 
could account for phenotypic differences.  To further test this assumption microarray 
analysis could be employed to identify global gene expression differences between the Apc 
homologs.  
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One of the most interesting findings from this study was that Apc2 loss increased intestinal 
cell migration. This is in stark contrast to that observed following intestinal Apc loss where 
epithelial cell migration is abrogated (Sansom et al., 2004; Andreu et al., 2005). It is known 
that Apc has a prominent role in cell migration (reviewed in Etienne-Manneville, 2009) and 
this role can occur independent of β-catenin regulatory ability (Nelson et al., 2012). Loss of 
migratory ability may highlight a Wnt independent function unique to Apc. Although Apc2 
has been suggested to have a role in directional neuronal migration (Shintani et al., 2012), 
our study shows that directional intestinal migration is not impaired. Intestinal epithelial 
cells deficient for Apc2 still migrate directionally in the same manner as control tissues 
albeit faster.  An explanation as to why Apc2 deficient cells migrate faster may simply be as 
a consequence of altered cell density.  The intestinal epithelial cells consist of a polarised 
monolayer and more epithelial cells being ‘born’ through increased cell division, could lead 
to cells being forced further up the crypt-villus axis. Although intestinal cell migration can 
still occur independent of cell division (Kaur & Potten, 1986) other models have shown 
reduced intestinal proliferation correlates with reduced migration (Simmen et al., 2007).  
 
Upon aging mice from each genotype we can see that Apc2 loss does not induce intestinal 
tumour formation, or indeed tumour formation in any other tissue. This answers a very 
important question and suggests that Apc2 loss does not have initiating oncogenic potential. 
From these experiments we can hypothesise that the reduced APC2 expression noticed in 
human cancer is more than likely linked to tumour progression rather than initiation. As 
both Apc and Apc2 have the ability to alter intestinal Wnt signaling and homeostasis but 
only Apc loss has the potential to initiate tumour formation, it allows us to dissect out roles 
of Apc unique to tumour formation. Interestingly, increases in intestinal Wnt signalling, 
proliferation, and intestinal stem cell markers through Apc2 loss are not enough to disrupt 
intestinal physiology or induce tumour formation. However, this may just be a consequence 
of a weaker Wnt signal achieved with Apc2 loss compared to that of Apc. It is also known 
that Apc’s role in tumour suppression is multifunctional (reviewed by Aoki and Taketo, 
2007; Senda et al., 2007). Perhaps some of the non-canonical functions of Apc (Fodde et al., 
2001; Kaplan et al., 2001; Näthke, 2006; Prosperi et al., 2009; Qian et al., 2008; Harris & 
Nelson, 2010) may be unique to Apc and play a more substantial role than previously 
thought. 
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Migratory ability may underline an essential and important anti-tumour quality in intestinal 
epithelium only abrogated following Apc loss. Micro-adenomas in Apcmin mice which 
progress to adenomas, initiate from a lack of directed cell migration (Oshima et al., 1997). 
These adenomas have gained a second mutation such that both copies of Apc are 
compromised. Several studies have suggested an overall reduction in intestinal migration in 
Apcmin mice is a contributing factor to tumour formation (Mahmoud et al., 1997; Javid et al., 
2004). Interestingly, Apc2-/- intestinal epithelia which have retained migratory ability still 
maintain homeostasis although Wnt is perturbed and factors such as cell division are 
increased. This retained directional migration may substantially influence the lack of 
pathology noticed in Apc2-/- intestines.  
 
To conclude, the findings presented here suggest that Apc2 does have a role in intestinal 
homeostasis through mediation of Wnt signaling. Loss of Apc2 can induce transcription of 
some Wnt target genes in a subset of cells which, in turn, can lead to increases in cell 
division and/or markers of stemness. Alone, Apc2 loss is not enough to induce 
tumorigenesis. This study highlights important attributes of Apc loss, such as lack of 
migration, unique to tumour formation.   
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Chapter 4 
Investigating the effects of Apc2 loss in the context of 
intestinal Apc mutation 
 
4.1 Introduction 
In the previous chapter it was shown that murine Apc2 loss can partially modify intestinal 
Wnt signaling and alter the proliferative state of epithelial cells. However, although a 
number of human studies have linked APC2 loss with colorectal tumorigenesis (Schuebel et 
al., 2007; Hsieh et al., 2007; Chan et al., 2008; Mokarram et al., 2009; Kumar et al., 2009),  
Apc2 loss alone was insufficient to induce tumourigenesis. Perturbations of the Wnt 
signaling pathway occur in more than 90% of all human colorectal cancers (Giles et al., 2003) 
making it an attractive pathway for therapeutic intervention. Nevertheless, Wnt targeted 
therapies remain scarce and total understanding of the pathway remains incomplete. While 
both APC proteins share the ability to negatively regulate Wnt and both are highly 
evolutionally conserved (Van Es et al., 1999) only APC has been extensively studied in either 
humans and animal models of colorectal cancer (for review see Klaus & Brirchmeier, 2008). 
This in part may be due to the fact that APC2 was discovered relatively recently to APC and 
mutations in APC2 are seen less frequently in cancer.  Importantly, epigenetic silencing 
through promoter hypermethylation is now a highly accepted process of gene expression 
loss in cancer (reviewed in Herman and Baylin, 2003; Jones and Baylin, 2007) and APC2 
hypermethylation occurs remarkably frequently, being seen in 90-100% of human colorectal 
tumours (Chan et al., 2008; Mokarram et al., 2009; Kumar et al., 2009).  
Although murine Apc2 alone loss is insufficient to induce tumourigenesis it has the potential 
to alter some attributes consistent with Apc loss. The dual influence of Apc and Apc2 in 
intestinal Wnt signaling, proliferation and stemness suggest some functional redundancies  
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may exist between mammalian Apc proteins. In Drosophila, Apc proteins do display co-
operation in negative regulation of Wnt in a variety of tissues (McCartney et al., 1999; 
McCartney et al., 2006; Ahmed et al., 2002; Akong et al., 2002) and functional redundancies 
have been exposed through complementary rescue (Kunttas-Tatli et al., 2011; Roberts et al., 
2012). In human colorectal cell lines with reduced APC, transfection with APC2 can rescue β-
catenin destruction and reduce Wnt-responsive gene transcription (Van Es et al., 1999; 
Roberts et al., 2012). Together these experiments suggest that functional redundancies are 
present between Apc proteins and may be evolutionarily conserved. Thus, Apc and Apc2 
could potentially co-operate in intestinal Wnt signal transduction.  
In order to elucidate dual roles of the Apc proteins and deepen the understanding of this 
complex pathway in intestinal homeostasis and pathogenesis, transgenic mouse models 
were used to study concurrent intestinal loss of both Apc proteins. In this chapter I wished 
to pursue two aims; Foremost to expose any effects of additional Apc2 loss on immediate 
intestinal homozygous Apc loss, and secondly to delineate any role Apc2 may play in 
tumourigenesis in the context of a Wnt driven, Apc heterozygous tumour model. 
 
 
4.2 Results 
 
4.2.1 Induction of Villin-CreER Apcfl/fl mice causes Apc loss in the small intestinal 
epithelium 
 
To conditionally knockout Apc from the intestinal epithelia a Cre/loxP transgenesis system 
was employed.  The Apc allele used (Apcfl/fl) was engineered with two loxP sites flanking 
exon 14. If exposed to Cre recombinase, exon 14 is spliced out introducing a stop codon to  
the open reading frame resulting in expression of a truncated, loss of function protein 
(Shibata et al., 1997). The Villin-CreER transgenic mouse expresses Cre recombinase  
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conditionally and specifically in the intestinal epithelium following a tamoxifen induction 
regime (Colnot et al., 2004;  Marjou et al., 2005; Andreu et al., 2005). Villin-CreER Apcfl/fl mice 
were induced, intestinal sections collected and stained for Apc at different time points 
following tamoxifen induction. Fluorescent IHC using an antibody raised against the C-
terminus end of the Apc protein was used to assess protein status (Figure 4.1). Pre induction 
(Day 0), Apc was expressed at its highest levels in differentiated villus cells with a decrease 
in staining intensity toward the crypt and at lowest detectable levels in crypt cells at the 
crypt base. Apc was mostly cytoplasmic and membrane associated. However, by Day 3 post 
induction, Apc staining intensity was considerably decreased in most villus cells. It was 
mostly nuclear associated, some residual membrane bound Apc remained however minimal 
cytoplasmic staining was apparent. Interestingly, at this time point clumps of crypt cells also 
expressed nuclear Apc.  By Day 4, Apc staining was further reduced and by Day 5 staining 
was undetectable. Translocation and overall reduction of Apc by Day 3 is consistent with 
previous studies indicating a phenotypical onset 3 days following induction (Andreu et al., 
2005).  Progression of phenotype with time noted in these studies may correlate with 
increased reduction of Apc protein expression. 
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Figure 4.1 Induction of Villin-CreER Apcfl/fl mice caused a loss of Apc protein in the small intestines.  
Fluorescence IHC using an antibody specific for Apc showed mis-localisation then depletion of Apc 
protein over time.  At Day 0 Apc was cytoplasmic and/or membrane associated and expressed at its 
highest intensity in differentiated villus cells. By Day 3 Apc was partly depleted, expression was now 
mostly nuclear associated in the villus compartment with occasional clumps of cells displaying 
expression within the crypt. Through days 4 and 5 it became completely depleted and undetectable 
in all cells (scale bar represents 50μm). Bottom higher magnification of villus (L=lumen, scale bar 
represents 10μm) and crypt (scale bar represents 50μm) cells. 
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4.2.2 Apc2 deficiency delays onset of Villin-CreER Apcfl/fl morbidity 
In order to elucidate any functional redundancies or interactions that may exist between 
Apc and Apc2 in intestinal homeostasis, Villin-CreER Apcfl/fl mice were crossed with Apc2-/- 
mice. Cohorts were induced (see methods for regime) and inspected every 6 hours for signs 
of intestinal morbidity. Whilst un-induced animals and induced Villin-CreER- animals 
displayed no signs of pathology over the study period (data not shown), all Villin-CreER Apcfl/fl 
(referred to as Apcfl hereafter) mice were culled due to signs of ill health with a median 
survival of 4.5 Days Post induction.  Surprisingly, although Villin-CreER Apcfl/fl Apc2-/- (referred 
to as DKO hereafter) mice also developed signs of ill health, the addition of the Apc2-/- 
mutation delayed the onset of morbidity (median survival post induction, Apcfl=4.5 Days 
{n=8} vs DKO=6 Days {n=5}) (Figure 4.2). Overall analysis of survival probability revealed a 
statistical difference between the two cohorts (Log-rank test, p=0.002). 
 
 
 
Figure 4.2 Addition of an Apc2-/- mutation on a Villin-CreER Apcfl/fl background extended short term 
lifespan. Cohorts of Villin-CreER Apcfl/fl (black line) and Villin-CreER Apcfl/fl Apc2-/- (dotted gray line) mice 
were aged out and sacrificed upon signs of ill health (survival presented as Kaplan-meier). A 
significant difference between overall survival was observed between genotypes (Log-rank test, 
p=0.002, Villin-CreER Apcfl/fl n=8, Villin-CreER Apcfl/fl Apc2-/- n=5). 
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4.2.3 Additional loss of Apc2 in DKO mice delays/attenuates the ‘crypt 
progenitor’ phenotype associated with immediate Apc loss 
The ‘crypt progenitor’ phenotype associated with immediate intestinal Apc loss has been 
extensively studied previously (Sansom et al., 2004; Andreu et al., 2005). Lack of 
differentiated intestinal cell types leading to inept water and nutrient uptake, along with 
increased intestinal ‘bulk’, either directly compressing/compromising other organs/systems 
or through indirect means are plausible explanations for health deterioration in mice 
following Apc loss.  To expose any effects of Apc2 loss on the Apcfl crypt progenitor state, 
cohorts of each genotype were culled at 24h time intervals following induction and 
intestinal sections stained with H&E (Figure 4.3). The ‘Crypt like’ region was defined by cell  
 
 
Figure 4.3 Loss of Apc led to a ‘crypt progenitor’ phenotype, which microscopically appeared delayed 
and attenuated in DKO.  Intestinal sections from each genotype were taken at 24 hour intervals 
following tamoxifen induction and stained with H&E. Both Day 1 and Day 2 appeared phenotypically 
indifferent from un-induced mice (Day 0) in both genotypes. Crypt expansion was noticed in both 
genotypes through Days 3-5 however, somewhat delayed and attenuated in DKO intestines. Apcfl 
(Villin-CreER Apcfl/fl), DKO (Villin-CreER Apcfl/fl Apc2-/-), scale bar represents 50μm.  
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morphology. In Apcfl intestines, consistent with previous studies (Andreu et al., 2005) both 
Day 1 & 2 were phenotypically indifferent from Day 0 (un-induced), this was also the case in 
DKO intestines. Both genotypes then displayed expansion of the ‘crypt like’ region through 
days 3 to 5 with an attenuated appearance in DKO intestines. Quantitative analysis of both 
crypt and total crypt-villus size was carried out and displayed schematically and graphically 
(Figure 4.4). At Day 3 there was an attenuation of crypt expansion in DKO mice compared to 
Apcfl intestines (27.40±1.41 vs 34.58±1.50 cell height per half crypt respectively {23.6 
average crypt size in un-induced mice}, p≤0.05, Mann-Whitney U-test, n=4). There were no 
significant differences at Day 4.  However, by Day 5 both crypt size (DKO 101.88±6.91 vs 
Apcfl 141.40±7.41 cell height per half crypt-villus structure {23.6 average crypt size in un-
induced mice}, p≤0.05, Mann-Whitney U-test, n=4) and total crypt-villus size (DKO 
141.40±7.41 vs Apcfl 101.88±6.91 cell height per half crypt-villus structure {98.6 average 
crypt-villus size in un-induced mice}, p≤0.05, Mann-Whitney U-test, n=4) were significantly 
reduced in DKO compared to Apcfl intestines. Taken together these results suggest that 
additional Apc2 loss attenuates ‘crypt progenitor’ zone expansion. 
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Figure 4.4 In DKO mice the Addition of an Apc2-/- mutation delayed and attenuated the crypt 
progenitor phenotype noticed in Apcfl intestines. Total crypt-villus length and crypt length were 
scored for each genotype at each time point (n=4 for each comparison). (A) Diagram of crypt size 
and total crypt-villus length for Apcfl over time. (B) Diagram demonstrating differences between 
DKO (right panels) and Apcfl (left panels) over time. Graphical representation of (C) total crypt-villus 
length and (D) crypt length. Note delay in increase of crypt size at Day 3 in DKO intestines, and also 
statistical reduction of size in both crypt and total crypt-villus length in DKO intestines at Day 5. 
Blue= total crypt-villus length in Apcfl, light blue= total crypt-villus length in DKO, red= crypt length in 
Apcfl, yellow= crypt length in DKO. Asterisks mark statistically significant pair wise comparison, 
Mann-Whitney U-test, p≤0.05.  
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4.2.4 Apc2 deficiency alters Wnt pathway changes associated with immediate 
intestinal Apc loss 
It is proposed that the majority of phenotypes associated with intestinal loss of Apc arise 
due to compromised β-catenin degradation, nuclear translocation and subsequent over 
activation of Wnt target gene expression (Sansom et al., 2004; Andreu et al., 2005).  Apc2 
shares this ability to degrade β-catenin (Nakagawa et al., 1998; Van Es et al., 1999) and its 
loss also activates certain Wnt targets within the intestines (Chapter 3). In order to 
investigate  how additional Apc2 loss influences Wnt signaling in Apcfl  intestines, 
quantitative analysis of Wnt target/repressor gene expression was performed on intestinal 
samples from DKO animals and compared directly against levels in Apcfl intestines at 
different time points (n=4). As no phenotype is observed in either genotype at Day 1 or 2 
further analyses in this chapter is only carried out on Days 0, 3, 4, & 5.  Total RNA was 
extracted from epithelial enriched samples of the small intestine and subjected to reverse 
transcription. Quantitative real-time PCR (qRT-PCR) was used to compare expression levels 
of a subset of Wnt associated genes between genotypes at different time points (Figure 
4.5).  
 
The intestinal phenotype of un-induced Apcfl mice was identical to that of Wt, consequently 
comparisons of gene expression levels on Day 0 effectively compare Apc2-/- and Apc2+/+ 
genotypes (see chapter 3). DKO intestines did not display any significant increases in Wnt 
target gene expression in comparison to Apcfl at any post induction time point. On Day 3, 
qRT-PCR revealed reduced levels of Wnt target gene expression in DKO compared to Apcfl 
intestines for all analysed targets (statistically significant for cMyc, Ephrin B2 and Ephrin B3, 
three out of four targets analysed {3/4}). On Day 4 fewer Wnt targets were significantly 
reduced in DKO compared to Apcfl intestines (Cyclin D1 and CD44 {2/6}). By Day 5 there was 
no significant difference between genotypes in any of the Wnt target genes analysed {0/4}. 
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Figure 4.5 Addition of an Apc2-/- mutation altered Wnt target/Wnt repressor gene expression in 
Apcfl intestine. Quantitative RT-PCR was used to directly compare Wnt gene expression levels of 
DKO vs Apcfl intestinal cell extracts at different time points. (A) All Wnt target genes analysed were 
expressed at lower levels in DKO intestine on Day 3, most were expressed at lower levels on Day 4 
but by Day 5 there were no significant differences in Wnt target gene expression. (B) The Wnt 
repressor Groucho was significantly increased in DKO intestines prior to induction (Day 0). On Day 3 
and Day 4 although Wnt repressor Dickkopf 2 shows a trend toward an increase in expression there 
were no significant differences. By Day 5 both Groucho & Dickkopf 2 displayed significantly increased 
expression in DKO intestines (asterisks mark the comparisons that were found to be significantly 
different in DKO intestines, p≤0.05, Mann-Whitney U-test, n≥4, error bars represent SEM of Ct 
values). 
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Interestingly, the Wnt repressor Groucho was significantly increased in DKO intestines pre 
induction (Day 0 {Apc2-/- vs Apc2+/+}). No significant differences between genotypes were 
noticed in Days 3 or 4 in either Wnt repressor. However, by Day 5 both Groucho and 
Dickkopf 2 displayed significant increases in expression levels in DKO intestines compared to 
Apcfl (for all significantly different comparisons p≤0.05, Mann-Whitney U-test, n=4). 
Together these results suggest that additional Apc2 deficiency initially inhibits Wnt gene 
activation, this inhibition becomes less apparent to nonexistent by Day 5 and Wnt 
repressors may play some role in this inhibition. 
 
4.2.5 Additional Apc2 deficiency alters proliferative potential in Apcfl intestines 
As intestinal cell division is closely coupled with Wnt signalling, BrdU labelling was used to 
compare composition of dividing cells between genotypes at days 3 & 4. Intestinal Apc loss 
has previous been shown to lead to substantial increases in cell division and proliferative 
compartment (Sansom et al., 2004; Andreu et al., 2005). To assess additional effects of Apc2 
on Apcfl intestinal cell division, Apcfl and DKO mice were injected with BrdU 2 hours before 
death on Day 3 and Day 4. Cells incorporating BrdU were detected on intestinal sections 
using anti-BrdU antibody and quantitative analysis performed between genotypes (Figure 
4.6).  Surprisingly, at Day 3 whilst the ‘crypt Progenitor’ phenotype was attenuated in DKO 
intestines, BrdU distribution (proliferative compartment) and total number of BrdU positive 
cells were comparable between genotypes. On Day 4 there was a significant increase in the 
number of BrdU positive cells in DKO intestines (DKO 53.33±0.70 vs Apcfl 35.90±0.17 BrdU+ 
cells per half crypt-villus structure p≤0.05, Mann-Whitney U-test, n=4). Although ‘crypt 
progenitor’ phenotype/crypt sizes were now comparable at Day 4 between genotypes, the 
proliferative compartment was expanded in DKO intestines. Distribution of BrdU positive 
cells was significantly different (Kolmogorov-Smirnov Z test, p≤0.05, n=4). In DKO mice on 
both Day 3 & Day 4 villus epithelial cells were capable of incorporating BrdU outside of the 
‘crypt’ region. 
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Figure 4.6 Addition of an Apc2-/- mutation increased the proliferative compartment of Apcfl 
intestine. Cohorts of mice from each genotype were injected with BrdU 2h before death. Intestinal 
sections from (A) Day 3 and (B) Day 4 where stained with an anti-BrdU antibody and compared next 
to corresponding H&E’s. Villus cells outside the ‘crypt’ region had the potential to incorporate BrdU 
in DKO intestines at both time points (black line represents average crypt boundary assessed from 
H&E sections. Black arrowheads = BrdU positive cells outside ‘crypt’ region, scale bar represents 
50μm. Positional analysis of BrdU positive cells was carried out at (C) Day 3 and (D) Day 4 (Black line 
represents average crypt boundary, see methods for graph description). Whilst at Day 3 there were 
no obvious differences in distribution, at Day 4 the proliferative compartment is expanded. A 
cumulative frequency plot of BrdU positive cells on (E)  Day 3 and (F) Day 4 demonstrated a 
significant difference in distribution on Day 4 (asterisk marks p≤0.05, Kolmogorov-Smirnov Z test, 
n=4).  Total BrdU remained consistent between genotypes on (G) Day 3 but statistically increased on 
(H) Day 4 (error bars represent standard deviation, asterisks mark p≤0.05, Mann-Whitney U-test, 
n=4). 
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4.2.6 Additional Apc2 loss alters the fate of BrdU labelled cells in Apcfl 
intestines 
Previous studies have shown intestinal Apc loss abrogates epithelial cell migration (Sansom 
et al., 2004; Andreu et al., 2005).  Experiments from the previous chapter demonstrate that 
Apc2 loss can effectively increase the rate of epithelial cell migration (Chapter 3).  In order 
to analyse the effects of additional Apc2 loss on epithelial cell migration and fate in Apcfl 
intestines a BrdU pulse chase experiment was carried out and compared between 
genotypes. Cohorts of Apcfl and DKO mice were injected with BrdU on Day 4 (n=8). Half of 
each genotype where culled after 2h (n=4) and the remainders at 24h (n=4). BrdU is only 
bio-available for <2 h but will stay incorporated inside positively labelled cells effectively 
‘tagging’ them.  This allows us to determine the fate of these cells after 24 hours (Figure 
4.7). In contrast to previous studies (Sansom et al., 2004; Andreu et al., 2005), scoring of 
BrdU positive cells in Apc deficient intestines (Figure 4.2.7B,D) did reveal statistical 
differences in distribution following 24 hours (Kolmogorov-Smirnov Z test, p≤0.05, n=4). This 
difference however was negligible compared to that observed in Wt intestines (Figure 3.6). 
There were a comparable number of BrdU positive cells in Apcfl intestines after 24 hours 
(Figure 4.7F).  Conversely, in DKO intestine although no differences were observed in BrdU 
distribution after 24 hours (Figure 4.7C,E), there were significantly less BrdU positive cells 
(2h 53.33±0.46 vs 24h 31.90±0.37 BrdU+ cells per half crypt-villus structure p≤0.05, Mann-
Whitney U-test, n=4).  This decrease in number of BrdU cells after 24h is indicative of 
increased cell death. 
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Figure 4.7 Altered fate of BrdU labelled cells in DKO intestines following 24 hour migration. Apcfl and 
DKO mice were injected with BrdU on Day 4, half of each group were culled at 2h and the remainder 
at 24h. (A) Anti-BrdU stained intestinal tissue from each group (scale bar represents 50μm). 
Positional analysis of BrdU positive cells 2h vs 24h for both (B) Apcfl and (C) DKO intestines and  
cumulative frequency plots  (D)  and (E) respectively,  demonstrated a difference in position of BrdU 
positive cells following 24 allowed migration in Apcfl cells but not in DKO intestines (asterisk marks 
p≤0.05, Kolmogorov-Smirnov Z test, n=4). (F) Quantitative analysis of total numbers of BrdU positive 
cells showed a comparable numbers of labelled cells in Apcfl intestines after 24h however in DKO 
intestines there was a statistical reduction indicating loss of some of the BrdU positive cells following 
24h (error bars represent standard deviation, asterisks mark p≤0.05, Mann-Whitney U-test, n=4). 
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4.2.7 Additional Apc2 loss increases the mitotic and apoptotic indices in Apcfl 
intestines 
 
H&E stained intestinal sections from each time point were used to quantify and compare 
mitotic figures (mitosis) between genotypes (Figure 4.8A). Both genotypes displayed 
increases in levels of mitosis with time. A statistical difference in indices of mitotic figures 
was observed between genotypes on Day 0, this difference is consistent with results from 
chapter 3 where Apc2 deficiency alone can increase cell division (Apcfl 0.87±0.21 vs DKO 
1.59±0.21 percent of cells displaying mitotic figures, p≤0.05, Mann-Whitney U-test, n=4). 
Day 4 also displayed a statistically significant increase in levels of mitosis in DKO intestines 
(Apcfl 1.74±0.46 vs DKO 260±0.20 percent of cells displaying mitotic figures, p≤0.05, Mann-
Whitney U-test, n=4).  Days 3 & 5 displayed no statistical difference in levels of mitosis 
between genotypes. 
  
 
 
Figure 4.8 DKO mice displayed an increase in both mitosis and apoptosis at various time points 
compared to Apcfl intestines. H&E stained intestinal sections from each study group were scored for 
(A) mitotic indices and (B) apoptotic fragments.  Quantitative analysis between genotypes revealed 
statistical differences in both mitosis and apoptosis at certain time points (error bars represent 
standard deviation, asterisks mark p≤0.05, Mann-Whitney U-test, n=4). 
 
Previous studies have shown an increase in levels of apoptosis following intestinal Apc loss 
(Sansom et al., 2004; Andreu et al., 2005) whilst Apc2 loss results in no apoptotic change 
(Chapter 3). H&E stained intestinal sections from each time point were used to quantify and 
compare apoptotic bodies (apoptosis) between Apc and DKO intestine (Figure 4.8B).  Both 
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genotypes displayed increases in levels of apoptosis with time.  At day 0 there are were no 
statistically significant differences in levels of apoptosis between genotypes. However, 
statistically significant increases were observed across all other time points in DKO 
intestines compared to Apcfl (Day 3= Apcfl 1.44±0.23 vs DKO 2.80±0.68, Day 4= Apcfl 
2.30±0.41 vs DKO 3.40±0.38, Day 5= Apcfl 2.77±0.25 vs DKO 3.54±0.37, percent of cells 
displaying Apoptotic bodies, p≤0.05, Mann-Whitney U-test, n=4). 
 
4.2.8 Additional Apc2 loss attenuates paneth cell disruption in Apcfl intestines 
 
Apc deficient intestines displayed perturbed differentiation with disruptions in paneth cell 
differentiation and position (Sansom et al., 2004; Andreu et al., 2005). In order to analyse 
the effects of additional Apc2 loss on paneth cells within Apcfl intestines, sections from Apc 
and DKO mice from different time points were stained with lysozyme (Figure 4.9A). 
Quantification of paneth cell number per half crypt revealed increases in paneth cell 
number in both genotypes over time (Figure 4.9B). There were no significance differences 
between genotypes at any time point. To evaluate paneth cell composition in comparison to 
total cell number, paneth cell counts were normalized against crypt-villus structure size 
(Figure 4.9C). This would give a relative number of differentiated paneth cells independent 
of varying degrees of structure expansion. On Day 5 there were statistically more paneth 
cells in comparison to total cell number in DKO intestines compared to Apcfl (DKO 9.20±1.82 
vs Apcfl 5.62±0.83 comparative paneth cell number, p≤0.05, Mann-Whitney U-test, n=4). 
Position analysis was performed (Figure 4.9D) also represented as cumulative distribution 
(Figure 4.9E). On Day 3, additional Apc2 loss rescued paneth cell mis-positioning in Apcfl 
intestines. On Day 4 the mis-positioning of paneth cells was attenuated. By Day 5 there 
were no significant differences (for statistical comparisons see Figure 4.9E). 
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Figure 4.9 Attenuated paneth cell disruption in DKO intestines. (A) Intestinal sections from each 
genotype at the different time points were stained with lysozyme (scale bar represents 50μm). 
Quantitative analysis of paneth cell number per half crypt (B) demonstrated an increase in Paneth 
cell number from Day 3 through to Day 5 in both genotype but insignificantly different between 
genotypes.  As each genotype displays different degrees of crypt-villus expansion, paneth cell 
number was normalized against structure size thus giving a value of paneth cells comparable to total 
cell number. (C)There was a statistical difference in comparative paneth cell number between 
genotypes at Day 5 (error bars represent standard deviation, asterisks mark p≤0.05, Mann-Whitney 
U-test, n=4).  (D) Paneth cell position was plotted between genotypes at each time points (black line 
indicates average crypt boundary, blue=Apcfl, red=DKO) (E) also represented as cumulative 
frequency plots.  In DKO intestines the Addition of an Apc2-/- mutation delayed paneth cell 
displacement noticed in Apcfl intestine (asterisks mark p≤0.05, Kolmogorov-Smirnov Z test, n=4). 
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4.2.9 Additional Apc2 loss rescues goblet cell depletion in Apcfl intestines 
 
Previous studies have shown loss of intestinal Apc leads to depletion of goblet cells (Sansom 
et al., 2004; Andreu et al., 2005). In order to analyse the effects of additional Apc2 loss on 
goblet cells within Apcfl intestines, sections from Apc and DKO mice from different time 
points were stained with alcien blue (Figure 4.10A). Quantification of goblet cell number per 
half crypt (Figure 4.10B) revealed an initial increase in goblet cell number in both genotypes. 
By Day 5 there was a vast loss of goblet cells in Apcfl intestines, this loss was rescued in DKO 
mice (DKO 14.18±0.80 vs Apcfl 7.23±2.17  goblet cells per half crypt, p≤0.05, Mann-Whitney 
U-test, n=4). To evaluate goblet cell composition in comparison to total cell number, goblet 
cell counts were normalized against crypt-villus structure size (Figure 4.10C). This would give 
a relative number of differentiated goblet cells independent of varying degrees of structure 
expansion. On Day 5 there were statistically more goblet cells in comparison to total cell 
number in DKO intestines compared to Apcfl (DKO 12.65±0.71 vs Apcfl 5.01±1.88 
comparative goblet cell number, p≤0.05, Mann-Whitney U-test, n=4). Position analysis was 
performed (Figure 4.10D) also represented as cumulative distribution (Figure 4.10E). Goblet 
cell distribution disruption was apparent by Day 4 however, there was no statistical 
difference between genotypes. By Day 5 there was an attenuation of goblet distribution 
disruption in DKO intestines (for statistical comparisons see Figure 4.10E). 
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Figure 4.10 Attenuated goblet cell disruption in DKO intestines. (A) Intestinal sections from each 
genotype at the different time points were stained with alcien blue (scale bar represents 50μm). 
Quantitative analysis of goblet cell number per half crypt (B) demonstrated an increase in number 
from Day 0 to Day 4 comparable in both genotypes. However, there was substantial loss of goblet 
cells in Apcfl intestines at Day 5 significantly different from DKO intestines (error bars represent 
standard deviation, asterisks mark p≤0.05, Mann-Whitney U-test, n=4).  As each genotype displays 
different degrees of crypt-villus expansion, goblet cell number was normalized against structure size 
thus giving a value of goblet cells comparable to total cell number (C). There was a statistical 
difference in comparative goblet cell number between genotypes at Day 5 (error bars represent 
standard deviation, asterisks mark p≤0.05, Mann-Whitney U-test, n=4).  (D) Goblet cell position was 
plotted between genotypes at each time points (black line indicates average crypt boundary, 
blue=Apcfl, red=DKO) (E) also represented as cumulative frequency plots.  In DKO intestines the 
Addition of an Apc2-/- mutation attenuated goblet cell displacement noticed in Apcfl intestine on Day 
5 (asterisks mark p≤0.05, Kolmogorov-Smirnov Z test, n=4). 
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4.2.10 Additional Apc2 deficiency reduces expansion of the stem cell 
population in Apcfl intestines  
 
Intestinal stem cells contribute to the normal repopulation of intestinal epithelium and are 
critically reliant on Wnt signaling (for review see Reya & Clevers, 2005). It has been reported 
previously that markers for intestinal ‘stemness’ increase following Apc loss (Jubb et al., 
2006; Merlos-Suarez et al., 2011). As crypt expansion is more prominent in Apcfl intestine 
yet differentiated cell types were sparser in comparison to DKO, ISC composition was 
compared between genotypes. Day 4 was chosen as a good time point for comparison as 
crypt sizes were comparable.  In order to compare state of ISC populations, ‘in situ’ 
hybridisation analysis of Ascl2 and Olfm4 expression was carried out (performed by M. 
Young). Small intestinal sections from Day 0 (control), Apcfl and DKO intestines at Day 4 
were stained using anti-Ascl2 and anti-Olfm4 riboprobes (Figure 4.11A). In control intestines 
both markers were expressed at the crypt base, consistent with the suspected stem cell 
compartment. Expansion of the stem cell compartment was evident in both genotypes 
following induction however, expression was sparse and intensity considerably reduced in 
DKO compared to Apcfl intestines, consistent with a reduction in stem cell population. 
 
qRT-PCR was used to compare expression levels of ISC markers Ascl2 and Lgr5 between 
control (Day 0), Apcfl and DKO (both Day 4) intestinal RNA samples (Figure 4.11B).  
Expression levels of Ascl2 and Lgr5 were significantly elevated in both Apcfl and DKO 
compared to control intestines (Mann-Whitney U-test, p≤0.05, n=4), indicative of a stem cell 
expansion.  However, Ascl2 expression levels were significantly reduced in DKO compared to 
Apcfl intestines (Mann-Whitney U-test, p≤0.05, n=4). Lgr5 also displayed a trend toward 
reduced expression in DKO intestines however, statistical significance was not met.   
Reduced expression levels of ISC markers coupled with reduced intensity of ‘in situ’ staining 
indicates an attenuation of ISC expansion in DKO mice compared to Apcfl. Taken together, 
these results suggest whilst Apc loss permits a suitable environment for ISC expansion, 
additional loss of Apc2 reduces this capacity.  
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Figure 4.11 Additional Apc2 loss attenuated expansion of the small intestinal stem cell compartment 
seen in Apcfl intestines at Day 4. (A) ‘In situ’ hybridisation analysis of Ascl2 and Olfm4 expression 
revealed a substantial expansion of the stem cell compartment in the intestinal epithelium of Apcfl 
(Day 4) mice compared to control animals (Day 0). Whilst expansion of a ‘crypt progenitor’ cell type 
was observed in the small intestine of DKO mice, expression levels of  both Ascl2 and Olfm4, 
appeared to be considerably reduced compared to that of Apcfl  intestines (Scale bars represent 50 
μm). (B) Quantitative RT-PCR expression analysis revealed a significant up-regulation of intestinal 
stem cell markers Ascl2 and Lgr5 in Apcfl (blue bars) and DKO (red bars) intestines compared to 
control (white bars) at Day 4. Expression levels of Ascl2, but not Lgr5 were found to be significantly 
reduced in the small intestine of DKO mice compared to that of Apcfl intestine(error bars represent 
standard deviation, asterisks mark pair wise comparison p≤0.05, Mann-Whitney U-test, n=4, error 
bars represent SEM of Ct values). 
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4.2.11 Apc2 deficiency does not alter survival or tumourigenesis in the context 
of a Wnt driven heterozygous Apc tumour model 
 
Heterozygous inactivation of Apc is a well-established protocol for the induction of Wnt-
driven tumourigenesis in the gastrointestinal tract of mice. Spontaneous mutation of the 
normal residing allele of Apc results in the development of aberrant crypt foci, which 
inevitably progress to adenomas. Additional Apc2 mutation has the ability to alter some 
attributes of immediate intestinal homozygous Apc loss, deemed significant for tumour 
formation such as stem cell control and cell death.  In order to examine the effects of Apc2 
deficiency on the survival of mice with heterozygous inactivation of Apc, previously 
established cohorts of mice expressing Ah-Cre recombinase and a targeted Apc allele 
carrying loxP sites (Sansom et al., 2004) were crossed with Apc2-/- mice to obtain cohorts of 
Ah-Cre+ Apc+/fl Apc2+/+ (ApcHET) and Ah-Cre+ Apc+/fl Apc2-/- (ApcHET Apc2-/-) mice. Heterozygous 
inactivation of Apc was achieved through induction with 3 intraperitoneal injections of 80 
mg/kg β-naphthoflavone over 24 hours in both cohorts. Mice were aged and regularly 
inspected for signs of intestinal tumourigenesis. Upon signs of ill health, due to extensive 
tumour burden, mice were sacrificed (initiated by Dr. P. Shaw). Whilst very few un-induced 
or induced Ah-Cre+ Apc+/+ Apc2+/+ mice displayed signs of ill health within the time frame of 
the experiment, both ApcHET and ApcHET Apc2-/- mice started developing signs of intestinal 
neoplasia, becoming ill as early as 120 days post induction. Analysis of the overall survival 
probability revealed no statistically significant difference between the two experimental 
cohorts (Figure 4.12A, median survival 243 and 212 days for ApcHET and ApcHET Apc2-/- mice 
respectively, Log-Rank test p=0.65, n≥16). 
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Figure 4.12 The Addition of an Apc2 mutation did not alter tumorigenesis in Apc heterozygous mice.  
(A)Cohorts of ApcHET (black line) and ApcHET Apc2-/- (gray dotted line) mice were aged out and 
sacrificed upon signs of ill health (survival presented as Kaplan-meier). No significant differences in 
overall survival were observed (Log-rank test, p=0.65, ApcHET n=18, ApcHET Apc2-/- n=16). Tumour 
burden was analysed in the intestinal epithelium of ApcHET and ApcHET Apc2-/- animals at the time of 
death. There were no statistical differences in (B) total tumour number or split down into (C) small 
or (D) large intestinal tumour counts in ApcHET and ApcHET Apc2-/- animals. Data are presented as a 
box plot (p˃0.05, Mann-Whitney U-test, n≥15). 
 
In order to analyse whether additional Apc2 deficiency affected tumourigenesis in mice 
heterozygous for Apc mutation, the alimentary tract of ApcHET and ApcHET Apc2-/- animals 
was dissected at the time of sacrifice and analysed for tumour burden. Statistical analysis 
revealed no significant difference in total, small or large intestine between the two cohorts 
(Figure 4.12B,C,D). Microscopic examination of H&E stained intestinal sections from each 
genotype identified tumours as adenomas. No differences in tumour morphology, 
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progression or grade between genotypes were observed.  Together with the lack of 
difference in survival, these observations indicated that Apc2 loss neither attenuated nor 
accelerated intestinal tumourigenesis in ApcHET mice. 
 
 
4.3 Discussion  
The effects of Apc2 loss on intestinal homeostasis were analysed in the previous chapter. 
Despite evidence linking APC2 loss with human tumourigenesis, murine Apc2 loss alone 
failed to initiate tumours. However, it did possess the potential to alter some attributes 
consistent with Apc loss.  Previous studies in Drosophila have suggested functional 
redundancies exist between the two Apc homologs (McCartney et al., 1999; McCartney et 
al., 2006; Ahmed et al., 2002; Akong et al., 2002; Kunttas-Tatli et al., 2011; Roberts et al., 
2012). This, along with the fact that induced APC2 over-expression can rescue Wnt 
activation achieved through reduced APC expression in human colorectal cancer cell lines 
(Van Es et al., 1999; Roberts et al., 2012) suggests these proteins may have overlapping 
roles in mammalian intestines.  In this chapter I utilised mouse transgenics to concurrently 
delete both Apc proteins from the intestinal epithelium and pursue two aims; foremost to 
expose any effects of additional Apc2 loss on immediate homozygous Apc loss and secondly 
to delineate any role Apc2 may play in tumorigenesis in the context of an Apc heterozygous 
tumour model. Data presented in this chapter revealed that additional Apc2 loss in the 
context of intestinal homozygous Apc deletion initially attenuates Wnt over-activation and 
associated phenotypes. Crypt progenitor expansion was reduced although cells ‘marginal’ to 
the crypt progenitor displayed increased proliferative capacity. Increases in cell death and 
attenuated expansion of the ISC pool most likely implement this reduction of crypt 
progenitor expansion. Although additional Apc2 loss had profound effects on immediate 
intestinal homozygous Apc loss, Apc2 deficiency neither attenuated nor accelerated overall 
tumorigenesis in a Wnt driven Apc heterozygous intestinal tumour model.  
Apc is indispensable for normal mouse development (Moser et al., 1995) so a conditional, 
inducible Cre-lox system was employed to conditionally delete Apc from the murine 
intestines (previously used by Andreu et al., 2005). Upon induction, Apc depletion only 
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started manifesting a phenotype after 3 days and complete loss took up to 5 days. This is 
most likely due to time required for tamoxifen absorption, Cre mechanics and dynamics of 
Apc RNA and protein turnover. Interestingly, by Day 3 where Apc levels are being 
substantially reduced, its cellular location was altered from being mostly cytoplasmic to 
exclusively nuclear and membrane bound. Apc protein can usually be found in a variety of 
subcellular locations (for review see Bienz, 2002) consistent with its multifunctional role. As 
Apc protein is reduced, relocation to the nucleus and retained membrane binding may 
highlight the most vital roles of Apc.  The intrinsic ability of Apc to shuttle to and from the 
nucleus is essential for its role as negative regulator of Wnt signaling (Henderson, 2000). 
Further experiments demonstrate that Apc directly blocks transcription of some Wnt target 
genes within the nucleus (Sierra et al., 2006).  Relocation of Apc to the nucleus may 
highlight this location as the most effective location in blocking Wnt in an Apc depleted 
setting.  Apc is also found in adherens junctions and is essential for cellular adhesion (for 
review see Bienz and Hamada, 2004). Apc’s membrane location noticed in an Apc depleted 
setting may also highlight its role in cellular adhesion as a critical one.  Interestingly, at Day 3 
post induction occasional clumps of crypt cells displayed high levels of nuclear Apc staining 
which were subsequently lost by Day 4. These cells could represent progeny of un-
recombined cells unable to survive in an Apc deficient background or cells recently exiting 
quiescence un-affected by Villin-CreER until Days 3-4. 
Previous studies have demonstrated morbidity in mice following homozygous intestinal Apc 
deletion (Sansom et al., 2004; Andreu et al., 2005; Sansom et al., 2007). The aberrant 
phenotypes are thought to occur primarily as a consequence of over-activation of the Wnt 
signaling pathway. Interestingly, although loss of either Apc or Apc2 possesses the ability to 
disruptively activate Wnt, combined loss loss delayed the onset of morbidity associated with 
intestinal Apc loss. Morbidity in mice with intestines deficient for Apc could, in part, be 
accounted for by the lack of differentiated cell types and/or the vast increase in intestinal 
cell numbers causing an increased intestinal ‘bulk’. Less comparatively differentiated cell 
types with relevant physiological function in the intestines would hinder the organs main 
role of water/nutrient uptake leading to morbidity. Increased intestinal ‘bulk’ could induce 
morbidity a number of ways; either directly through reduced peristalsis or compression of 
other organs/systems or indirectly through means such as sequestering of blood. Additional 
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loss of Apc2 delayed and attenuated crypt progenitor expansion reducing intestinal ‘bulk’ 
and also helped retain more comparatively differentiated intestinal cell types. 
Loss of Apc within the intestines has profound effects on intestinal differentiation (Sansom 
et al., 2004; Andreu et al., 2005). Reduction or mis-positioning of terminally differentiated 
cell types undoubtedly will affect intestinal function and lead to morbidity in affected mice. 
Interestingly, additional Apc2 mutation attenuated perturbations in terminally 
differentiated cell types, noticed in Apc deficient intestines. Paneth cells function both as a 
secretor of antimicrobial peptides (Ganz, 2003; Wehkamp et al., 2005) and as an essential 
stem cell niche, providing essential Wnt, EGF and Notch signals (Sato et al., 2011; Parry et 
al., 2013). Wnt signaling is essential for terminal maturation of Paneth cells (Van Es et al., 
2005) and loss of Apc leads to perturbation in paneth cell number and positioning (Sansom 
et al., 2004; Andreu et al., 2005). Whilst this study also confirmed those findings, additional 
Apc2 loss delayed and attenuated perturbations in paneth cell positioning. This can be 
explained by attenuated cMyc and subsequently Ephrin B2 and Ephrin B3 expression in 
intestines deficient for both Apc proteins.  
 
The ephrin system is responsible for creating tissue boundaries, defining paths of cell 
migration and maintaining proper cellular positioning (reviewed in Crosnier et al., 2006). 
Disruptions in ephrin signaling and increases in expression of Ephrin B2 and Ephrin B3 are 
responsible for paneth cell disruption in intestines deficient for Apc (Sansom et al., 2004; 
Andreu et al., 2005).  A model with concurrent intestinal deletion of cMyc and Apc rescued 
most attributes of Apc loss including paneth cell positioning (Sansom et al., 2007). This was 
partly attributed to attenuated Ephrin B2 and Ephrin B3 expression. Interestingly, additional 
Apc2 loss at early time points in our experiment, drastically attenuated cMyc expression. 
This was concomitant with highest levels of Ephrin B2 and Ephrin B3 attenuation and 
rescued paneth disruption. This confers with the consensus that effects of intestinal Apc loss 
are cMyc dependent (Sansom et al., 2007) and modulation of Cmyc may be a good 
therapeutic approach in colorectal cancer prevention.  
 
Goblet cells secrete mucins into the intestinal lumen which form the mucus layer. This layer 
is indispensable for digestion and acts as an essential barrier between the luminal contents 
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and the epithelial surface (Shirazi et al., 2000). Goblet cells are another terminally 
differentiated cell type affected by Apc loss (Sansom et al., 2004; Andreu et al., 2005). In our 
study, Apc loss led to the depletion of goblet cells by Day 5. This was attenuated by 
additional loss of Apc2. Although Notch signaling is mostly associated with goblet cell 
differentiation (Fre et al., 2005; Van Es et al., 2005), crosstalk between Wnt and Notch in 
intestinal homeostasis exists (Nakamura et al., 2007; Fre et al., 2009). Increases in intestinal 
Wnt through Apc loss may inadvertently affect Notch, disrupting goblet cell differentiation. 
Attenuated Wnt expression in intestines deficient for both Apc proteins may indirectly 
rescue goblet cell disruption through Notch signaling. This is an avenue for further research. 
 
ISC’s are critically reliant on Wnt signaling and contribute to the normal repopulation of 
intestinal epithelium (for review see Reya & Clevers, 2005). It has been reported previously 
that markers for intestinal ‘stemness’ increase following Apc loss (Jubb et al., 2006; Merlos-
Suarez et al., 2011). Crypt progenitor expansion noticed in Apc deficient intestines could, in 
part, be attributed to increases in the ISC pool and subsequently born progenitors. Upon 
analysis of stem cell markers it was revealed that additional loss of Apc2 attenuated ISC 
expansion. This proposes that whilst Apc loss permits a suitable environment for ISC 
expansion, additional loss of Apc2 reduced this capacity. As ISC’s are reliant on high Wnt, 
attenuated Wnt signaling may account for a reduced ISC pool. Conversely, increased cell 
death and/or promotion of terminal differentiation of ISC’s may  be causative factors in 
reduced Wnt signaling observed in intestines deficient for both Apc proteins. Regardless of 
mechanism, reduced ISC/precursor cells and comparatively more terminally differentiated 
cells types would contribute to an extended post induction survival. 
 
Analysis of proliferative potential between genotypes using BrdU revealed some interesting 
findings. In Apc deficient intestines, positively labelled cells resided within the expanded 
crypt/progenitor zone, however, intestines deficient for both Apc proteins displayed 
positively labelled cells outside this region. These cells marginal to the crypt progenitor 
region were capable of incorporating BrdU but displayed normal villus cell histology. This 
suggests that additional Apc2 loss in Apc deficient intestines has the potential to activate a 
proliferative program within cells higher up the crypt-villus axis at a lower gradient of 
secreted Wnt, and this can occur independently to the crypt progenitor phenotype. As Wnt 
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target gene expression was attenuated in intestines deficient for both Apc proteins at the 
studied time points, the mechanisms behind increased BrdU labelling remain unclear. 
Although increased cell division and expansion of the proliferative compartment were 
noticed in intestines deficient for both Apc proteins compared to that of just Apc deficiency, 
there was a reduction in survival of labelled cells, indicative of cell death. In contrast to 
previous reports (Sansom et al., 2004; Andreu et al., 2005; Sansom et al., 2007), Apc 
deficient intestines did display a mild positional difference in labelled cells following 24h 
allowed migration. Surprisingly, although intestines deficient for both Apc proteins 
displayed an overall attenuated phenotype, no positional differences were apparent in 
labelled cells following 24h. This suggests a more severe migrational retardation following 
intestinal loss of both Apc proteins. There are two caveats to this interpretation. Foremost, 
higher rates of crypt expansion were noted in intestines deficient for Apc, this may force 
cells higher up the crypt-villus axis rather than reflecting true migration.  Furthermore, the 
increased cell death noted in intestines deficient for both Apc proteins may well complicate 
the interpretation of migration.  
 
The majority of alterations in Apc deficient intestines are thought to act through increased 
expression of Wnt target genes (Sansom et al., 2004; Andreu et al., 2005). Apc2 deficiency 
also shares this ability to modify Wnt signaling (Chapter 3). Interestingly, cumulative loss 
initially attenuated Wnt target gene expression (cMyc, Cyclin D1, CD44, Ephrin B2 and Ephrin 
B3) in comparison to Apc loss alone.  This attenuation of Wnt target gene expression 
concomitant with an increase in cell death are a possible explanation for phenotypical 
differences between genotypes. This prompts the question as to how additional Apc2 loss 
induces cell death and attenuation of Wnt activation in Apc deficient intestines. Three 
plausible hypotheses seem relevant; more effective Wnt repression, overall reduction due 
to death of selective Wnt hyper-active cells, and/or overall reduction due to selective death 
of cells by Wnt independent means.  
 
Apc2 loss is achieved through a constitutive mutation (Van der Meer et al., 2001). Re-
adjustment of Wnt repression due to insults on Wnt may have occurred as a program of 
developmental compensation. The recruitment of Groucho to TCF/LEF gene regulatory 
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sequences results in transcriptional repression (Cavallo et al., 1998; Levanon et al., 1998; 
Buscarlet & Stifani, 2007). Indeed Groucho was up-regulated before induction in intestines 
deficient for Apc2. Other pre-established methods of Wnt repression, with molecular 
machinery already in place could also contribute to attenuation of Wnt target gene 
expression. A further explanation as to why intestines deficient for both Apc protein display 
reduced Wnt signalling, may lie with increases in negative feedback signals. Dickkopf 2 is a 
secreted antagonist of the Wnt signaling pathway, inhibiting binding of Wnt ligands to the 
LRP5/6 receptor (Kawano Y, et al., 2003; Niehrs et al., 2006). Murine loss of Dickkopf 2 
causes intestinal increases in Wnt target gene expression (Li at el., 2012).  At Day 5 post 
induction, Dickkopf 2 and Groucho were both significantly up-regulated in intestines 
deficient for both Apc proteins, representing both extra and intra-cellular means of Wnt 
repression, respectively. Stronger negative feedback signals would explain greater increases 
in expression of Wnt repressors. To further elucidate other potential mechanism of Wnt 
repression or potential increases in negative feedback signals microarray technology could 
be employed to study global transcriptome changes. 
 
Another possible explanation for the attenuated phenotype may lay with selective cell 
death due to hyper-activation of the Wnt signaling pathway.  A ‘Just right’ hypothesis 
regarding levels of Wnt signaling has been suggested for oncogenesis and neoplastic growth 
in colorectal cancer cell lines (Lamlum et al., 1999; Albuquerque et al., 2002; Lucero et al., 
2010) Interestingly, although moderate increases in Wnt signaling lead to incurred growth 
advantage, higher increases induce cell death (Lazarova et al., 2004; Bordonaro et al., 2008). 
In intestines deficient for both Apc proteins there was an increase in cell death across all 
post induction time points. Cells with higher levels of Wnt (Wnthigh), such as ICS’s may be 
selected against, due to accumulative Wnt hyper-activation caused by loss of both Apc 
proteins. Indeed, a reduction in markers for stemness was observed in intestines with 
combined loss. Selective death of Wnthigh cells due to Wnt Hyper-action in intestines 
deficient for both Apc proteins, whilst permitted survival of Wnthigh cells in Apc deficient 
intestines could explain global Wnt intestinal differences between genotypes. 
 
A third explanation as to why additional Apc2 loss attenuates phenotype and Wnt target 
gene expression in Apc deficient intestines may lay with disrupted functional redundancies 
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which are Wnt independent. Apc’s role is multi-functional (reviewed by Aoki and Taketo, 
2007; Senda et al., 2007) and non-canonical functions of Apc are being intensively reported 
(Fodde et al., 2001; Kaplan et al., 2001; Näthke, 2006; Prosperi et al., 2009; Qian et al., 2008; 
Harris & Nelson, 2010). As Apc2 shares structural homology to Apc (Vans Es et al., 1999), it 
undoubtedly too has Wnt independent functions which may overlap with those of Apc. Both 
Apc and Apc2 loss have been reported to induce Wnt independent cytoskeletal defects in 
mouse neurons (Yokoto et al., 2008; Shintani et al., 2012). Compromised Wnt independent 
redundancies in intestines deficient for both Apc proteins may indirectly affect Wnt 
transduction, ISC dynamics or induce cell death in particular cell types leading to an 
attenuated phenotype. 
 
Results regarding immediate intestinal homozygous Apc loss indicate additional Apc2 loss 
attenuates this phenotype and delays the onset of morbidity. This appears to be achieved 
through a combination of reduced perturbations in differentiated cell types, reduced 
ISC/progenitor expansion and increased cell death. From these findings, one would 
postulate that additional Apc2 loss would exert some effect on tumorigenesis caused by Apc 
loss. To test this assumption, mice with and without Apc2 were analysed in the context of a 
heterozygous deletion of Apc. Initiation of tumours in this validated model, develop due to a 
spontaneous mutation of the normal residing Apc allele. Surprisingly, analysis of tumour 
burden and survival probability failed to detect differences in tumour incidence and 
progression between Apc heterozygous mice with or without Apc2 deficiency. Taken 
together, this indicates that Apc2 deficiency provides no selective advantage or 
disadvantage in Wnt driven intestinal tumourigenesis. 
 
A potential explanation for this surprising finding may come from a detailed examination of 
the tumour driving mutations found in the Apc gene. Evidence from human data suggests 
that although most colorectal cancer patients contain constitutively activating mutations of 
the Wnt pathway, tumours frequently retain a certain degree of pathway regulation (Le et 
al., 2008; Vermeulen et al., 2010; Sousa et al., 2011). Germline mutation of APC in FAP 
patients influence the nature of the second hit/mutation of the normal residing APC allele 
(Lamlun et al., 1999) and this never results in complete loss of function of the protein 
(Albuquerque et al., 2002). Together, these results suggest that some residual β-catenin 
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degradation function is needed and selected for in tumours, and this fine-tuned balance of 
Wnt activity optimal for cell transformation. Interestingly, Apc2 loss has the ability to alter 
Wnt levels and phenotype in Apc deficient intestines. As different Apc mutations can result 
in differing levels of Wnt transduction (Gaspar & Fodde, 2004), it would be of significant 
interest to see how additional Apc2 loss altered the nature/position of the second hit/Apc 
mutation in our model. One could assume, to obtain an ‘optimum’ Wnt level needed for 
tumour formation, the position or pattern may change in intestines with additional Apc2 
loss. This may explain why no overall differences in tumorigenesis between groups were 
observed. 
 
To conclude, the findings presented in this chapter revealed that additional Apc2 loss in the 
context of intestinal homozygous Apc deletion initially attenuated Wnt over-activation and 
associated phenotypes. Crypt progenitor expansion was reduced although cells marginal to 
the crypt progenitor displayed increased proliferative capacity. Increases in cell death and 
attenuated expansion of the ISC pool most likely implement this reduction of crypt 
progenitor expansion. Although additional Apc2 loss had profound effects on immediate 
intestinal homozygous Apc loss, Apc2 deficiency neither attenuated nor accelerated overall 
tumorigenesis in a Wnt driven Apc heterozygous intestinal tumour model. 
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Chapter 5 
Investigating the combined effects of Apc and Apc2 loss in 
the mammary epithelium  
 
 
5.1 Introduction 
In the previous chapters it was shown that in the intestine, Apc2 has the ability to partially 
modify Wnt signaling and can influence the phenotype associated with intestinal Apc loss. 
However, a range of studies have implicated Apc2 in other tissues. It is known that both Apc 
proteins are expressed in a range of mammalian tissues (Van Es et al., 1999) and work in 
Drosophila point toward a co-operation in negative regulation of Wnt in a variety of organs 
(McCartney et al., 1999; McCartney et al., 2006; Ahmed et al., 2002; Akong et al., 2002). 
Functional redundancies in Wnt control have been exposed through complementary rescue 
in both Drosophila and human tissue (Kunttas-Tatli et al., 2011; Roberts et al., 2012; Van Es 
et al., 1999), although the role Apc protein play in the mammary gland and/or how they 
contribute to Wnt signaling is undetermined. Aberrant activation of Wnt signaling pathway 
is among the most common signaling defect in human cancers (Reya & Clevers, 2005) 
however, much controversy exists over its role in human breast cancer (Smalley & Dale, 
2001; Howe & Brown, 2004). Some studies suggest dysregulation of the Wnt signaling 
pathway is an important contributor to the initiation of breast cancer (Mohinta et al., 2007), 
whilst others suggest a more prominent role in cancer progression (Khalil et al., 2012). 
Although activating mutations in CTNNB1 (β-catenin) are rare in breast cancers (Geyer et al, 
2010), both elevated levels of β-catenin (Lin et al., 2000) and reduced levels of membrane 
expression are common and  associated with poor prognosis (Dolled-Filhart et al., 2006; 
Khalil et al., 2012). This suggests that defects are exerted though inappropriate localization 
and regulation. 
 
Both APC and APC2 can regulate β-catenin/Wnt signaling (Van Es et al., 1999; Roberts et al., 
2012) and both are expressed in human mammary epithelium (Kashiwaba et al., 1994; 
Schlosshauer et al., 2000; Jarrett et al., 2001).  Reduction of APC has been reported in breast 
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cancers through loss of heterozygosity (Kashiwaba et al., 1994; Thompson et al., 1993), 
promoter hypermethylation (Jin et al., 2001; Ho et al., 1999; Schlosshauer et al., 2000; 
Sarrio et al., 2003; Van der Auwera et al., 2008) and somatic mutation (Furuuchi et al., 
2000).  Reduced APC2 has also been implicated in breast cancer through loss of 
heterozygosity (Sobottka et al., 2000; Yang et al., 2004; Wang et al., 1999), allelic imbalance 
(Jarrett et al., 2001) and promoter hypermethylation (Chan et al., 2008). Interestingly, APC2 
is located within a chromosome region lost with Peutz-Jeghers syndrome (PJS). Patients with 
PJS are more susceptible to certain cancers including those of the breast (Mehenni et al., 
1998; Bignell et al., 1998). Although loss of the LKB1 gene is responsible for most of the 
symptoms of PJS, this gene is not mutated in sporadic cancers suggesting the existence of 
another tumour suppressor within this region. Importantly, combined status of both APC 
proteins in breast cancer has never been addressed.  
Transgenic models altering the Wnt signaling pathway in the murine mammary have also led 
to controversy. Expression of an activated form of β-catenin has been reported to cause 
mammary gland hyperplasia, precocious development and tumour formation in some 
studies (Michaelson et al., 2001; Imbert et al., 2001). However in others, active β-catenin 
resulted in metaplasia but failed to induce neoplasia (Miyoshi et al., 2002). This confusion 
also extends to mammary Apc loss. It is known that ApcMin mice, along with a predisposition 
to intestinal tumorigenesis, also have a higher incidence of mammary tumours (Moser et al., 
1993). Some studies targeting Apc mutation specifically to the mammary led to 
tumorigenesis (Kuraguchi et al., 2009), whilst others fail to observe tumour formation unless 
combined with other oncogenic mutations (Gallagher et al., 2002; Meniel et al., 2005). 
As both APC proteins regulate Wnt, both are expressed in mammary epithelium and loss of 
either has been linked with breast cancer, there is a possibility redundancies exist between 
them. In this chapter I aimed to test the importance of Apc proteins in the murine mammary 
epithelium. Utilising mouse transgenics, I aimed to study the consequence of Apc loss, Apc2 
loss and concomitant loss of both to elucidate possible functional redundancies. 
The mammary gland represents a unique organ whereby the majority of development 
occurs postnatally (Figure 5.0). Whilst the ductal epithelial network can lay relatively 
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quiescent in mature virgins, pregnancy and associated hormone fluxes increase and 
transform this tissue into a milk producing organ capable of nourishing offspring.  
 
 
Figure 5.0 Mammary gland development. During puberty a ductal epithelial network extends from 
the nipple growing into and occupying the fat pad.  Mature virgin mammary glands display a fat pad 
filled with this ductal network though the tissue remains quiescent (H&E stained cross section 
through one of these ducts reveals the tissue architecture). The mammary gland will remain in this 
state throughout adulthood unless pregnancy is attained. During pregnancy and through to lactation 
a plethora of hormones induce epithelial changes that prompt formation of milk producing alveola. 
This milk is released into the remaining duct structures and can be suckled through the nipple by the 
offspring. Following weaning the mammary gland tissue reverts back to a stage reminiscent of that 
of a mature virgin gland through the process of involution.  
 
 
5.2 Results 
 
5.2.1 Both Apc proteins are expressed in murine mammary epithelial tissue 
Mammary glands were dissected from adult wild type (Wt) virgin mice and sections stained 
using fluorescent IHC with antibodies raised against Apc and Apc2 (Figure 5.1). Both Apc 
proteins displayed overlapping expression in mammary epithelial cells.  As both of the 
antibodies used were raised against the C-terminus tails of Apc and Apc2 respectively where 
they share the least homology, this was less likely to be the effect of cross reactivity.  
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Figure 5.1 Both Apc and Apc2 proteins are expressed in the mammary epithelium. The top image 
represents a whole mounted mouse mammary gland, cleared for fat and stained with carmine alum 
(scale bar represents 1cm). Note ductal network of epithelial cells. The middle images represents 
H&E stained mammary gland section. Fluorescent IHC on Sections through ducts revealed both Apc 
and Apc2 are expressed in mammary epithelial cells (scale bar represents 50µm). 
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5.2.2 Targeting loss of Apc proteins in the mammary epithelium 
To achieve Apc2 loss in the mammary epithelium, the constitutive Apc2-/- mouse was used 
(as described in previous chapters). Fluorescent IHC revealed comprehensive loss of Apc2 
protein from Apc2-/- mammary epithelium (Figure 5.2).  
 
Figure 5.2 Apc2 expression is lost in Apc2-/- mammary epithelium. Fluorescent IHC was used to 
confirm Apc2 loss in the mammary epithelium (scale bar represents 50µm). 
Constitutive Apc loss is embryonic lethal (Moser et al., 1995), so a Cre/loxP transgenesis 
system was employed to delete Apc from the mammary epithelium.  The Apcfl/fl allele was 
used (described in Chapter 4) targeted by the Blg-Cre+ promoter (Selbert et al., 1998). Blg-
Cre+ mice were crossed with a Cre ROSA26 reporter strain (Soriano et al., 1999) to quantify 
cre mediated recombination in the mammary gland.  Expression of the Cre recombinase 
resulted in recombination of the loxP flanked stop-cassette thus allowing the expression of 
the β-galactosidase gene. Mammary glands from 10wk old virgin Blg-Cre+ ROSA26+ mice 
were dissected and incubated with X-gal (a substrate for β-galactosidase). LacZ positivity 
indicated the recombination events had occurred in epithelial cells in a heterogeneous 
manner (Figure 5.3A). Fluorescent IHC with an anti- β-galactosidase antibody revealed 
recombination events in both luminal and myoepithelial cells in a mosaic fashion (Figure 
5.3B).  Fluorescent IHC against Apc on sections of Blg-Cre+ Apcfl/fl mammary glands validated 
this heterogeneous pattern of loss in epithelial cells (Figure 5.3C). Epithelial cells retaining 
Apc expression showed nuclear localisation.  
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Figure 5.3 Apc deletion is driven heterogeneously using the Blg-Cre transgene.  (A)Virgin Blg-Cre+ 
Rosa26+ mice were sacrificed at 10wks of age. Mammary whole mounts incubated with X-gal 
revealed a heterogeneous pattern of Cre recombination (scale bar 2mm). (B) Blg-Cre+ Rosa26+ 
mammary sections stained with a β-galactosidase antibody displayed recombination events in both 
luminal and myoepithelial  cells, again in a mosaic manner (white arrowheads=recombination in 
luminal cells, grey arrowhead=recombination in myoepithelial cells, scale bar represents 50µm in 
main image, 25µm in higher magnified image). (C) IHC for Apc in Blg-Cre+ Apcfl/fl mice revealed a 
heterogeneous pattern of loss in epithelial cells. Epithelial cells retaining Apc expression showed 
nuclear localisation. (grey arrowheads indicate cells which have lost Apc expression, scale bar 
represents 50µm in main image, 25µm in inlet). 
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5.2.3 Combined loss of Apc and Apc2 induces loss of epithelial integrity and 
atypical ductal hyperplasia 
In order to test the functions of Apc proteins in mammary homeostasis, four cohorts were 
generated (Wt, Apc2-/-, Blg-Cre+ Apcfl/fl and Blg-Cre+ Apcfl/fl Apc2-/- {termed DKO hereafter}). 
Virgin animals from each genotype were culled at 10wks of age (n≥3) and mammary glands 
examined.  Following a 2h fixative period, mammary glands were stained overnight with 
carmine alum and cleared for fat (Figure 5.4A). Whole mount and H&E stained sections 
revealed both Apc and Apc2 alone are dispensable for epithelial integrity. Ductal branching, 
polarity and epithelial structure remained similar to Wt glands.  Apc loss has previously been 
reported to show minimal effects on epithelial structure in virgin mice (Gallagher et al., 
2002; Meniel et al., 2005). Strikingly, concurrent loss of both Apcs led to severe epithelial 
disruption. Carmine alum stained DKO whole mounted glands revealed an epithelial 
thickening, reduced branching and disruption of epithelial structure. This occurred with 
100% penetrance in all glands of DKO mice (4 additional H&E stained biological replicate 
gland sections are displayed in Figure 5.4B). H&E stained sections of DKO glands displayed 
an increase in epithelial filled fat pad, increase in peri-ductal stroma and appearance of 
aggregates of ‘ghost cells’. These have been reported extensively in a variety of human 
tumours and consist of anucleate ‘cells’ which stain positive for hard keratins and are most 
likely necrotic (Tanaka et el., 2007). Also, the epithelium had lost cohesion along with severe 
defects in polarity. Furthermore, an inflammatory response was also observed with 
macrophage giant cells being present. 
Upon histopathological inspection (performed in collaboration with Prof. Geraint T. 
Williams) DKO lesions were classed as atypical ductal hyperplasia. As no mammary 
phenotype was observed in Blg-Cre+ Apc+/fl Apc2-/- mice (data not shown), these phenotypic 
changes are thought to arise due to homozygous Apc loss in conjunction with Apc2 
deficiency. Quantification of epithelial and stromal cells was carried out between genotypes 
by counting cell types per field of view (Figure 5.4C).  Whilst loss of either Apc or Apc2 alone 
did not give rise to changes in cell number, combined loss induced statistically significant 
increases in both epithelial and stromal cell types per field of view (statistically significant 
verses all other genotypes p≤0.001, Mann-Whitney U-test, n≥3). 
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Figure 5.4 Combined loss of both Apc and Apc2 caused severe epithelial disruption, appearance of  
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‘ghost’ cells and increased epithelial and stromal cell number. (A) Top image displays comparative 
carmine alum stained whole mount glands and H&E stained sections from 10wk old virgin mice of 
each genotype. Whilst loss of either Apc protein alone is tolerated, combined loss caused severe 
defects in ductal branching and epithelial thickening (scale bar represents 2mm).  H&E stained 
sections of mammary tissue from each genotype revealed epithelial disruptions in glands deficient 
for both Apc proteins (middle images=scale bar represents 1mm, bottom images=scale bar 
represents 50µm). (B) 4 additional H&E stained DKO biological replicate mammary epithelial 
sections;- a= ‘ghost cell’ aggregate, b= ductual thickening/hyperplasia/loss of polarity, c= increase in 
peri-ductual stroma and immune response, d= loss of epithelial cohesion/adhesion (scale bar 
represents 200µm). (C) Epithelial and stromal cells from each genotype were scored and quantified. 
Loss of either Apc or Apc2 had no effect on cell populations. However, combined loss lead to 
statistical increases in both epithelial and stromal cells (error bars represent standard deviation, 
asterisks mark p≤0.001 compared against all other genotypes, Mann-Whitney U-test, n≥4). 
 
Rates of cell turnover are relatively low in the mammary epithelium (Neese et al., 2002) 
especially compared to that of the intestines (Reya & Clevers, 2005), a tissue grossly 
affected by Apc loss (Sansom et al., 2004). Mitotic figures were readily observable in DKO 
epithelium whilst seldom in other genotypes, consistent with a hyperplastic phenotype. To 
confirm increases in proliferation, mammary sections from each genotype were labelled 
using an anti-Ki-67 antibody (Figure 5.5A). Quantification of positively labelled cells revealed 
a statistical increase in percent of dividing cells in DKO mammary epithelium compared to all 
other genotypes (statistically significant DKO verses all other genotypes p˂0.01, Mann-
Whitney U-test, n≥3). Interestingly, Apc2-/- displayed a significant decrease in proliferation 
compared to Wt mammary epithelium (p≤0.05, Mann-Whitney U-test, n≥3). 
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Figure 5.5 Combined loss of Apc and Apc2 induced proliferative increases. (A) Sections from each 
genotype where stained with an anti-Ki-67 antibody. An increase in labelled cells was noticed in 
epithelium deficient for both Apc proteins (arrows indicate positively labelled cells, scale bar 
represents 50µm). (B) Quantification of positively labelled cells revealed a reduction in proliferation 
in Apc2-/- compared to Wt epithelium.  However, a statistical increase was noticed in epithelium 
deficient for both Apc proteins verses all other genotypes (error bars represent standard deviation, * 
marks p≤0.05 verses Wt, ** marks p≤0.01 compared against all other genotypes, Mann-Whitney U-
test, n≥3).  
 
 
5.2.4 Functional redundancies exist between Apc proteins in mammary 
epithelial Wnt transduction 
The majority of intestinal phenotypes associated with Apc loss are thought to occur due to 
its influence on Wnt signaling (Hanson et al., 2005; Nathke, 2005; Polakis, 2000). Both Apc 
proteins share the ability to mediate Wnt signaling through β-catenin degradation 
(Nakagawa et al., 1998; Van Es et al., 1999) and activating β-catenin mutations have been 
previously reported to induce mammary gland hyperplasia (Michaelson et al., 2001; Imbert 
et al., 2001), thus this pathway was addressed. Mammary epithelium from each genotype  
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were labelled using IHC with an anti- β-catenin antibody. Mammary epithelium from Apc2-/- 
and Blg-Cre+ Apcfl/fl displayed no difference in β-catenin protein location in comparison to 
Wt (Figure5.7). β-catenin status was compared using fluorescent IHC  between DKO 
epithelium and Blg-Cre+ Apcfl/fl as a control (Figure 5.6). β-catenin in Blg-Cre+ Apcfl/fl 
epithelium displayed a cytoplasmic and membrane bound expression pattern, similar to that 
observed in Wt tissue. The highest expression was detected on the apical surface in a 
polarised manner (Figure 5.6A). Additional loss of Apc2 (DKO epithelium) disrupted this 
staining pattern in a heterogeneous manner. Some cells displayed a generalised expression 
pattern where all cellular locations were labelled (Figure 5.6B). Other single cells and clumps 
of cell displayed up-regulation including classical nuclear β-catenin staining (Figure 5.6C). 
Unexpectedly, some regions appeared to lose detectable β-catenin from all cell locations 
(Figure 5.6D). ‘Ghost cells’ labelled for neither β-catenin nor nuclear material (Figure 5.6E).  
Serial section from each genotype at 10wks of age were labelled using IHC for Apc, β-
catenin, cMyc and CD44 (Figure 5.7). Loss of Apc2 or Apc alone did not display changes in β-
catenin localisation or detectable changes in cMyc or CD44 expression. However, combined 
loss in certain areas, induced increased staining intensity along with nuclear translocation in 
mammary epithelium. cMyc was also detectable in cells displaying nuclear β-catenin 
consistent with an activation of the Wnt signaling pathway, However, CD44 remained 
undetectable in cells deficient for both Apc proteins. Taken together, these results suggest 
that Apc proteins co-operate in Wnt signal transduction within the mammary epithelium 
however, that this pattern is complex and does not lead to uniform activation of the Wnt 
pathway in the majority of cells. 
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Figure 5.6 Combined loss of both Apc proteins disrupted β-catenin. Sections from Blg-Cre+ Apcfl/fl and 
DKO mammary epithelium were stained fluorescently with an anti-β-catenin antibody and 
compared. Higher magnification images of top image displayed below. (A) Epithelium deficient for 
Apc alone displayed a cytoplasmic and membrane associated staining pattern consistent with other 
genotypes. Staining was at its highest intensity towards the apical surface in a polarised manner. In 
mammary tissue deficient for both Apc proteins, epithelial β-catenin was disrupted. Certain areas 
displayed (B) mis-localized, (C) strong nuclear or even (D) absent epithelial β-catenin staining. (E) 
Ghost cells display no Dapi or β-catenin staining (scale bar represents 50µm in top image, 25µm in 
bottom image). 
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Figure 5.7 Combined loss of Apc and Apc2 caused activation of the Wnt signaling pathway in a 
subset of cells. Serial sections of mammary epithelium from each genotype were labelled with Apc, 
β-catenin, cMyc and CD44. Inactivation of either Apc protein alone did not induce changes in β-
catenin localisation or status of Wnt targets. Combined loss induced up-regulation & nuclear 
translocation of β-catenin and activated expression of the Wnt target gene cMyc. CD44 expression 
was undetectable in any genotype (arrow indicates area deficient for Apc, scale bar represents 
50µm). 
 
5.2.5 Combined Apc and Apc2 loss induce ghost cell formation and increases in 
apoptosis 
‘Ghost cells’ have been reported extensively in a variety of human tumours and consist of 
anucleate ‘cells’ which stain positive for hard keratins (hair proteins) and are most likely 
necrotic (Tanaka et el., 2007). Principally, tumours containing these cells arise in the head 
and neck region (Hong et al., 1991; Marrogi et al, 1992; Kumaran et al., 2006) although 
occurrence has been reported in the breast (Raman et al., 2000; Rosner et al., 2002; 
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Hernanz et al., 2012).  A previous report has suggested aberrant Wnt signaling may 
influence ghost cell formation in odontomas (Tanaka et el., 2007). Ghost cells occur in all 
DKO mammary epithelium indicative that Wnt signaling likely plays some role, at least in the 
context of mammary epithelial origin.  Sections of DKO mammary glands stained for H&E 
occasionly revealed areas of apparent transition between normal seeming epithelium 
through to structures with a ghost cell appearance (Figure 5.8). As cells move through 
transition apoptotic bodies become perceptible, the cells start expressing a pink material 
reminiscent of keratin and become increasingly anucleate.  Serial sections through  
 
Figure 5.8 Ghost cells appear associated and may arise from Wnt activated cells. A foci of cells 
stained with H&E display transition from epithelial to a ghost cell appearance. Cells become 
anucleate during transition with an increase in apoptotic fragments. IHC on serial sections revealed  
nuclear translocation and up-regulation of β-catenin in the in the early stages before transition, 
concurrent with Ki-67 staining. As cells leave this region they gradually adopt a ghost cell appearance 
(scale bar represents 25µm). 
 
these foci suggest in the early stages of possible transition Wnt signaling is activated and the 
cells are cycling. Taken together these results suggest combined loss of Apc and Apc2 leads 
to activation of the Wnt signaling pathway, hyper-proliferation of epithelial cells and an 
ultimate transition to a ghost cell morphology, at least in a subset of cells. To assess the 
extent of cell death, mammary gland sections from each genotype where stained with an 
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anti-cleaved caspase-3 antibody (Figure5.9A). Positive cells were seldom observed in Wt 
epithelium or epithelium deficient for either Apc protein. However, in glands deficient for  
 
 
Figure 5.9 Loss of both Apc proteins led to an increase in cell death.  (A) Sections from each 
genotype were stained with an anti-caspase-3 antibody. Wt cells or epithelial cells deficient for 
either Apc or Apc2 alone, very rarely labelled for caspase-3. In DKO epithelium there was an increase 
in labelled cells (arrows indicate positively labelled cells, scale bar represents 50µm). (B) 
Quantification of positively labelled cells revealed a statistical increase in apoptosis in epithelium 
deficient for both Apc proteins (error bars represent standard deviation, asterisks marks p≤0.001 
compared against all other genotypes, Mann-Whitney U-test, n≥3).  
 
both Apc proteins there was a vast increase in labelled cells. Quantification of these cells 
(Figure 5.9B) revealed a statistical increase in DKO tissue compared against all other 
genotypes (statistically significant for DKO verses all other genotypes p≤0.001, Mann-
Whitney U-test, n≥3). 
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5.2.6 Apc proteins co-operate in maintaining epithelial polarity  
Along with hyperplasia and ghost cell formation at 10 weeks of age, DKO epithelium display 
defects in polarity (Figure 5.10). Apc-/- and Blg-Cre+ Apcfl/fl glands appear indifferent from 
Wt. Subsequent analyses were therefore performed between Blg-Cre+ Apcfl/fl and DKO 
mammary glands to compare the effects of additional Apc2 loss in the context of Apc 
deletion. Sections from DKO and Blg-Cre+ Apcfl/f were double labelled for cytokeratin 8 
(luminal cell marker) and cytokeratin 5 (myoepithelial cell marker) using fluorescent IHC. In 
Blg-Cre+ Apcfl/f epithelium cells were organised in a highly polarised manner consistent with 
that observed in Wt tissue. Loss of both Apc proteins induced severe disruption of polarity. 
Luminal and basal (myoepithelial) cells lost positional identity and were located 
haphazardly. E-cadherin is the principle component of adheren junctions imperative in cell-
cell adhesion (for review see Gumbiner, 1996).  Zo-1 is a component of tight junctions 
critical for maintaining barrier function (Umeda et al., 2006) Together these proteins help 
establish and maintain epithelial polarity (Ando-Akatsuka et al., 1999). In Blg-Cre+ Apcfl/f 
epithelium, Zo-1 is normally maintained in an apical position and E-cadherin at a position 
consistent with cell-cell contacts. However, in DKO epithelium Zo-1 was almost completely 
diminished along with cells displaying a loss of E-cadherin. Together these results show 
functional redundancies between Apc proteins in the maintenance of polarity and tight 
junction functionality.  
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Figure 5.10 Combined loss of both Apc proteins led to polarity defects.  Top image represents H&E 
stained mammary sections from epithelium with Apc loss compared to epithelium deficient for both 
Apc and Apc2.  Bottom left image represents the same comparison with sections double labelled 
using fluorescent IHC for cytokeratin 8 (CK 8, luminal cell marker) and cytokeratin 5 (CK 5, basal cell 
marker). Note disruption in polarisation of epithelium deficient for both Apc proteins. Bottom right 
image represents again the same comparison but double labelled using fluorescent IHC for both Zo-1 
and E-cadherin. Note loss of polarity marker Zo-1 and E-cadherin in mammary epithelium deficient 
for both Apc proteins (scale bar represents 50µm). 
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5.2.7 Combined epithelial loss of both Apc proteins leads to local tissue 
invasion and characteristics reminiscent of EMT  
Upon further examination of H&E stained DKO mammary sections, occasional epithelial cells 
appeared to lose continuity with neighbouring epithelium and ‘invade’ local surrounding 
tissue (Figure 5.11). ‘Invading’ cells lost β-catenin expression but some still retained residual 
cytokeratin 5 and/or 8 labelling indicating an epithelial lineage origin.  These cells may occur 
as a consequence of duct rupture caused by a build-up of ghost cell aggregates. However, 
cell damage was not overtly obvious and nor was death of these cells.  Indicators of 
epithelial-mesenchymal transition (EMT) further corroborate the hypothesis that these cells 
have acquired invasive capabilities. Whilst Blg-Cre+ Apcfl/f epithelium retained E-cadherin 
expression and were negative for vimentin, some DKO mammary epithelial cells displayed a 
loss of E-cadherin coincident with strong vimentin expression (Figure 5.12). Snail expression 
showed no correlation with these cells or with β-catenin status (data not shown).  
Given both Apc and Apc2 possess the ability to directly interact with the cytoskeleton and 
microtubules (Näthke, 2006; Shintani et al., 2012), microtubule status was provisionally 
assessed in both Blg-Cre+ Apcfl/f and DKO mammary sections using an anti-α-tubulin 
antibody (Figure 5.12). In Blg-Cre+ Apcfl/f, epithelium staining displayed a tightly bound 
pattern consistent with a maintained regulation. However, in DKO mammary epithelium, 
staining revealed a disorganised pattern consistent with a disruption of microtubules.  High 
magnification images comparing Blg-Cre+ Apcfl/f and DKO epithelial cells reveal Apc loss in 
the context of Apc2 deficiency can lead to β-catenin loss, as oppose to nuclear accumulation 
(Figure 5.13A). Cells also lost E-cadherin and Zo-1 expression suggesting a non-canonical 
route of cytoskeletal disruption. Confocal images comparing α-tubulin between genotypes 
revealed a reduction of microtubules (Figure 5.13B). Together these results suggest some 
phenotypes associated with combined loss of both Apc proteins may be exerted through 
compromised functional redundancies relating to cytoskeletal regulation.  This is consistent 
with the consensus for a multi-functional role for Apc proteins (Aoki and Taketo, 2007; 
Senda et al., 2007; Hanson et al., 2005; Nathke, 2005; Polakis, 2000). 
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Figure 5.11 Apc loss in the context of Apc2 deficiency leads local tissue invasion.  Top image 
represents H&E stained mammary sections from epithelium with Apc loss compared to epithelium 
deficient for both Apc and Apc2 (scale bar represents 150µm). Note cells ‘floating’ in extracellular 
matrix with epithelial appearance in glands deficient for both Apc proteins.  Bottom image 
represents epithelium deficient for Apc on left and both Apc and Apc2 on the right. Serial sections 
were labelled using fluorescent IHC for β-catenin and double labelled for both CK 5 and CK 8. In 
glands deficient for Apc, β-catenin remained membrane bound with strong apical localisation, 
consistent with maintained epithelial architecture. In mammary glands deficient for both Apc 
proteins, β-catenin was disrupted along with disrupted epithelial architecture.  Occasional cells lost 
β-catenin expression and detached from the epithelial structure maintaining some cytokeratin 5 
and/or 8 expression (scale bar represents 50µm). 
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Figure 5.12 Epithelial cells deficient for both Apc proteins displayed evidence of EMT and disruption 
in microtubules.  Images on the left represent glands deficient for Apc and on the right glands 
deficient for both Apc proteins. In epithelium with Apc loss, E-cadherin was expressed in all cells and 
mostly membrane associated. Combined loss led to a disruption in E-cadherin expression and a loss 
in some cells. Cells negative for E-cadherin now stain positive for vimentin, consistent with EMT.  
Staining with α-tubulin revealed a disruption in microtubules in epithelium deficient for both Apc 
proteins (scale bar represents 50µm). 
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Figure 5.13 Apc loss in the context of Apc2 deficiency caused cytoskeletal disruptions. (A) Sections of 
epithelial cells labelled for Apc, β-catenin, Zo-1 and E-cadherin compared between glands deficient 
for Apc and glands deficient for both Apc and Apc2. Loss of Apc in addition to Apc2 deficiency caused 
loss of β-catenin, E-cadherin and Zo-1 (arrows represents cells with additional Apc loss, scale bar 
represents 15 µm). (B) Confocal images display disrupted microtubules in epithelial cell deficient for 
both Apc proteins (scale bar 5µm). 
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To further explore the consequences of combined mammary epithelial Apc and Apc2 loss 
whilst excluding the influence of Apc2 deficient non-epithelial cells, mammary epithelial 
culture was employed. Mammary epithelium from Apcfl/f and Apcfl/f Apc2-/- mice were 
separated from other cell types and grown in culture (see methods). Apc2 deficiency did not 
adversely affect epithelial cells or affect the ability of these cells to form a polarised 
monolayer. An adenovirus containing a Cre-recombinase expression construct (Ad-CMV-Cre) 
was used to infect epithelial cells and target Apc loss. Previous studies have proven a high 
rate of recombination in infected mammary cultures (Rijnkels & Rosen., 2001; Naylor et al., 
2005). High rates of recombination were also observed with our chosen MOI (multiplicity of 
infection) of 50 gauged though titre experiments (data not shown). Infection of Apcfl/fl 
epithelial cultures and subsequent Apc loss caused negligible differences and these cells still 
maintained their ability to form a polarised monolayer. However, in infected cultures 
permitting combined Apc and Apc2 loss, cells lost their ability to grow in monolayer and cell-
cell contact was perturbed consistent with defects in adhesion and polarity. In addition to 
this, cell shape changes arose, with transformation from cuboidal epithelial towards a more 
fibroblastic appearance. Together these changes are consistent with an EMT event.  
Furthermore, these ‘in vitro’ experiments demonstrate functional redundancy exists 
between the two Apc proteins within the mammary epithelial cells, in order to maintain cell 
polarity, adhesion and prevent EMT.  The role of supportive non-epithelia cells, which would 
also be deficient for Apc2 in Blg-Cre+ Apcfl/fl Apc2-/- mice does not seem to be important or 
compensatory for this element of functional redundancy noticed within the ‘in vitro’ 
cultured epithelial cells. 
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Figure 5.14 Combined Apc and Apc2 deficiency induced loss of adhesion, polarity and cell shape 
changes reminiscent of EMT. Apcfl/fl and Apcfl/fl Apc2-/- mammary epithelial cells were harvested and 
grown in culture. Infection with an Adenoviral-Cre to delete Apc induced cellular changes only in 
conjunction with Apc2 deficiency. Cells lost their ability to grow in monolayer, indicative of polarity 
loss. Cells also displayed reduced adhesion and shape changes characteristic of EMT (scale bar 
represents 100µm). 
 
5.2.8 Apc proteins co-operate in tumour suppressor function 
The altered characteristics observed in mammary epithelium deficient for both Apc proteins 
at a short term time point (10 weeks of age) are physiognomies usually altered in 
tumourigenesis. Thus, to examine the role of both Apc proteins in tumourigenesis, cohorts 
containing different combinations of mutations were aged and sacrificed upon signs of ill 
health (Figure 5.15A). These cohorts were Wt, Apc2-/-, Blg-Cre+ Apcfl/fl, Blg-Cre+ Apcfl/fl Apc2+/- 
and Blg-Cre+ Apcfl/fl Apc2-/-. Mice deficient for Apc2 or Apc alone displayed no differences in  
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survival from Wt however, additional Apc2 loss in the context of Apc mutation led to 
reduced survival. Further reduced survival was observed in Blg-Cre+ Apcfl/fl Apc2-/- compared 
to Blg-Cre+ Apcfl/fl Apc2+/- mice, indicating an Apc2 gene dose dependent effect in the 
context of Apc loss. Mice with combined epithelial loss of both Apc proteins developed 
mammary tumours (Figure 5.15B). Upon histopathological inspection (Figure 5.15C) 
(performed in collaboration with Prof. Geraint T. Williams), tumours were deemed invasive 
with ‘spiky’ edges (Figure 5.15D). Ghost cells were still apparent (Figure 5.15E) and some 
areas displayed squamous differentiation with areas of keratin production prominent 
(Figure 5.15F). The majority of mammary tumours analysed displayed similar characteristics 
and together were classified as Squamous carcinoma.  Importantly, these findings 
demonstrate that functional redundancies exist between Apc proteins in tumour suppressor 
function.  
 
Given Blg-Cre+ Apcfl/fl Apc2+/- mice also developed tumours, mammary tissue was examined 
at an early time point (10wks of age). Whole mount and histological analyses revealed 
abnormalities similar to that in DKO glands although the severity was somewhat reduced 
(Figure 5.16). This suggests that Apc2 has a gene dose effect in maintaining epithelial 
integrity in the context of Apc loss. Mammary tumour incidence was recorded at the time of 
death for all genotypes (Figure 5.17A). Whilst Wt, Apc2-/- or Blg-Cre+ Apcfl/fl glands showed 
no signs of tumour formation, 46% of Blg-Cre+ Apcfl/fl Apc2+/- and 80% of Blg-Cre+ Apcfl/fl 
Apc2-/- mice had tumour tissue in one or more of their mammary glands. This suggests that 
Apc2 has a gene dose effect in tumour suppression in the context of Apc loss. 
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Figure 5.15 Combined deficiency of both Apc proteins in mammary epithelium resulted in mammary 
tumour formation with age. (A) Wt (yellow line), Apc2-/- (purple line), Blg-Cre+ Apcfl/fl (Blue line), Blg-
Cre+ Apcfl/fl Apc2+/- (green line) and Blg-Cre+ Apcfl/fl Apc2-/- (red line) mice were aged out and culled 
upon signs of ill health (survival presented as Kaplan-meier). Apc2-/- and Blg-Cre+ Apcfl/fl mice 
displayed no alterations in survival compared to Wt mice (Log-rank test, p>0.32, n≥11). Both Blg-Cre+ 
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Apcfl/fl Apc2+/- and Blg-Cre+ Apcfl/fl Apc2-/- mice displayed reduced survival compared to other 
genotypes (asterisks mark statistically different comparisons, p≤0.01, Log-rank test, n≥11). Both Blg-
Cre+ Apcfl/fl Apc2+/- and Blg-Cre+ Apcfl/fl Apc2-/- mice displayed reduced health due to mammary 
tumours. (B) Image of a mammary tumour ‘in situ’ before dissection. (C) Representative image of 
H&E stained section of dissected mammary tumour. Histopathological examination characterised 
tumours as squamous carcinoma (scale bar represents 2mm). Magnified images show (D) ‘spiky’ 
tumour periphery invicative of local area tumour invasion (black arrows) (scale bar represents 
200µm). (E) Ghost cells are still occasionly present (black arrows) (scale bar represents 50µm), (F) 
Squamous differentiation (black arrow) and keratin material/whirls are also present (gray arrow) 
(scale bar represents 50µm). 
 
 
 
Figure 5.16 Apc2 has a gene dosage effect in the context of homozygous Apc loss in mice at 10wks of 
age. Top image displays comparative whole mount sections stained with carmine alum and bottom 
images display corresponding H&E stained sections. Blg-Cre+ Apcfl/fl Apc2+/- mammary tissue 
displayed similar defects to Blg-Cre+ Apcfl/fl Apc2-/- although to a lesser extent (top images= scale bar 
represents 2mm, middle images=scale bar represents 1mm, bottom images=scale bar represents 
50µm). 
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Figure 5.17 Mammary tumours are only apparent in mice with combined Apc and Apc2 loss. (A) 
Mice were examined for presence of mammary tumours at death. Whist Wt, Apc2-/- and Blg-Cre+ 
Apcfl/fl mice display no signs of mammary tumorigenesis, 46% of Blg-Cre+ Apcfl/fl Apc2+/- and 80% of 
Blg-Cre+ Apcfl/fl Apc2-/- mice exhibited lesions. This suggests a gene dose dependent effect of Apc2 in 
the context of Apc deletion. (B) Cause of death was determined and confirmed by a pathologist.  
Three main pathologies were identified; mammary squamous carcinoma, sarcoma and other 
(comprising mainly of HCC, lymphoma and unknown).  Whilst Blg-Cre+ Apcfl/fl mice all fall into the 
‘other’ category, additional Apc2+/- or Apc2-/- mutation not only induced an increase in mammary 
squamous carcinoma, but also sarcoma. (C) Example of Sarcoma found in uterine (scale bar 
represents 1mm & higher maginification 100µm). (D) Representative images of mammary gland 
sections taken from aged mice.  Lesions are only present in DKO glands. However, small infrequent 
patches of ghost cells can be found in Blg-Cre+ Apcfl/fl mammary glands (arrow indicates a small patch 
of ghost cells, scale bar represents 1mm).  
 
Mice from aging cohorts were checked regularly and killed either if general health visually 
deteriorated or if mammary tumours arose and surpassed a set size, blistered or restricted 
movement. Cause of death was determined by internal inspection at time of death and/or 
histopatological examination of harvested organs (performed in conjunction with Prof. 
Geraint T. Williams). Three categories for the cause of death were comprised; ‘mammary 
squamous carcinoma’, ‘sarcoma’ or ‘other’ (mostly consisting of lymphoma, HCC and 
undetermined). Wt and Apc-/- fall into the ‘other’ category (discussed in Chapter 3). All Blg-
Cre+ Apcfl/fl mice also fall into the ‘other’ category (Figure 5.17B). However, although no 
differences were noticed in their survival, death was almost certainly attributed to HCC 
(Discussed in next chapter). Interestingly, in cohorts with deficiency for both Apc proteins, 
along with a cause of death due to mammary squamous carcinoma, there was an increase in 
the occurrence of sarcoma.  Sarcomas were mostly detected in the uterine and abdomen, in 
most cases they were poorly differentiated deeming origin hard to determine (Figure 
5.17C).  Histological analysis of mammary tissue taken at time of death revealed lesions only 
in glands deficient for both Apc proteins (Figure 5.17D).  Although no lesions were present 
in Blg-Cre+ Apcfl/fl mammary glands, occasional small clusters of ghost cells were observed.  
Activation of the Wnt signaling pathway is a common event in a range of tumours (Polakis, 
2000; Giles et al., 2003; Reya & Clevers, 2006) including those of the breast (Khalil et al., 
2012). As both Apc proteins share the ability to influence Wnt signaling (Nakagawa et al., 
1998; Van Es et al., 1999) and combined loss of both in the mammary epithelium leads to 
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Wnt perturbations, pathway status was addressed in harvested tumours (Figure 5.18). Serial 
sections from tumours were stained with H&E, β-catenin using florescent IHC and cMyc and 
CD44 using normal IHC. β-catenin displayed a heterogeneous pattern of nuclear expression. 
Tumours stained positive for both cMyc and CD44. Together, these results indicate 
activation of the Wnt signaling pathway in tumours that arise from mammary epithelium 
deficient for both Apc proteins. 
 
Figure 5.18 Mammary tumours arising in glands with epithelium deficient for both Apc proteins 
display Wnt activation. Serial sections of tumour tissue were stained with H&E, β-catenin, cMyc and 
CD44. β-catenin displayed a heterogeneous pattern of nuclear expression. Both cMyc and CD44 
were expressed in the tumours demonstrating Wnt activation (top + bottom images scale bar 
represents 50µm, middle images scale bar represents 100µm). 
 
Axillary lymph nodes represent the first ‘port of call’ for mammary tumour metastases and 
incidence of these metastases correlates with reduced patient survival (McGuckin et al., 
1996; Weigelt et al., 2005).  As combined epithelial loss of both Apc proteins caused local 
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tissue invasion in young mouse glands and also invasive properties in subsequently 
developing tumours, lymph nodes were analysed for signs of invasion and metastases. 
Sections of mammary glands containing lymph nodes from aged Blg-Cre+ Apcfl/fl and DKO 
mice with tumours were stained with H&E (Figure 5.19). Whilst lymph nodes from Blg-Cre+ 
Apcfl/fl displayed a true periphery with epithelial tissue remaining on the outside (all glands  
 
 
Figure 5.19 Tumours arising from mammary epithelium deficient for both Apc proteins display 
invasive properties.  Image shows a lymph node from a Blg-Cre+ Apcfl/fl mammary gland on left and a 
lymph node from DKO on right, both from aged animals. Note invasion of squamous carcinoma cells, 
characterised by production of keratinous material, into the DKO node (arrow indicates a clump of  
cancer cells producing keratinous material within the lymph node periphery,  top image scale bar 
represents 100µm,  higher magnification image scale bar represents 50µm ). 
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analysed), glands from DKO mice displayed invasion of epithelial tissue through the 
periphery and into the node (in 2 out of 3 nodes analysed from glands containing tumours). 
Invading cells within the node still express keratin reminiscent of the squamous carcinoma. 
This occurrence of lymph node metastasis highlights the invasive nature of tumours arising 
from epithelium deficient for both Apc proteins.  
 
5.3 Discussion  
Breast cancer is one of the most common malignancies in the western world and is 
accountable for a fifth of all women who die from cancer.  Despite increasing advancement 
in the understanding of this disease, the roles of the APC proteins remain undefined. 
Evidence has implicated both APC loss (Kashiwaba et al., 1994; Thompson et al., 1993; Jin et 
al., 2001; Ho et al., 1999; Schlosshauer et al., 2000; Sarrio et al., 2003; Furuuchi et al., 2000) 
and APC2 loss (Sobottka et al., 2000; Yang et al., 2004; Wang et al., 1999; Jarrett et al., 2001; 
Chan et al., 2008) in breast cancer, however, parallel assessment has never been conducted. 
It is known both APC and APC2 can regulate the β-catenin/Wnt signaling pathway with 
indications of functional redundancy in the intestines (Van Es et al., 1999; Roberts et al., 
2012). Beguilingly, both are expressed in human mammary epithelium (Kashiwaba et al., 
1994; Schlosshauer et al., 2000; Jarrett et al., 2001). In this chapter I utilised mouse 
transgenics to test the significance of Apc proteins in the mammary epithelium.  Apc loss, 
Apc2 loss and concomitant loss of both were analysed to test their importance in mammary 
epithelial homeostasis and elucidate possible functional redundancies. Results indicate that 
both Apc and Apc2 alone are dispensable for mammary epithelial homeostasis. However, 
combined loss led to a range of defects including; atypical ductal hyperplasia, ghost cell 
formation, loss of polarity and cohesion, local tissue invasion and subsequent formation of 
invasive tumours. The role these proteins play in tumour suppression may extend beyond 
that of Wnt signaling. 
Consistent with human tissue, both Apc proteins are expressed in murine mammary 
epithelium. Apc2 loss in this tissue was achieved through use of the Apc2-/- mouse 
(described in Chapter 3). Loss of Apc2 alone did not lead to any overt mammary phenotype, 
epithelial tissue retained its ductal architecture and remained polarised. Aged mice 
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displayed no alterations in lifespan nor developed any lesions within their mammary glands. 
This, in part, could be attributed to a lack of change in β-catenin intensity, localisation or 
detectible signs of Wnt pathway alteration. Interestingly, Apc2-/- mice did display a 
statistically significant reduction in mammary epithelial proliferation compared to Wt. The 
reasons behind this decrease remain elusive, but one could speculate that as the mouse 
model is a constitutive knock out, developmental compensation may have occurred 
prenatally and perhaps subtle increases in Wnt repression could implement reductions in 
proliferation. Importantly, this is the first study to analyse Apc2 loss in the context of the 
mammary gland and together these findings indicate Apc2 alone is dispensable for 
mammary homeostasis.  
Constitutive Apc loss is embryonic lethal (Moser et al., 1995), so a Cre-lox system was 
employed utilising the Apcfl/fl allele (Shibata et al., 1997) and the Blg-Cre+ promoter (Selbert 
et al., 1998) to delete Apc from the mammary epithelium. Previous studies using the Blg-
Cre+ Apcfl/fl model have reported a delay in ductal growth although no overall alterations in 
virgin mammary epithelial physiology. Tumour formation only resulted when combined with 
an additional Tcf-1 or p53 mutation (Gallagher et al., 2002; Meniel et al., 2005). In another 
recent study targeted mammary epithelial Apc loss using the WAP-Cre promoter also failed 
to induce tumorigenesis (Kuraguchi et al., 2009). Results in this chapter confer with these 
studies where Apc was dispensable for mammary epithelial integrity and tumour suppressor 
function. Loss of Apc neither affected the ductal architecture, polarisation of the epithelium 
or proliferative state. Although loss of Apc in the intestinal epithelium has profound effects 
on the Wnt signaling pathway (Sansom et al., 2004; Andreu et al., 2005), analysis of this 
pathway following mammary epithelial Apc loss failed to display any detectable differences. 
This, in part, could explain the lack of phenotype in Apc deficient mammary epithelium in 
our study.  
 
Interestingly, along with the fact that mice with a heterozygous Apc mutation have a higher 
incidence of mammary tumours (Moser et al., 1993), two recent animal studies have also 
implicated altered Apc in mammary tumorigenesis (Kuraguchi et al., 2009; Gaspar et al., 
2009). In the first study, a K14-Cre promoter was used to target mammary epithelial Apc 
loss, which induced tumour formation. Although this promoter does induce recombination 
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in the mammary epithelium, it is not tissue specific (Kuraguchi et al., 2006). Contributions of 
other recombined cells in tumour formation cannot be delineated. In the second study, a 
constitutive Apc hypomorph was generated, permitting intermediate levels of Wnt signaling 
which pre-disposed mice to mammary tumours as appose to intestinal. This is in line with 
the consensus that varying levels of aberrant Wnt signaling effect different tissues (Buchert 
et al., 2010). However again, contribution of other cell types deficient for Apc hinder true 
consequences of specific epithelial Apc loss. Apc2 status was not addressed in any of these 
studies.  
 
Strikingly, combined loss of both Apc and Apc2 in these experiments led to a range of 
extensive epithelial disruptions and subsequently tumour formation. This is the first study to 
date to demonstrate mammalian functional redundancies between the evolutionarily 
conserved Apc proteins ‘in vivo’. The implications of this finding are of great importance in 
the understanding of both of Wnt signaling transduction and cancer biology.  The following 
discussion of results will focus on the dual roles Apc proteins must play. 
 
Upon histopathological examination of presented lesions in young mammary glands with 
epithelium deficient for both Apc proteins, phenotype was reminiscent of atypical ductal 
hyperplasia (ADH). ADH is one of the most common premalignant lesions in humans and is a 
precursor of ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (Arpino et al., 
2005). Overall, patients with ADH have a 4-5 times higher risk of developing invasive breast 
carcinoma (Page et al., 1985). ADH is classified by an increase in ductal cell number and an 
unusual patterning of these cells (Rosen et al., 2008), both of which were seen in young 
glands with epithelium deficient for both Apc proteins. The effects of aberrant Wnt signaling 
on cell division are well documented (reviewed in Reya & Clevers, 2005) and increases in cell 
division and thus hyperplasia can be explained by the noticed increase in Wnt signaling. 
Although nuclear β-catenin is the indicative sign of active Wnt in the intestines, in the 
mammary, aberrant Wnt can be exhibited by both nuclear β-catenin and an increase in β-
catenin expression (Schlosshauer et al., 2000). The mechanisms behind an increase in β-
catenin expression are unknown. However, in mammary epithelium deficient for both Apc 
proteins there were regions which display both an increase and nuclear translocation of β-
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catenin concomitantly. These areas also displayed an increase in cMyc expression indicating 
aberrant activation of the Wnt signaling pathway.   
 
The other requisite for classification of ADH is aberrant positioning and patterning of ductal 
epithelial cells (Rosen et al., 2008). In mammary epithelium deficient for both Apc proteins, 
polarity and cell positioning was vastly perturbed. The luminal and myoepithelial layers 
were chaotically organised and grew into the lumen, and markers of polarity such as Zo-1 
and E-cadherin were lost.  It is known Zo-1 and E-cadherin co-localize with β-catenin at the 
plasma membrane and co-immunoprecipitate (Rajasekaran et al., 1996). Furthermore, β-
catenin has been shown to aid these proteins in the development of tight junctions, 
structural markers of polarised epithelial cells (Tsukita et al., 1999). Studies have suggested 
that activation of the Wnt signal pathway and nuclear translocation of β-catenin can 
suppress Zo-1 activity, diminishing polarity (Mann et al., 1999; Reichert et al., 2000). As 
concurrent loss of Apc and Apc2 caused nuclear translocation of β-catenin in our model, this 
is one proposed mechanism behind the aberrant cell positioning. 
 
Interestingly, mouse models with activating β-catenin mutations also display ductal 
hyperplasia, but not ADH (Imbert et al., 2001; Miyoshi et al., 2002; Michaelson et al., 2001; 
Teulière et al., 2005). This suggests that defects regarding cell positioning, the other 
requisite for ADH, cannot solely be explained through canonical Wnt signaling.  ‘In vitro’ and 
‘in vivo’ work suggest important roles of Apc proteins, independent of β-catenin 
transcriptional activity (reviewed in Aoki and Taketo, 2007; McCartney and Nathke, 2008) 
and evidence is emerging implicating a more direct role of Apc proteins in controlling 
epithelial polarity. Both Apc and Apc2 have been shown to localise to the apical membrane 
of polarised epithelial cells (Reinacher-Schick & Gumbiner, 2001; McCartney et al., 1999) 
and both are thought to play a role in polarity through direct interaction with the actin and 
microtubule skeleton (Wen et al., 2004; Collin et al., 2008; Etienne-Manneville et al., 2005; 
Inaba et al., 2010). Cytoskeletal defects were noticed in this study in mammary epithelium 
deficient for both Apc proteins, consistent with a redundant role of Apc proteins beyond 
Wnt signaling. Regardless of exact mechanism, the evidence suggests that Apc proteins have 
dual roles in both controlling cell division and maintaining polarity, and combined defects in 
these functions converge to cause ADH. Although there is a high frequency of ADH in human 
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patients (Arpino et al., 2005) and an associated increased risk in development of invasive 
breast cancer (Page et al., 1985), animal models of ADH are seldom. Young Blg-Cre+ Apcfl/fl 
Apc2-/-glands could present an admirable model of ADH for a whole range of benefits 
ranging from identification of biomarkers through to screening of therapeutics. 
 
Mammary epithelium deficient for both Apc proteins also led to the appearance of ghost 
cells. These are characterised as anucleate ‘cells’ which stain positive for hard keratins and 
are most likely necrotic (Tanaka et al., 2007). They are extensively reported in a variety of 
human cancers, including those of the breast (Raman et al., 2000; Rosner et al., 2002; 
Hernanz et al., 2012). However, their highest occurrence is within tumours of the head and 
neck region (Hong et al., 1991; Marrogi et al, 1992; Kumaran et al., 2006). Studies of 
Pilomatricoma (type of Skin tumour), Craniopharyngioma (type of brain tumour) and 
Odontoma (type of Dental tumour), all of which contain ghost cells, all reveal aberrant β-
catenin localisation in surrounding cells (Hassanein et al., 2003; Tanaka et el., 2007). This 
implies Wnt signaling plays some role in the development of these lesions. However, the 
status of other Wnt pathway genes, such as APC or APC2 was never addressed. In our 
model, ghost cells occurred in almost every gland analysed and areas could be found were 
cells showed transition from normal appearing epithelium to ghost cell like. Upon further 
analysis it was revealed that in the early stages of transition, cells displayed nuclear/up-
regulation of β-catenin and were cycling.  As we move furthered through this zone of 
transition, cells become increasingly anucleate with observable apoptotic bodies and 
production of a pink material reminiscent of keratin.  
 
A number of mechanisms could be responsible for epithelial transition to ghost cells; Wnt 
induced cell death, lack of vascularity and supportive cells or genetic re-programed 
differentiation. It is known cells require a ‘just right’ level of Wnt signaling for growth 
incurred advantage (Lamlum et al., 1999; Albuquerque et al., 2002; Lucero et al., 2010) and 
levels too high induce cell death (Lazarova et al., 2004; Bordonaro et al., 2008). Concurrent 
Apc and Apc2 loss causing high levels of Wnt may initially induce proliferation which could 
then be followed by cell death and subsequent keratinisation of cells which remain ‘in situ’. 
Indeed, concomitant loss of Apc proteins in the intestines induced cell death (discussed in 
Chapter 4) and in the mammary epithelium where there was an increase in caspase-3 
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staining. However, this increase in cell death could occur due to other reasons in addition to 
Wnt hyper-activation, one example being increased DNA damage. Another mechanism 
behind this transition may lie with reduced vascularity. As these Wnt activated cells 
proliferate, nutrients or cell signals may not be able to penetrate this increased mass, 
inducing necrosis and/or differentiation. A further mechanism may lie with re-programed 
differentiation. It is known keratin genes are Wnt targets (St-Jacques et al., 1998) and the 
Wnt signaling pathway is imperative in terminal hair shaft differentiation (Tsuji et al., 2001; 
Zhou et al., 1995; Dunn et al., 1998), a tissue that requires cell keratinisation. Loss of both 
Apc proteins in the mammary epithelium may activate transcription of these keratin genes 
through increased Wnt signaling and induce trans-differentiation and thus formation of 
ghost cells.  The mechanisms behind formation of ghost cells in our model do warrant 
further investigation. One could speculate that this switch from a Wnt hyper-active cell to a 
terminally differentiated ghost/keratinocyte and the mechanisms behind this switch could 
expose new potential strategies in the treatment of cancer. 
 
In mammary epithelium deficient for both Apc protein, along with areas which displayed 
miss-localised, up-regulated or nuclear β-catenin, groups of cells appeared to lose 
detectable expression altogether.  From these experiments it cannot be determined if this 
heterogeneous patterns of β-catenin expression is a progressive sequence of events caused 
by loss of both Apc proteins or the effect of recombination in different cell types. In any 
case, complete loss of detectable β-catenin was also affiliated with epithelial defects. Upon 
inspection of epithelium in our model, cohesion was lost and cells and/or clumps of cells 
appeared to detach from the epithelial layer and ‘invade’ surrounding tissue. Occasionally 
these cells still retained some cytokeratin labelling suggesting an epithelial origin. These 
cells may result as a consequence of duct rupture caused by a build-up of ghost cell 
aggregates. However, cell damage was not overtly obvious and nor was death of these cells. 
As β-catenin is mostly undetectable in these cells, it is possible that this phenotype is not 
associated with canonical Wnt signaling. As mentioned previously, the role of Apc proteins 
in tumour suppression is multifunctional (reviewed in Aoki and Taketo, 2007; McCartney 
and Nathke, 2008) and evidence toward direct cytoskeletal roles in addition to that of β-
catenin degradation is mounting (reviewed in Prosperi & Goss, 2011).  
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The ability of cells to invade and metastasize is paramount in cancer progression. In order 
for this to occur, cells from epithelial origin must obtain the ability to alter cohesion and 
adhesion. Loss of both Apc and Apc2 have been implicated independently in adhesion 
defects (Reichert et al., 2000; Bienz and Hamada, 2004; Faux et al., 2004 Hamada and Bienz, 
2002) and it has been reported previously that this role is mutually exclusive from that of β-
catenin degradation (Prosperi et al., 2009; Harris & Nelson, 2010). Apc proteins’ role in 
adhesion is most likely linked with the fact that they both localise with adherens and tight 
junctions (Reichert et al., 2000; Bienz and Hamada, 2004; McCartney et al., 1999). In our 
model, areas displayed loss of E-cadherin and Zo-1 which mark both adherens junctions and 
tight junctions respectively. One could speculate that a direct cytoskeletal presence of at 
least one Apc homolog is a necessity for formation or maintenance of these junctions and 
loss of both Apc’s leads to dissociation. The exact role Apc and Apc2 play in regulating 
adhesion and/or how loss of both proteins induces loss of β-catenin, E-cadherin and Zo-1 is 
unknown. However, disturbed tissue organisation through disrupted adherens junctions and 
tight junction protein integrity is frequently observed in cancer (Schmalhofer et al., 2009) 
and correlated with a more aggressive and advanced state (Thiery, 2002; Huang & 
Muthuswamy, 2010). How combined Apc and Apc2 loss influences adherens junctions and 
tight junctions is an exciting avenue for further research. Together these results imply that 
Apc proteins are functionally redundant in controlling cohesion and adhesion, and this may 
be a role independent of canonical Wnt signalling. 
 
A property associated with invasive ability of cells is epithelial-mesenchymal transition 
(EMT). This is characterised by a loss of adhesion, cell shape changes and increased motility 
(reviewed in Thiery et al., 2009; Sleeman et al., 2012). Previous studies have associated Wnt 
signaling with promotion of EMT (Fu et al., 2011; Valenta et al., 2012; Anson et al., 2012; 
DiMeo et al., 2009). In mammary epithelium deficient for both Apc proteins, there are cells 
which displayed positive staining for vimentin concomitant with a loss of E-cadherin. 
Together these characteristics are indicative of EMT (Blanco et al., 2004).  However, 
although there is a noticed increase in Wnt signaling in our model, cells which display 
invasive properties were usually negative for β-catenin staining.  This suggests a different or 
concurrent mechanism behind the transition. Indeed, there was no correlation between 
nuclear β-catenin staining, ‘invasive’ cells or expression of snail (a known inducer of EMT 
 161 
 
influenced by Wnt signaling (Cano at al., 2000)). This is another aspect of this model that 
warrants further research. 
 
Cultured mammary epithelial cells were used to explore the consequences of combined Apc 
and Apc2 loss. Pure epithelial cultures help delineate influences on epithelial cell from 
supportive non-epithelia cells, which would also be deficient for Apc2 in Blg-Cre+ Apcfl/fl 
Apc2-/- mice.  Mammary epithelial cells deficient for Apc2 or Apc through targeted 
recombination with an adenovirus, failed to display overt differences from control tissue. 
However, combined loss of both Apc proteins led to both polarity and adhesion defects, 
cells also displayed prominent shape changes consistent with EMT. These ‘in vitro’ 
experiments help validate the functional redundancies noticed in epithelial cells ‘in vivo’.  
Further ‘in vitro’ work concurrent with mammary epithelial transplants (discussed in 
Raijnkels & Rosen, 2001) could help expose true invasive potential of these cells. 
 
To summarise so far, both Apc proteins alone are dispensable for mammary epithelial 
homeostasis. However, combined loss led to a range of epithelial defects and these defects 
may be contributed to by a component beyond that of canonical Wnt signaling. Previous 
reports have shown defects caused by Apc loss in the intestines can be rescued through 
additional cMyc mutation (Sansom et al., 2007). cMyc is a Wnt target gene (He et al., 1998) 
and a global regulator of transcription (Dang et al., 2006). As only combined loss of Apc and 
Apc2 induced detectible increases in cMyc, it would be interesting to see how much of the 
phenotype can be accredited to its over-expression. Although transcription of some genes 
upon nuclear translocation of β-catenin are cMyc independent (Sansom et al., 2007), 
concomitant mammary epithelial loss of both Apc proteins and cMyc may help delineate 
Wnt dependent and Wnt independent functions Apc proteins may play in mammary 
homeostasis. 
 
Upon aging mice with mammary epithelial deficiency for Apc or Apc2 alone, neither 
displayed survival differences from control mice within the timeframe of the experiment. No 
lesions were present within the mammary glands of either genotype upon time of death, 
although occasional small aggregates of ghost cells were present in glands deficient for Apc. 
It would be interesting to test the status of Apc2 in epithelium surrounding these aggregates 
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given the vast occurrence of ghost cells in glands with epithelial deficiency for both Apc 
proteins. Some mechanism causing reduction of Apc2 concomitant with Apc loss in these 
cells could be a causative explanation. Taken together, these results suggest both Apc and 
Apc2 alone are dispensable for tumour suppression within the mammary epithelium. 
 
Strikingly, combined deletion of both Apc proteins induced mammary tumourigenesis and 
significantly reduced survival. Although no redundant roles in tumour suppression are 
eminent between Apc proteins within the intestine (discussed in Chapter 3 & 4), in the 
mammary epithelium the redundancies are paramount. Functional redundancies in tumour 
suppression in a range of other tissues may explain why even though APC is ubiquitously 
expressed, its loss is mostly associated with intestinal tumourigenesis (Kinzler et al., 1991; 
Groden et al., 1991; Nishisho et al., 1991). In addition to mammary tumorigenesis, mice with 
epithelial deficiency of both Apc proteins also occasionally developed sarcomas. These are a 
type of tumour that is thought to arise from connective tissue origin (Helman & Meltzer, 
2003). Most were located within the uterine or abdomen in experimental mice, however, 
origin of these tumours was difficult to determine. As occurrence of both tumour types 
requires the Blg-Cre+ transgene in addition to mutations of both Apcs, sarcomas either arise 
as a consequence of metastasis from the mammary tumours or ‘de novo’ occurrence due to 
tissue non-specific recombination. Both require further exploration. 
 
Mice with both homozygous and heterozygous Apc2 mutation in the context of mammary 
epithelial Apc loss developed mammary tumours and occasional sarcomas. The incidence of 
these tumours and reduction in lifespan were not as severe in the heterozygous mice. This 
along with the fact they also displayed similar epithelial defects at a young time point, 
although not as intense, suggests a gene dose dependent effect of Apc2 in the context of 
Apc loss. Interestingly, whilst APC2 mutation is infrequent, gene silencing through varying 
degrees of promoter hypermethylation is extremely common in human breast cancers 
(Chan et al., 2008). Levels of promoter methylation correlate with levels of reduced protein 
expression (Suzuki & Bird, 2008; Chan et al., 2008). This complies that reduced expression 
levels of APC2 are sufficient for tumourigenesis in the right context. APC also displays high 
levels of promoter hypermethylation (Van der Auwera et al., 2008). It would be interesting 
to quantify levels of both APC and APC2 expression concurrently in human breast cancer. It 
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can be speculated that combined reductions are needed in human tissue to induce 
tumorigenesis.  
 
Following histopathological inspection, the majority of collected mammary tumours were 
classified as squamous carcinoma. This cancer is a relatively rare human breast carcinoma 
(Cardoso et al., 2000). However, it is aggressive, invasive and associated with a poor patient 
prognosis (Wargotz & Norris, 1990). Consistent with human diagnosis, tumours in mice were 
deemed invasive with some areas of squamous differentiation and characteristic areas of 
keratin production. It is interesting that whilst most human cancers display aberrations in 
APC and/or APC2 expression, loss of murine Apc proteins led to a rare cancer subtype. 
Indeed, the majority of mouse models causing aberrant Wnt signaling in the mammary lead 
to some sort of squamous differentiation (Sasai et al., 2000; Brennan & Brown, 2004; Gaspar 
et al., 2009; Kuraguchi et al., 2009), which is uncommon in human breast cancer. This 
discrepancy might highlight evolutionary differences between human and mouse tissue. 
However, a more plausible explanation may lay with the additional genetic mutations found 
in human breast cancers. It is known that most breast cancers contain more than 80 non-
silent mutations (Wood et al., 2007) and varying patterns of gene expression can define 
cancer subtype (Sotiriou & Pusztai, 2009). Regardless of dissimilarities, mice with concurrent 
mammary epithelial Apc and Apc2 loss mimic human cancer progression as lesions develop 
from ADH through to invasive carcinoma.  
 
Most of the tumour sample collected displayed a heterogeneous pattern of nuclear β-
catenin. This was concomitant with activation of the Wnt gene targets cMyc and CD44 in the 
majority of cells, indicating tumours are Wnt activated. As the Wnt signaling pathway was 
only activated in a subset of epithelial cells at an early time point, It is unknown if these 
tumours arise due to Wnt activation in specific cell types, which one could speculate to be 
mammary stem cells or due to an accumulation of other oncogenic mutations in other cell 
types. APC loss has been shown to induce chromosome instability in other tissues (Fodde et 
al., 2001; Green & Kaplan et al., 2003) and in another mouse model targeting mammary 
epithelial Apc loss, additional activating mutations in H-Ras or K-Ras were present in a 
subset of arising mammary tumours (Kuraguchi et al., 2009). Further analysis of obtained 
tumour samples from this study will help elucidate contribution of other genetic factors.   
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The importance of the Wnt signaling pathway and aberrations of this pathway on adult stem 
cells is closely tied with cancer initiation in a range of tissues (Reya & Clevers, 2005). Indeed, 
the origin of intestinal cancer can be attributed to Wnt alterations in these cells (Barker et 
al., 2009). The contribution mammary stem cells play, as well as the contribution of aberrant 
Wnt signaling in these cells, is not well defined in breast cancer.  Mammary stem cells have 
been characterised (Shackleton et al., 2006; Stingl et al., 2006; Van Keymeulen et al., 2011; 
Shehata et al., 2012) and implicated in tumour initiation (Al-Hajj et al., 2003; Dontu et al., 
2003; Ginestier et al., 2007). It has also been show that markers of these stem cells increase 
in Wnt activated mammary tumours (Shackleton et al., 2006). However, influence of Wnt 
signaling in these cells and their relationship with cancer origin remain inconclusive 
(reviewed in Lindvall & Williams, 2007).  As concurrent loss of mammary epithelial Apc 
proteins induces both activation of the Wnt signaling pathway and initiation of tumours, it 
poses an excellent model to study the role Wnt signaling plays on mammary stem cells in 
tumourigenesis.  
 
Mammary tumours arising from epithelium deficient for both Apc proteins also possessed 
invasive capabilities. Histopathological analysis of tumours revealed invasive qualities; local 
tissue invasion was present as well as occurrence of invasion and metastasis into the 
mammary lymph nodes. In cancer progression, invasion into the vascular or lymphatic 
system is a key step in tumour cell dissemination (Fidler, 2003; Christine et al., 1989; Gupta 
& Massague, 2006). Distant metastases were not confirmed although some mice did display 
occurrence of multiple tumours (classified as sarcomas of unidentifiable origin). The 
mechanisms behind promotion of invasion may be two-fold, both indirect through aberrant 
Wnt signaling and/or direct through cytoskeletal and adhesion alterations.  It is known 
nuclear translocation of β-catenin and subsequent Wnt activation can promote both 
reductions in adhesion and EMT (Yook et al., 2005; Fu et al., 2011; Valenta et al., 2012; 
Anson et al., 2012; DiMeo et al., 2009). Also, analysis of mammary epithelium deficient for 
both Apc proteins at an early time point display diminished junctional complexes, adhesion 
and cohesion which occurred concomitant with complete β-catenin loss. As mentioned 
previously, from these experiments we cannot confirm if the differing patterns of β-catenin 
localisation are a sequence of events. Nuclear translocation of β-catenin and activation of 
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Wnt may induce adhesion changes and EMT which could then be followed by β-catenin loss. 
Indeed, the majority of primary tumour cells did display Wnt activation. Interestingly, 
confusion of β-catenin status in invasion extends to human breast samples. Both β-catenin 
nuclear translocation (Lin et al., 2000; Geyer et al., 2011; Khramtsov et al., 2010) and 
protein loss (Dolled-Filhard et al., 2006; Park et al., 2007) have been correlated with 
metastasis and poor patient outcome. Together this evidence increases the probability of a 
concomitant Wnt independent influence of loss of Apc proteins, in invasion. 
 
Invasion and metastasis of cancer account for more than 90% of cancer-related deaths 
(Chaffer & Weinberg, 2011). The pathological progression of human breast cancer is well 
documented and well understood, however, the molecular factors which control this 
progression are less well characterised. Progression from deregulated epithelial 
proliferation, into atypical hyperplasia, carcinoma ‘in situ’, and invasive carcinoma, which 
may develop metastasis, is the accepted biological pathway in human breast cancer 
progression (Rosen et al., 2008). Mammary deficient for both Apc proteins implement 
epithelial changes which assist in all these stages from increased proliferation through to 
increased invasive capabilities. Although Apc proteins are redundant in these functions, it is 
not clear how much can be account for through effects on Wnt signaling.  
 
To summarise, results in this chapter indicate that both Apc and Apc2 alone are dispensable 
for mammary epithelial homeostasis. Combined loss led to a range of epithelial defects 
which subsequently led to tumour formation. This exposes functionally redundant functions 
between Apc proteins within the mammary gland in homeostasis and tumour suppressor 
function. While Wnt activation was subtle at an early time point and some defects may be 
attributed to Wnt independent means, combined loss of Apc and Apc2 synergise to drive 
Wnt activated tumours. The contrasts and parallels between this model and human disease 
provide important insights into the factors driving human tumours through subtle 
deregulation of Wnt. 
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Chapter 6  
Investigating the liver phenotypes associated with reduced 
levels of Apc proteins  
 
6.1 Introduction 
Apc proteins play key roles throughout development, homeostasis and induction of 
pathogenesis in a variety of tissues. The previous chapters have exposed the roles of Apc 
proteins in the intestines and mammary gland. The Wnt signaling pathway is increasingly 
implicated in regulating liver homeostasis, thus the roles of the Apc proteins were explored 
in this tissue.  
 
The liver is one of the largest organs in mammals and the largest gland. It has many 
functions but some of the most important include detoxification and production of 
biochemicals for digestion. The liver can be broken down into basic functional units termed 
hepatic lobules (Figure 6.0). 
 
Figure 6.0 The liver and its basic functional unit (hepatic lobule). The liver receives a dual supply of 
blood from both the portal vein and hepatic artery. Whilst the hepatic artery supplies the liver cells 
 167 
 
with oxygenated blood directly from the heart, the portal vein brings nutrient rich blood from the 
small intestines for processing and metabolising. The liver can be broken down into basic functional 
units termed hepatic lobules. Blood flows into these lobules through the hepatic artery and portal 
space, travels through the network of hepatocytes enduring metabolic processes and is collected by 
the central vein. The central veins of each unit congregate to eventually form the hepatic vein which 
transports the cleansed blood to the heart. The liver also supplies bile to the small intestine to aid 
digestion.  Bile is produced by the hepatocytes and collected via a network of bile ducts. These ducts 
congregate into the common bile duct which either directly supplies bile to the small intestine or 
stores it in the gallbladder. 
 
Analysis of cultured embryonic murine livers and use of knockdown studies ‘in vitro’ suggest 
a role for β-catenin in hepatocyte proliferation and differentiation (Micsenyi, 2004: Monga 
et al., 2003). Targeted loss of Apc or activating mutations in β-catenin in Hepatoblasts 
during development resulted in underdeveloped livers and subsequent embryonic lethality 
(Decaens et al., 2008: Tan et al., 2008). These experiments demonstrate the importance of 
Wnt signaling during liver embryogenesis however, control of this pathway is also important 
in adult liver homeostasis. In adult mice targeted disruption of Apc or activating mutations 
of β-catenin in hepatocytes resulted in abnormal Wnt activation and subsequent 
hyperproliferation leading to hepatomegaly-associated mortality (Colnot et al., 2004: Reed 
et al., 2008: Benhamouche et al., 2006).  Conversely, loss of β-catenin was dispensable for 
normal liver function but did result in liver weight reduction (Sekine et al., 2006) and a delay 
in hepatocyte proliferation after partial hepatectomy (Sekine et al., 2007).  
 
Previous experiments have demonstrated the importance of Wnt signaling in liver cellular 
patterning, referred to as ‘zonation’. Expression of metabolic genes involved in drug 
metabolism, ammonia detoxification, carbohydrate metabolism, and bile production and 
secretion are dictated by a cells position along the porto-central axis of the liver lobule. 
Differential zones of “periportal” (PP) or “perivenous” (PV) hepatocytes are established 
which express different patterns of metabolic gene expression. Contrasting localization 
patterns are observed for active β-catenin expressed in PV hepatocytes and Apc, which is 
expressed in PP hepatocytes (Benhamouche et al., 2006). Various studies inactivating Apc in 
the murine liver induced a PV genetic program, at a PP expense, supposedly through β-
catenin activation (Benhamouche et al., 2006; Reed et al., 2008; Burke et al., 2009).  
Conversely inactivation of β-catenin expression or over expression of Dickkopf 1 (a Wnt 
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inhibitor) resulted in an induction of a PP genetic program at the expense of the PV program 
(Burke et al., 2009; Sekine et al., 2006; Benhamouche et al., 2006). The importance of Apc2 
in the regulation of liver zonation has yet to be investigated, but given its known ability to 
regulate Wnt signaling, it is reasonable to speculate it may also have a role in liver 
homeostasis. 
 
Aberrations in the Wnt signaling pathway have been noted in a variety of pathological liver 
conditions ranging from hepatitis to carcinoma (reviewed by Thompson et al., 2007). 
Patients with mutations in APC are at an increased risk of developing hepatoblastoma 
(Giardiello et al 1996; Hirschman et al 2005) a rare, rapidly progressive, usually fatal 
childhood malignancy.  Although Patients with FAP are usually associated with intestinal 
malignancies, hepatic tumours have been reported and can include adenoma, fibrolamellar 
carcinoma, and hepatocellular carcinoma (HCC) (Gruner et al., 1998; Toiyama et al., 2011; Li 
et al., 2012). A significant fraction of cholangiocarcinomas as well as HCC’s exhibit 
alterations in Wnt signaling (Taniguchi et al., 2002; Tokumoto et al., 2005) suggesting that 
Wnt can act on several cell types in the liver to induce carcinogenesis. HCC is the most 
prevalent primary liver cancer, ranking as the fifth most common cancer in the world and 
being the third most common cause of cancer-related death (Bosch et al., 1999). Studies 
have shown inappropriate β-catenin signalling in at least 30% and up to 70% of all HCC (de 
La Coste et al., 1998: Wong et al., 2001: Giles et al., 2003). Hypermethylation of the APC 
promoter in HCC in patients occurs in >80% of cases and results in a reduction of APC 
protein expression (Sun et al., 2003; Jain et al., 2011; Cspregi et al., 2008). The higher 
occurrence of APC hypermethylation in tumours compared to the level of β-catenin 
activation suggests, a Wnt independent role, in addition to the Wnt dependent role, for APC 
in HCC development. Although Wnt signalling may play a part, the major mechanisms at 
play during the development of HCC remain poorly understood, hindering the development 
of novel therapeutic approaches (Farazi and DePinho, 2006).   
 
As discussed in the previous chapters, both Apc proteins have the ability to regulate Wnt 
signaling and harbour overlapping roles in a variety of tissues.  Apc2 is highly expressed 
throughout liver development and in the adult tissue (Shintani et al., 2012) although its role 
in this organ has never been addressed. One possible way in which Apc2 may play a role is 
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through its interaction with Proline/serine-rich coiled-coil 1 (PSRC1) an oncogene commonly 
over expressed in human HCC (Yang et al., 2011). PSRC1 is a micro-tubule-associated protein 
that promotes cell growth by several different mechanisms, one of which is through binding 
to APC2 and enhancing β-catenin dependent transactivation of Wnt target genes (Hsieh et 
al., 2007). In this chapter I wished to characterise and compare the effects of Apc, Apc2 and 
combined loss within the liver using a range of transgenic approaches.  
 
 
 
6.2   Results 
6.2.1 Targeting loss of Apc and Apc2 proteins in the murine liver 
In order to investigate the role of Apc proteins within the adult liver, a variety of transgenic 
approaches were employed*. Foremost, to analyse the consequences of high level Apc loss, 
a Cre recombinase conditional knock-out system was used to circumvent the embryonic 
lethality associated with constitutive Apc loss (Moser et al., 1995). The Tg(Cyp1a1-cre)1Dwi 
transgene (abbreviated here as Ah-Cre+) targets Cre recombination in a variety of tissues, 
including the liver following intraperitoneal administration of β-napthoflavone (Ireland et 
al., 2004). To test liver targeted recombination, Ah-Cre+ mice were crossed with mice 
containing the ROSA26+ reporter allele (described in Chapter 5) and harvested 4 days after a 
β-naphthoflavone induction regime (see methods). Whole mount liver pieces incubated 
with X-gal revealed high levels of recombination in livers positive for the Ah-Cre transgene                        
(Figure 6.1A). β-galactosidase antibody staining of induced Apcfl/fl and un-induced Ah-Cre+ 
Apcfl/fl  liver sections revealed no spontaneous recombination in liver cells. However, more 
than 95% of induced Ah-Cre+ Apcfl/fl liver cells displayed recombination events following 
induction (Figure 6.1B). Un-induced Ah-Cre+ Apcfl/fl livers displayed no staining for β-
galactosidase activity, which revealed recombination was dependent on induction (data  
 
 
 
 
*Animals involved in the experiments using Ah-Cre
+
 were induced and dissected by Dr Karen Reed. X-gal liver 
whole mount performed by Dr. Reed. The subsequent analysis of the tissue sections was carried out by me. 
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Figure 6.1 Induced Ah-Cre+ ROSA26+mice displayed efficient Cre recombination within the liver. (A) 
Whole mount pieces of induced Ah-Cre+ and Ah-Cre– livers, incubated with X-gal, revealed high levels 
of recombination only in Ah-Cre+ mice following induction (scale bar 2.5mm). (B)  β-galactosidase 
antibody staining of Apcfl/fl and Ah-Cre+ Apcfl/fl liver sections displayed no spontaneous recombination 
in Apcfl/fl cells however, more than 95% of Ah-Cre+ Apcfl/fl  cells  displayed recombination events (scale 
bar 100um). 
 
not shown). In contrast to acute levels of Apc loss within the liver following Cre-
recombinase activation, more subtle levels of reduction can be investigated through non-
induced Apcfl/fl livers. This is due to the hypomorphic nature of the genetically modified Apcfl 
allele which causes reduced levels of Apc mRNA expression in mice (Shibata et al., 1997). 
These reduced Apc levels are sufficient to induce a phenotype within the liver (Buchert et 
al., 2010). Fluorescent IHC  staining using an antibody raised against the C-terminal tail of 
Apc revealed a slight reduction of Apc protein in un-induced Apcfl/fl livers and a vast 
reduction in induced Ah-Cre+ Apcfl/fl livers (Figure 6.2A).  
In order to evaluate Apc2’s role in the liver, the constitutive Apc2-/- mouse was used 
(described in Chapter 3).  Fluorescent IHC using an antibody raised against the C-terminal 
tail of Apc2 revealed an abundance of Apc2 specific staining in the Wt livers, which was lost 
in Apc2-/- livers (Figure 6.2B).    
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Figure 6.2: Reduction of Apc proteins shown by fluorescent IHC. (A)Wt, Apcfl/fl and induced Ah-Cre+ 
Apcfl/fl Liver sections were stained with an anti-Apc antibody raised against the C-terminal tail of Apc.  
Ah-Cre+, Apcfl/fl    liver cells displayed a reduction in Apc protein 4 days post induction compared to 
Wt. Non-induced Apcfl/fl (or induced Apcfl/fl negative for Ah-Cre {not shown}) displayed a slight 
reduction Apc protein. This was due to the hypomorphic nature of the Apcfl allele. (B) Wt and 
constitutive Apc2-/- liver sections were stained with an Anti-Apc2 antibody raised against the C-
terminal tail. No cells in the Apc2-/- livers stain for Apc2 (scale bar 100um). 
 
To directly test the functions of Apc proteins in liver homeostasis and elucidate any 
functional redundancies that may exist, mice were inter-crossed to create six combinations 
of genotypes (summarised in Figure 6.3). These could allow us to test all possible 
combinations. However, due to low level embryonic expression of the Ah-Cre+ transgene, 
Ah-Cre+ Apcfl/fl Apc2-/- mice die ‘in utero’ due to compromised functional redundancies that 
must exist during development.  Full characterisation of liver phenotypes in the other 
genotypes was carried out. 
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Figure 6.3: Experimental design to test the function of Apc proteins in liver homeostasis.  Wt : livers 
contains full length Apc & Apc2. Apc2-/- : full length Apc protein combined with a constitutive 
truncating Apc2 mutation. Mice displayed un-altered survival as shown in chapter 3.   Ah-Cre+ Apcfl/fl  
: full length Apc2 but induced Cre mediated Apc truncating mutation in the liver. Mice only survived 
4-5 days following induction due to recombination in other tissues, mainly the intestinal track.  Ah-
Cre+ Apcfl/fl  Apc2-/- : mice die ‘in utero’ due to low level embryonic expression of the Ah-promoter 
compromising functional redundancies that exist between Apc proteins in embryonic development. 
Apcfl/fl : consists of full length Apc2 but had reduced levels of Apc due to the genetically inserted loxP 
sites. These mice are known to develop HCC at around 400 days of age.  Apcfl/fl Apc2-/- : consists of 
both the hypomorphic Apcfl/fl alleles and constitutive truncating Apc2 mutation. These mice were 
viable and thus allowed us to directly test the significance of Apc2 on the development of HCC. 
Heterozygous combinations were not assessed (protein schematics adapted from Webb et al., 2009). 
  
6.2.2 Levels of cell division and liver integrity are only altered following loss of 
Apc 
To compare the effects of acute loss of either Apc or Apc2 on liver homeostasis cohorts of 
Wt, Apc2-/- or Ah-Cre+ Apcfl/fl mice were established. To induce high level liver loss of Apc, 
Ah-Cre+ Apcfl/fl mice were induced with a β-naphthoflavone regime. Although loss of Apc2 
alone did not lead to alterations in animal survival (Chapter 3), acute loss of Apc using the 
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Ah-Cre+ transgene led to morbidity 4-5 days following induction. This is due to both 
manifestations of the intestinal tract (Samson et al., 2004) and liver hepatomegaly (Reed et  
 
Figure 6.4: loss of Apc2 had no effect on liver histology or proliferation. However, acute loss of Apc 
caused hepatomegaly and hyper proliferation. (A) H&E stained liver sections from Wt, Apc2-/- and 
Ah-Cre+ Apcfl/fl mice, bottom row higher magnification of top panel (PS= Portal Space, CV= 
Centrilobular vein).  Apc2-/- livers displayed normal histology compared to Wt, however, Ah-Cre+ 
Apcfl/fl livers displayed an increase in cell number and increase in liver to body weight ratio (data not 
shown) (scale bar represents  200um). (B) Liver sections were stained with an anti-Ki-67 antibody to 
assess levels of cell division. Whilst Wt and Apc2-/- had a comparably relatively few cells cycling 
within the liver, Ah-Cre+ Apcfl/fl livers displayed a high frequency of KI-67 labelled cells. Inlet shows 
same image at higher magnification. (C)Quantitative analysis of Ki-67 positively labelled cells 
revealed no significant difference between Wt and Apc2-/- livers however, Ah-Cre+ Apcfl/fl livers 
exhibited a statistically significant increase (error bars represent SD, asterisks mark p≤0.01, Mann-
Whitney U-test, n≥3). 
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al 2008). This compromised use of these mice for long term study. Cohorts were sacrificed 
at similar time points between Wt, Apc2-/- and Ah-Cre+ Apcfl/fl mice following a β-
naphthoflavone induction regime (n≥3). Only livers from Ah-Cre+ Apcfl/fl mice displayed 
hepatomegaly (Data not shown) as previously reported (Reed et al., 2008). Histological 
analysis using H&E stained liver sections did not reveal major structural differences between 
genotypes (Figure 6.4A). All genotypes displayed similar frequencies of centrilobular veins 
(CV) and portal spaces (PS). However, Ah-Cre+ Apcfl/fl livers did seem more compacted with a 
possible increased cell number. Liver sections from each genotype were stained with a Ki-67 
antibody to label proliferative cells (Figure 6.4B). Quantitative analysis revealed no statistical 
difference in Ki-67 positive cells between Wt and Apc2-/- livers (1.56±0.11 and 1.49±0.21, 
p=0.865, Mann-Whitney U-test, n≥3). However, Ah-Cre+ Apcfl/fl livers displayed a more than 
a 3 fold increased in positively labelled cells (1.56±0.11 and 6.89±0.79, p≤0.01, Mann-
Whitney U-test, n≥3) compared to Wt (Figure 6.4C). 
 
6.2.3 Increased cytoplasmic levels of β-catenin occur due to loss of either Apc 
or Apc2 however Lect2 is only up regulated following Apc loss 
Liver sections were co-labelled with β-catenin and Leukocyte cell-derived chemotaxin-2 
(Lect2) antibodies, using florescent IHC. This allowed us to assess protein co-localisation 
(Figure 6.5). Previous studies have implicated Lect2 as a β-catenin target within the liver 
(Ovejero et al., 2004; Cadoret et al., 2002). In Wt liver, β-catenin is exclusively membrane 
associated. However, as previously reported following loss of Apc, β-catenin displayed an 
increase in cytoplasmic and nuclear accumulation (Colnot et al., 2004; Reed et al., 2008; 
Benhamouche et al., 2006). In Apc2-/- livers, the majority of cells still displayed membrane 
associated β-catenin. However, there were occasional cells which displayed an increase in 
cytoplasmic/nuclear staining. In Wt livers, Lect2 expression is limited to a layer a few cells 
thick surrounding the CV, with proposed activated β-catenin (Benhamouche et al., 2006). 
Following loss of Apc, Lect2 is expressed in the majority of cells regardless of position. Cells 
co-labelled with increased cytoplasmic/nuclear β-catenin, although this was not a requisite. 
Interestingly although Apc2-/- livers display alterations in β-catenin staining patterns, Lect2 
status is maintained, even cells with clear nuclear β-catenin accumulation fail to stain for 
Lect2.  
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Figure 6.5: Loss of either Apc or Apc2 led to nuclear/cytoplasmic β-catenin accumulation. However, 
Lect2 was only up regulated following Apc loss. Double label fluorescent IHC was performed on liver 
sections to assess β-catenin and Lect2 status. In the Wt β-catenin staining was membranous and 
Lect2 expression limited to a few cells around the centrilobular vein. In the Apc2-/- livers, although 
the majority of cells displayed membranous β-catenin, a few cells showed increased nuclear/ 
cytoplasmic β-catenin. Interestingly, these cell did not display an up regulation of the Wnt target 
gene Lect2 (white arrowheads) and the pattern of expression remained similar to Wt. Following 
induction, Ah-Cre+ Apcfl/fl livers almost completely lost membrane associated β-catenin, the majority 
of cells now show nuclear or cytoplasmic β-catenin staining concurrent with an up-regulation of 
Lect2 (black arrowheads).  The Lect2 pattern of expression seen in Wt and Apc2-/- is lost in Ah-Cre+ 
Apcfl/fl livers and now the majority of cell displayed expression regardless of position. Inlet shows a 
higher magnification of bottom panel (scale bar 200um). 
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6.2.4 Liver zonation is maintained with loss of Apc2 but severely perturbed 
following loss of Apc 
In order to evaluate the effects on liver zonation due to loss of either Apc or Apc2, liver 
sections from each genotype were co-labelled using fluorescent IHC for glutamine 
synthetase (GS) and carbamoyl phosphate synthetase (CPS). GS is an enzyme related to 
ammonia detoxification, part of a gene signature pattern zonally expressed in PV 
hepatocytes and a direct liver β-catenin target gene (Cadoret et al., 2002; Ovejero et al., 
2004). CPS is a urea cycle enzyme, part of a gene signature pattern expressed mostly in PP 
hepatocytes, intermediates, and the first few layers of the PP zone. Loss of Apc2 did not 
lead to changes in liver zonation (Figure 6.6). However, loss of Apc led to an increase in GS 
and a decrease in CPS staining. This is in agreement with previous studies showing an 
increase in a PV genetic program, at a PP expense (Benhamouche et al., 2006; Reed et al., 
2008; Burke et al., 2009).  Whilst Lect2 was only expressed in a layer of a few cells around 
the CV in Wt and Apc2-/- livers, Ah-Cre+ Apcfl/fl livers displayed labelled cells regardless of 
zone. This data indicates that although Apc loss effects liver zonation, Apc2 was dispensable 
for this function. 
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Figure 6.6: Acute loss of Apc alone altered Liver zonation. (A) Fluorescent IHC for CPS and GS 
displayed normal zonation in Wt and Apc2-/- animals, GS was located in a layer a few  cells thick 
surrounding the central vein and CPS was located in a complementary fashion in periportal, 
intermediate, and the first few layers of the perivenous zone. However, in Ah-Cre+ Apcfl/fl mice, CPS 
was expressed in a few cells whilst GS was expressed in most cells regardless of position in regards 
to portal space or centilobular vein position. (B)  Analysis of expression patterns of Lect2 in cells 
surrounding the portal space or centilobular vein indicated that Apc2-/- livers displayed a similar 
pattern to Wt with Lect2 only expressed in a few cells surrounding the centrilobular vein. However, 
in Ah-Cre+ Apcfl/fl mice, Lect2 was expressed in the majority of cells regardless of position to portal 
space or centilobular vein position (scale bar 200um). 
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6.2.5 Aberrant Wnt signaling occurs following loss of either Apc or Apc2 but 
differs in each situation 
To determine if Apc2 loss altered gene expression within the liver and how these changes 
might compare to those of Apc loss, quantitative analysis of known Wnt target and 
repressors genes was performed. Total RNA from liver samples was extracted, subjected to 
reverse transcription and compared using quantitative real-time PCR (qRT-PCR).  Apc2-/- liver 
gene expression levels were directly compared to that of aged matched Wts. Induced Ah-
Cre+ Apcfl/fl gene expression levels were directly compared to that of induced age matched 
Apcfl/fl controls. The shortened lifespan following induction of Ah-Cre+ Apcfl/fl mice, combined 
with the hypomorphic nature of the Apcfl allele (assessed in 6.2.9) necessitated the 
requirement of separate controls for the different comparisons. Indirect comparisons were 
made between Wnt gene expression profiles following Apc2 or Apc loss (Figure 6.7). β-
catenin and Dickkopf2 expression levels remained unchanged following either Apc2 or Apc 
loss. C-Myc and CD44 expression were unchanged in Apc2-/- livers compared to control. 
However, Ephrin B2 and Ephrin B3 were significantly increased in Apc2-/- livers, whilst Cyclin 
D1 and Groucho where significantly decreased. cMyc, CD44, Cyclin D1 and Groucho were all 
significantly increased following Apc loss, whilst Ephrin B2 and Ephrin B3 remained 
unchanged from controls. Axin2 is part of a Wnt negative feedback loop and both a Wnt 
target gene and Wnt repressor. It was significantly up-regulated following lack of either 
Apc2 or Apc in the liver (Figure 6.7, for all statistically significantly differences p≤0.05, 
Whitney U-test, n≥3). 
 
6.2.6 Apc2 deficiency attenuates the HCC phenotype associated with reduced 
levels of Apc expression 
Apc2-/- mice did not display altered survival compared to Wt (chapter 3) or any associated 
liver pathology. Conversely, it has been reported that mice with reduced Apc expression 
through low level Cre mediated deletion develop HCC (Colnot et al., 2004). Indeed, work 
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Figure 6.7: Expression analysis of Wnt target genes and Wnt repressors displayed different profiles 
following loss of either Apc or Apc2 protein. Quantitative RT-PCR was used to compare expression 
levels between i, Wt control vs. Apc2-/- aged match livers (light gray vs. dark gray bars) and ii, Apcfl/fl 
control vs. Ah-Cre+ Apcfl/fl livers  4 days following tamoxifen Induction (light gray vs. Black bars). β-
catenin and Dickkopf 2 expression levels remained unchanged following either Apc2 or Apc loss. 
cMyc and CD44 expression was unchanged in Apc2-/- livers compared to control. However, Ephrin B2 
and Ephrin B3 were significantly increased whilst Cyclin D1 and Groucho where significantly 
decreased.  Following Apc loss, cMyc, CD44, Cyclin D1 and Groucho were significantly increased 
whilst Ephrin b2 and Ephrin b3 remained unchanged compared to control liver. Axin2 is part of a Wnt 
negative feedback loop and both a Wnt target gene and Wnt repressor, It was significantly up 
regulated due to lack of either liver Apc2 or Apc (Gray asterisks mark the comparisons that were 
found to be significantly different between Wt and Apc2-/- aged matched livers, black asterisks 
between Apcfl/fl and Ah-Cre+ Apcfl/fl livers 4 days following tamoxifen Induction p≤0.05, Mann-
Whitney U-test, n≥3, error bars represent SEM of Ct values). 
 
 
from our laboratory and others has shown that the attenuated expression of Apc in un-
induced Apcfl/fl mouse leads to HCC development with a 100% penetrance by 400 days of 
age (Buchert et al., 2010). As Cre negative Apcfl/fl Apc2-/- mice are viable, we were able to 
directly test the significance of Apc2 on HCC development. Cohorts of Wt, Apc2-/-, Apcfl/fl, 
and Apcfl/fl Apc2-/- mice were aged to 400 days, sacrificed and livers harvested for analysis. 
Upon sacrifice it was noticed that Apc2-/- livers appeared normally sized, while Apcfl/fl, 
displayed an increase in liver size (Figure 6.8A). This was attenuated in Apcfl/fl Apc2-/- mice. 
Quantitative analysis of liver to body weight ratio (Figure 6.8B) revealed a significant 
increase in Apcfl/fl mice which was rescued in Apcfl/fl Apc2-/- mice (statistically significant 
differences p<0.01, Whitney U-test, n≥3). Strikingly, macroscopic tumours were  
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Figure 6.8: loss of Apc2 did not lead to a liver weight increase or macroscopic tumour formation in 
aged animals. However, it attenuated the phenotype associated with reduced levels of Apc 
expression. Mice from cohorts of Wt, Apc2-/-, Apcfl/fl and Apcfl/fl Apc2-/- were aged and sacrificed at 
400 days. (A) Macroscopic examination revealed no difference in Apc2-/- livers but an increase in liver 
size in Apcfl/f mice. This increase in liver size was not observed in Apcfl/fl Apc2-/- livers (white dotted 
line indicates liver outline) suggesting a rescued phenotype. (B) Quantitative analysis of liver to body 
weight ratio revealed a statistical increase in Apcfl/fl livers compared to other genotypes. Additional 
Loss of Apc2 on an Apcfl/fl background rescued this phenotype. Asterisks mark the pair-wise 
comparisons that were found to be significantly different p≤0.05, for all comparisons n≥3, error bars 
represent SD.  (C) Macroscopic tumours were only visible in the Apcfl/fl aged livers. Additional loss of 
Apc2 rescued the HCC phenotype (white Arrows indicate macroscopic HCC). 
 
only visible in Apcfl/fl livers (Figure 6.8C). Liver sections from Apcfl/fl and Apcfl/fl Apc2-/- mice 
were stained with H&E to assess histology. Large tumours were present in Apcfl/fl mice with 
100% penetrance, consistent with previous studies. Astonishingly, no macroscopic tumours  
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Figure 6.9: Histological analysis revealed the presence of large tumours in Apcfl/fl livers attenuated by 
the loss of Apc2. (A) H&E staining of sections from Apcfl/fl and Apcfl/fl Apc2-/- livers revealed large 
tumours in livers with reduced levels of Apc (Gray asterisks) and small abnormal foci in livers with 
reduced levels of Apc and loss of Apc2 (Black asterisks). Lower panel represents higher magnification 
of top image (150µm and 500µm respective scale bars). Dotted line represents outline of abnormal 
tissue. (B) Scoring of tumour area between liver section from Wt, Apc2-/- , Apcfl/fl and Apcfl/fl Apc2-/- 
livers shows no tumour formation following loss of Apc2 and an attenuation of tumour growth in 
Apcfl/fl livers with additional Apc2 loss (error bars represent SD, asterisks mark p≤0.01, Mann-
Whitney U-test, n≥3). 
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were visible in Apcfl/f Apc2-/- livers. Upon histopathological examination of H&E stained liver 
sections (performed in collaboration with Prof. Geraint T. Williams), Apcfl/fl livers all 
displayed large tumours which were classified as HCC (Figure 6.9A). HCC was not present in 
any Apcfl/fl Apc2-/- livers, although small abnormal foci were observed which were classified 
as microadenomas. In order to provide a quantitative value of tumour area per animal, the 
area of abnormal tissue was scored and divided by total area of liver (Figure 6.9B). Whilst 
Wt and Apc2-/- mice did not develop liver lesions, almost 18% of Apcfl/fl liver was tumour 
tissue. Additional Apc2-/- mutation attenuated this to ~ 2.5% (p≤0.01, Whitney U-test, n≥3). 
This reduction in tumorigenesis suggests that the presence of Apc2 in a hypomorphic Apc 
background positively contributes to tumour development. This contribution may be 
directly though modulating the level of Wnt signalling required for a neoplastic initiation or 
indirectly though providing an environment that positively contributes to tumour 
progression/growth or a combination of both. 
 
6.2.7 Additional loss of Apc2 reduced the amount of dividing cells found within 
abnormal foci of livers with reduced Apc expression  
As a means of determining the contribution of Apc2 to tumour initiation/progression, serial 
sections of abnormal foci from both Apcfl/fl and Apcfl/fl Apc2-/- were stained for β-catenin and 
Ki-67 (Figure 6.10). Nuclear β-catenin is well documented as a Wnt signal with potential to 
induce a proliferative program (for review see Reya &Clevers, 2005). Both Apcfl/fl and Apcfl/fl 
Apc2-/- lesions displayed a heterogeneous pattern of increased cytoplasmic/nuclear β-
catenin however, only Apcfl/fl lesions displayed an increase in Ki-67 positive cells compared 
to surrounding tissue. This suggests additional loss of Apc2 has an effect downstream of β-
catenin reducing the proliferative signal.  
 183 
 
 
 
Figure 6.10: Both Apcfl/fl and Apcfl/fl Apc2-/- lesions within the aged livers displayed elevated 
cytoplasmic levels of β-catenin  however,  less actively cycling cells were present within lesions of 
Apcfl/fl, Apc2-/- livers compared to that of Apcfl/f.  IHC carried out on abnormal foci found in both 
genotypes showed elevated cytoplasmic levels of β-catenin suggesting perturbed Wnt signalling. Ki-
67 antibody was used to label actively dividing cells. Less dividing cells were seen in the abnormal 
foci of Apcfl/fl Apc2-/- livers compared to that of Apcfl/fl (Scale bar 200um).  
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Lect2 is implicated as a direct target gene of β-catenin in the liver (Ovejero et al., 2004; 
Cadoret et al., 2002). In order to test the hypothesis that additional Apc2 loss attenuates 
activation of Wnt target gene expression produced by reduced Apc levels, lesions from each 
genotype were co-labelled with β-catenin  and Lect2 antibodies using florescent IHC (Figure 
6.11). Surprisingly, although there was an up regulation of Lect2 in both genotypes, the 
Lect2 staining pattern was mosaic and failed to correlate with nuclear β-catenin in either 
genotype.  
 
 
 
Figure 6.11: Abnormal foci from Apcfl/fl and Apcfl/fl Apc2-/- both display increased nuclear/cytoplasmic 
β-catenin. Lect2 status is not associated with β-catenin location or intensity in either genotype and 
displayed a mosaic expression pattern.  Fluorescent IHC was performed on lesions from Apcfl/fl and 
Apcfl/fl Apc2-/- livers staining for β-catenin and Lect2. Right hand panels show higher magnification of 
the left hand panels, white arrow heads indicate cells with elevated nuclear/cytoplasmic β-catenin, 
dark gray arrow heads indicate cells with only Lect2 expression, and light gray arrow heads indicate 
cells with combined elevated nuclear/cytoplasmic β-catenin and Lect2 expression (scale 200µm in 
left hand panel, 50µm in right). 
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6.2.8 Loss of liver zonation associated with reduced Apc expression can be 
partially rescued in double mutant mice  
In order to address if Apc2 contributes to a pro-tumour environment in an Apcfl/fl mouse 
liver, non-tumour tissue between Apcfl/fl and Apcfl/fl Apc2-/- was analysed and compared to 
Wt. Sections were co-labelled with β-catenin and Lect2 antibodies using florescent IHC to 
assess protein status (Figure 6.12).  In Wt liver β-catenin was exclusively membrane 
associated however in Apcfl/fl liver there were cells displaying increased cytoplasmic and 
nuclear β-catenin. This was also apparent in the Apcfl/fl Apc2-/- livers also but to a lesser 
extent. In Apcfl/fl liver, Lect2 was up regulated and displayed a mosaic pattern. No zonation 
was apparent and cells displayed Lect2 positivity regardless of PV or PP position. 
Interestingly in Apcfl/fl Apc2-/- livers, Lect2 was also up regulated but there was clear 
zonation.  A Lect2 free zone was maintained around the PS albeit it reduced compared to 
Wt liver. Lect2 status did not correlate with β-catenin location or intensity in either 
genotype.  
 
 
Figure 6.12:  Lect2 expression was increased in both Apcfl/fl and Apcfl/fl Apc2-/- livers however, in 
Apcfl/fl, Apc2-/- livers a Lect2 clear zone remained around the portal space. Fluorescent IHC was 
carried out on livers from each genotype to assess β-catenin and Lect2 expression patterns. β-
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catenin was membrane associated in the majority of all cells, in non-tumour tissue, regardless of 
genotype. However, in the Apcfl/fl livers there were more cells with increased cytoplasmic/nuclear β-
catenin compared to Wt controls, this was not so apparent in the Apcfl/fl Apc2-/- livers. Lect2 
expression was increased in Apcfl/fl livers compared to Wt; cells stained Lect2 positive regardless of 
perivenous or periportal position with a mosaic appearance.  Apcfl/fl Apc2-/- livers also displayed an 
increase in number of cell stained positive for Lect2 compared to Wt however, a clear lect2 free zone 
was maintained, albeit a lot smaller than in the Wt livers. Lect2 status did not correlate with β-
catenin location or intensity in any genotype (scale bar 200µm). 
 
To properly assess zonation, liver sections from Wt, Apcfl/fl and Apcfl/fl Apc2-/- mice were co-
labelled with GS and CPS using florescent IHC (Figure 6.13). Apcfl/fl livers show an increase in 
expression of the PV gene marker GS in comparison to Wt, GS is expressed in the majority of 
cells regardless of position in comparison to PS or CV position. Also, in the Apcfl/fl livers the 
PS marker CPS is down regulated and only a few sporadic cells show CPS expression.  In 
contrast, although Apcfl/fl Apc2-/- livers also displayed an increase in GS and decrease in CPS 
expression, a clear pattern of zonation is still apparent. CPS expression is not as reduced as 
in Apcfl/fl livers and clear zonation is maintained in PP hepatocytes surrounding the portal 
space. 
 
6.2.9 Additional loss of Apc2 altered the Wnt target gene profile associated 
with reduced Apc expression  
To address how additional Apc2 loss effected Wnt pathway changes invoked by reduced Apc 
levels, quantitative analysis of levels of known Wnt pathway genes was performed on aged 
liver tissue from Wt, Apcfl/fl and Apcfl/fl Apc2-/- animals (n≥3). Total RNA from liver tissue was 
extracted and subjected to reverse transcription. Gene expression levels of Wnt pathway 
genes were compared using quantitative real-time PCR (qRT-PCR) (Figure 6.14). 
Interestingly, Apcfl/fl Apc2-/- liver samples displayed reduced expression of β-catenin in 
comparison to Wt. cMyc and Axin2 expression levels were significantly higher in both Apcfl/fl 
and Apcfl/fl Apc2-/- liver samples compared to Wt however, no statistically significant 
differences were observed between these two genotypes. CD44 expression was reduced in 
Apcfl/fl Apc2-/- liver samples in comparison to both Wt and Apcfl/fl samples. Cyclin D1  
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Figure 6.13: Additional loss of Apc2 on an Apcfl/fl background helps maintain some liver zonation 
after aging, albeit zone sizes differ from Wt. Fluorescent IHC was carried out on livers from each 
genotype to assess perivenous (GS) and periportal (CPS) gene expression patterns. At 400 days Apcfl/fl 
livers show an increase in expression of the PV gene marker GS in comparison to Age matched Wt 
controls. GS is expressed in the majority of cells regardless of position in comparison to portal space 
or centilobular vein position. Also in the Apcfl/fl livers the PP marker CPS is down regulated and only a 
few sporadic cells show CPS expression in no organised manner.  In contrast, although Apcfl/fl Apc2-/- 
livers also show an increase in GS and decrease in CPS expression in comparison to age matched Wt 
controls, a clear pattern of zonation is still eminent. CPS expression does not seem as reduced as in 
Apcfl/fl and it is well ‘zoned’ in periportal cells surrounding the portal space (scale bar 200µm). 
 
expression levels were reduced in Apcfl/fl liver samples compared to Wt. Additional loss of 
Apc2 attenuated this reduced expression. Dickkopf2 displayed no statistically significant 
differences between any genotype. Apcfl/fl liver samples showed an increase in expression of 
the Wnt repressor Groucho compared to Wt controls. Additional loss of Apc2 significantly 
increased Groucho expression even more (for all statistically significantly differences p≤0.05, 
Whitney U-test, n≥3). 
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Figure 6.14: Additional Apc2-/- mutation on an Apcfl/fl background altered the expression pattern of 
some Wnt target genes and repressors. Quantitative RT-PCR was used to compare expression levels 
between Wt (light gray bars), Apcfl/fl (dark gray bars) and Apcfl/fl Apc2-/- (black bars) liver samples 
taken from animals sacrificed at 400 days of age. β-catenin  expression was shown to be down 
regulated only in Apcfl/fl Apc2-/- compared to Wt. cMyc and Axin 2 expression levels were significantly 
higher in both Apcfl/fl and Apcfl/fl Apc2-/- livers compared to Wt. CD44 was down regulated in Apcfl/fl 
Apc2-/- in comparison to both Wt and Apcfl/fl livers.  Cyclin D1 was down regulated in Apcfl/fl liver 
samples in comparison to Wt. Additional Apc2-/- mutation attenuated this reduced expression. Apcfl/fl 
livers displayed an increase in expression of Groucho compared to Wt controls. Apcfl/fl Apc2-/- livers 
exhibited an even greater increase in expression of expression of Groucho (asterisks mark the 
pairwise comparisons that were found to be significantly different, p≤0.05, Mann-Whitney U-test, 
n≥3, error bars represent SEM of Ct values). 
 
 
6.3 Discussion  
A transgenic approach was used to study the ‘in vivo’ consequences of loss of Apc proteins 
within the liver. As previously reported, acute loss of Apc resulted in liver hyperproliferation 
causing hepatomegaly, increased nuclear/cytoplasmic β-catenin, loss of zonation and an 
increase in Wnt target gene expression (Colnot et al., 2004; Reed et al., 2008; Benhamouche 
et al., 2006). Livers deficient for Apc2 however, failed to show changes in liver homeostasis 
and/or any liver associated pathology. Apc2-/- Liver size remained comparable to Wt even 
after 400 days, levels of cell division and zonation also remained indistinguishable from Wt. 
Interestingly livers deficient for Apc2 do have cells with increased nuclear/ cytoplasmic β-
catenin however, these cells fail to display abnormal histology or express Lect2 a known 
liver Wnt target gene.  
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Although both Apc proteins have the ability to mediate Wnt signaling through β-catenin, 
and loss of either within the liver can lead to changes in β-catenins’ sub-cellular intensity/ 
localisation, Wnt gene profiles differ between genotypes and only Apc loss induces a 
phenotype. This may be due to different affinities of β-catenin destruction between the two 
Apc homologs (Nakagawa et al., 1998) that extend to the liver. Loss of Apc or Apc2 may lead 
to different threshold levels of Wnt, indeed fewer cells did show aberrant β-catenin 
intensity/localisation in Apc2-/- livers compared to that of Apc deficient livers. However, 
Axin2, which is a commonly used readout of Wnt (Lustig et al., 2002; Jho et al., 2002) was 
up-regulated in both genotypes, suggesting high levels of Wnt activation in both genotypes. 
Another hypothesis is that, as the Apc2 mutation is constitutive, levels of Wnt may have 
been readjusted due to developmental compensation. However, Dickkopf 2 a known Wnt 
repressor (Mao et al., 2001; Kawano & Kypta, 2003) which antagonises Wnt in early hepatic 
development (Bi et al., 2009), did not display any difference in levels of expression between 
Apc2-/- and control livers. Groucho, another known Wnt repressor (Cavallo et al., 1998) 
which directly competes with β-catenin in Tcf/Lef binding (Daniels & Weis, 2005) 
surprisingly displayed reduced levels of expression in Apc2-/- livers compared to controls. 
The reasons behind this reduction remain unclear.  
A third explanation for why only Apc loss induces a phenotype may lay with unique 
functions of Apc either downstream or even independent of β-Catenin phosphorylation. 
Non-canonical functions of Apc have been reported in other tissues (Fodde et al., 2001; 
Kaplan et al., 2001; Näthke, 2006; Prosperi et al., 2009; Qian et al., 2008; Harris & Nelson, 
2010). β-catenin itself is dispensable for normal liver function (Skekine et al., 2006) and 
activation of β-catenin in hepatocytes (Cre mediated, low level) can lead to an increase in 
nuclear/cytoplasmic β-catenin in cells that still appear healthy and quiescent (Harada et al., 
2002). However, high levels of β-catenin activation have caused hepatomegally in some 
studies (Harada et al., 2002; Cadoret et al., 2001; Stein et al., 2011) although not all (Miyoshi 
et al., 2009; Nejak-Bowen et al., 2009).  Together the evidence raises the possibility of a β-
catenin phosphorylation independent role of Apc in liver homeostasis. However, immediate 
phenotypes of Apc loss can be rescued upon additional knockout of β-Catenin (Reed et al., 
2008) suggesting some function of β-catenin must be present to allow the effects of Apc loss 
to become manifest. β-catenin’s role in the liver, either independently or through 
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interaction with Apc or Apc2 is complex. Further studies are needed to elucidate their roles 
in liver homeostasis. 
Unfortunately due to low level embryonic expression of the Ah-Cre+ transgene, Ah-Cre+ 
Apcfl/fl Apc2-/- mice died ‘in utero’ due to compromised functional redundancies that must 
exist between the Apc proteins during development. This hindered our ability to study the 
immediate consequences of acute loss of both proteins within the liver. This could be 
circumvented by the use of a more tissue specific Cre promoter, for example, the Albumin-
Cre (Postic et al., 1999) or Transthyretin-Cre (Tannour-Louet et al., 2002) or Cre mediated 
deletion could be achieved through the use of an injectable adenoviral Cre (Colnot et al., 
2004).  Although acute loss of both Apc proteins within the liver was not achievable through 
our experimental design, this is the first study to analyse liver specific consequences of Apc2 
loss and compare them to that of Apc loss. 
The Hypomophic nature of the Apcfl allele (Shibata et al., 1997) allowed us analyse liver 
phenotypes associated with attenuated Apc expression. Furthermore, as Apcfl/fl Apc2-/- mice 
were viable it permitted us to directly test the significance of Apc2 in an attenuated Apc 
background. Consistent with other studies (Burke et al., 2009; Buchert et al., 2010), aged 
Apcfl/fl livers possessed cells with eminent nuclear/cytoplasmic β-catenin, aberrant zonation 
and mice developed HCC with 100% penetrance.  Strikingly, although livers from Apcfl/fl 
Apc2-/- mice still displayed cells with elevated nuclear/cytoplasmic β-catenin and some 
zonation perturbation, HCC was prevented. This reduction in tumorigenesis clearly 
demonstrates that the presence of Apc2 in the hypomorphic Apcfl/fl environment, positively 
contributes to liver tumour formation. Small microscopic areas of abnormal foci were 
noticed in Apcfl/fl Apc2-/- livers which failed to progress from microadenomas. On comparing 
β-catenin status between abnormal foci from each genotype, it was revealed that both 
displayed a heterogeneous pattern of increased cytoplasmic/nuclear staining. However, in 
the lesions in Apcfl/fl Apc2-/- livers, proliferation was attenuated in comparison to those in 
Apcfl/fl.  There are various possible explanations behind why additional Apc2 loss reduces 
proliferation and prevents tumour progression. 
‘Just right’ levels of Wnt signaling have been suggested to be required for oncogenesis in a 
variety of tissues (Lamlum et al., 1999; Albuquerque et al., 2002; Lucero et al., 2010). As 
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both Apc proteins have the ability to alter Wnt signaling, whilst attenuated Apc may lead to 
appropriate levels of Wnt for HCC formation and proliferation, addition of an Apc2 mutation 
may alter these levels outside of that permissive for tumour progression. In an attempt to 
estimate levels of Wnt, Lect2 status was examined. Unfortunately, in contrast to published 
data (Ovejero et al., 2004; Cadoret et al., 2002), Lect2 did not correlate with β-catenin 
expression. Interestingly, despite inappropriate β-catenin signalling in up to 70% of human 
HCC tissue (de La Coste et al., 1998: Wong et al., 2001: Giles et al., 2003), most mouse 
models with liver specific β-catenin activating mutations fail to develop tumours (reviewed 
in Nejak-Bowen & Monga, 2011). Lack of oncogenesis in mice with liver targeted activating 
β-catenin mutations and the fact that mutations in β-catenin are only found in HCC and not 
adenomas in diethylnitrosamine (DEN)-induced mice (Ogawa et al., 1999), suggest that 
activated β-catenin may be a secondary rather than causative event in liver tumourigenesis. 
How Apc loss induces tumourigenesis may lie with functions independent of Wnt signaling. 
However, it is important to note that β-catenin activation does define a genetically distinct 
subset of human HCC’s (Llovet and Bruix, 2008) clinically relevant to treatment strategies. 
The mechanisms at work during the development of HCC remain poorly understood (Farazi 
and DePinho, 2006). However, it is known the development of HCC is likely to result from a 
multistep process beginning with the accumulation of genetic and epigenetic alterations in 
regulatory genes (Tischoff et al., 2008). Along with Wnt alterations, the genetic changes 
accumulated during oncogenic progression can include mutations in p53, PTEN, pRB, 
CDKN2A, PIK3CA and RAS family members (Zender et al., 2010). How attenuated Apc 
expression in our mice leads to the accumulation of genetic and epigenetic alterations 
causing HCC remains unresolved. On one hand, reduced non-canonical functions of Apc can 
lead to chromosome instability (Fodde et al., 2001; Kaplan et al., 2001; Näthke, 2006) which 
may invoke genetic changes needed for HCC progression. On the other hand, HCC can be 
rescued by limiting expression of β-catenin (Buchert et al., 2010). This suggests β-catenin is 
needed and involved for HCC development in Apcfl/fl livers.  Interestingly Apcfl/fl Apc2-/- livers 
displayed reduced β-catenin expression in comparison to both Wt and Apcfl/fl livers. 
Although the mechanisms behind reduced β-catenin expression are unknown, it is possible 
that it contributes to attenuation of tumour progression seen in Apcfl/fl Apc2-/- mice.  
 192 
 
An alternative explanation of how attenuated Apc expression may lead to HCC through 
accumulation of genetic changes might lie with its effects on zonation. In Apcfl/fl mice, a PV 
genetic program was induced at the expense of a PP program, ‘zones’ were diminished and 
hepatocytes of either fate displayed a mosaic pattern. Whilst hepatocytes which express 
genes like GS, ornithine aminotransferase (OAT) and glutamate transporter (GLT1) were 
increased and mis-localized, hepatocytes which express genes like CPS, Arginase (ARG1) and 
succinate dehydrogenase (SDH) were reduced and also mis-positioned. Perturbation of 
these hepatocytes will undoubtedly have detrimental effects on metabolism. Metabolic 
changes have proven paramount in cancer progression (reviewed in Marín-Hernández et al., 
2009). CPS is a liver-specific, intramitochondrial enzyme which has a focal role in converting 
ammonia to less toxic urea (Haussinger et al., 1992). Various studies have demonstrated 
reduced to non-existent expression of CPS in HCC compared to normal tissue (Siddiqui et al., 
2002; Butler et al., 2008; Liu et al., 2011). It is unknown whether CPS loss is a consequence 
or cause of HCC progression however, it is known that exposure to its substrate ammonia is 
implicated in tumour initiation in rodents (Uzvölgyi & Boján, 1980; Tsujii et al., 1995) and 
humans (Garland et al., 2004). SDH a krebs cycle gene, is mutated both germinally and 
somatically in a large subset of human cancers (reviewed Bardella et al., 2011) leading to an 
accumulation of its substrate succinate. Succinate accumulation leads to alterations in 
genome-wide histone and DNA methylation that can initiate and contribute to 
tumorigenesis (Xiao et al., 2012). It would be of interest to directly test the significance of 
these substrates on HCC development in our mice. 
Interestingly, zonation was partially rescued in Apcfl/fl Apc2-/- livers, adding support to the 
premise that zonation alterations can provide a permissive environment for tumour 
progression. This rescue of zonation by additional loss of Apc2 in an attenuated Apc 
background could partially be explained by differences in Wnt signaling. It is unknown 
whether Wnt expression changes precede, cause or are consequences of zonation changes. 
A sub-set of genes involved in the Wnt signaling pathway were profiled and compared 
between aged non-neoplastic tissue from Wt, Apcfl/fl and Apcfl/fl Apc2-/- livers. Whilst cMyc 
and Cyclin D1 did show changes in expression between genotypes, phenotypes of liver Apc 
loss do not require cMyc (Reed et al., 2008), and neither are targets of β-catenin activation 
within the liver (Cadoret et al., 2001; Nejak-Bowen et al., 2009). CD44 was down regulated 
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in Apcfl/fl Apc2-/- livers and previous studies have indeed shown reduction of CD44 can 
reduce tumorigenesis in HCC cell lines (Xie et al., 2008). This reduction in CD44 expression 
may contribute towards the HCC prevention. Groucho was significantly up-regulated in 
Apcfl/fl Apc2-/- livers compared to both other genotypes. This suggests that increased Wnt 
repression may also contribute to the observed attenuation of HCC development. A genome 
wide array of expression changes could prove useful in delineating the molecular 
mechanisms behind the prevention of HCC in Apcfl/fl Apc2-/- mice.  
Surgical resection remains the treatment of choice for HCC patients with well-preserved 
liver function. However, it is associated with a high risk of post-operative complications and 
tumour recurrence (Nguyen et al., 2009).  Liver transplantation is another favoured 
treatment but is hindered by the shortage of suitable liver grafts (Mazzaferro et al., 2008). 
Chemotherapy could provide a feasible option however, most drugs to date have proved 
ineffective in patients (Cao et al., 2012). Therapeutic targeting of Wnt/β-catenin in 
chemoprevention or as a possible treatment of cancers has been previously suggested (Luu 
et al., 2004; Kundu et al., 2006).  Indeed, targeting of this pathway has shown some promise 
in animal models of HCC (Liu et al., 2006; Behari et al., 2007). As Apc2 is dispensable for 
normal liver function and has the ability to attenuate tumour progression poses it as an 
exciting therapeutic target. In this reported, it would be interesting to see how additional 
Apc2 loss may affect other models of HCC. 
To conclude, varied expression of Apc alone has the ability to alter liver homeostasis and 
induce tumorigenesis. Evidence from these experiments suggests a role in addition to that 
of β-catenin phosphorylation. Whilst Apc2 is dispensable for liver homeostasis and tumour 
suppression, additional loss on an Apcfl/fl background prevented HCC.   
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Chapter 7  
 
General discussion 
 
Cancer is the largest primary cause of death in the UK and one of the largest in the world. 
Although incidence is on the rise, increased understanding of the disease has led to earlier 
detection and better treatment strategies thus increasing patient survival. It is known that 
cancer is the endpoint of a transformation of cells from normalcy into malignant tumours.  
For any cells to become cancerous they must acquire a full collection of necessary 
physiological adaptions or ‘hallmarks’ (Hanahan & Weinberg, 2011). Cells accumulate these 
traits through the multi-step process of tumour pathogenesis. It is known that genetic 
alterations enforce this multi-step process, so an immense effort has been placed into 
understanding how these alterations implement the necessary hallmarks on a molecular 
level.  
 
Studying the genetics of cancer inducing syndromes and the genomic composition of 
sporadic tumours, gives us an insight into the genetic abnormalities that contribute to 
tumorigenesis. In colorectal cancer, the APC gene was mutated in the vast majority of cases 
(Kinzler et al., 1991; Groden et al., 1991; Powell et al., 1992; Nagase & Nakamura, 1993; 
Rowen et al., 1999, Ilyas et al., 2000). It was also mutated in a range of other cancers 
(Damjanov et al., 1996; Virmani et al., 2001; Furuuchi et al., 2000; Kashiwaba et al., 1994; 
Giardiello et al 1996; Hirschman et al 2005; Gruner et al., 1998; Toiyama et al., 2011; Li et 
al., 2012). This strongly suggests APC is important in tumour suppression. Through the use 
of mouse transgenics, alterations in Apc were proven sufficient to induce tumourigenesis 
(Moser et al., 1993; Kuraguchi et al., 2009; Gaspar et al., 2009).  
 
The APC gene has a highly evolutionally conserved homolog. APC2 displays structural 
similarities to APC (Van Es et al., 1999), so may have comparable functions. Loss of its gene  
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product has also been implicated in a range of human cancers (Jarrett et al., 2001; Sobottka 
et al., 2000; Yang et al., 2004; Wang et al., 1999; Nakagawa et al., 1999; Chan et al., 2008; 
Schuebel et al., 2007; Hsieh et al., 2007; Mokarram et al., 2009; Kumar et al., 2009). Both 
proteins are expressed in a wide range of human tissues (Van Es et al., 1999; Jarrett et al., 
2001) and work from Drosophila demonstrates that these proteins display functional 
redundancies (Ahmed et al., 2002). It has also been shown that APC2 can complement APC 
loss in human colorectal cancer cell lines (Nakagawa et al., 1998; Van Es et al., 1999; Roberts 
et al., 2012). Together, these studies suggest that APC2 is also important in tumourigenesis 
and may have overlapping roles with APC. 
 
Both APC proteins are known to mediate the Wnt signaling pathway, a pathway 
dysregulated in the majority of human cancers. Both have other roles beyond Wnt signaling 
regulation, which when disrupted may contribute to tumourigenesis. Although APC has 
been extensively studied, APC2 remains relatively uncharacterised.  Due to the availability of 
a mouse model with mutated Apc2 we could now study the relevance of Apc2 in a 
mammalian setting. The Aims of this thesis were: to elucidate Apc2’s functions in a range of 
tissues, expose any roles of Apc2 in tumour suppression, to test these factors in the context 
of tissue specific Apc loss and elucidate any functional redundancies between the two 
mammalian Apc proteins.  
 
Mice with homozygous Apc2 mutation did not die ‘in utero’ and were viable, in contrast to 
the situation with homozygous Apc mutations (Moser et al., 1995). Interestingly, whilst Ah-
Cre+ Apcfl/fl mice were also viable, addition of a homozygous Apc2 mutation induced 
embryonic lethality. Given that Apcfl/fl Apc2-/- are viable, low level embryonic expression of 
the Ah-Cre+ promoter and subsequent Apc loss in conjunction with Apc2 deficiency must 
account for this lethality. Together this highlights that functional redundancies exist 
between mammalian Apc homologs during embryonic development.  
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Although Apc2-/- mice were viable, on a purer C57BL/6 background, a proportion developed 
hydrocephalus. Apc2 is known to be expressed at its highest levels within the developing 
brain in both mice (Yamanaka et al., 2002) and humans (Van Es et al., 1999), so it is 
unsurprising that its loss affects this organ. This agrees with two recent studies whereby 
brain defects were apparent following Apc2 loss in both chick (Shintani et al., 2009) and 
mouse (Shintani et al., 2012) brains. Interestingly, in both studies Wnt signaling displayed no 
detectable differences and the phenotypes were attributed to direct cytoskeletal defects. 
 
Upon aging mice that displayed no residing brain defects, loss of Apc2 did not induce 
tumour formation in any tissue nor did it alter overall lifespan. This suggests that Apc2 is 
dispensable for tumour suppression and that the loss of APC2 observed in human tumours 
is most likely associated with tumour progression rather than initiation or is just a passive 
event.  Analysis of APC2 status alongside tumour grade and/or other genetic alterations may 
help elucidate APC2’s true role in human cancers.  
 
Within the intestines, Apc2 did display a role in regulation of the Wnt signaling pathway and 
this occurred in a gene dose dependent manor, suggesting that the level of Apc2 is 
important. Although no differences were noticed in macro- or microscopic intestinal 
morphology or composition of terminally differentiated cell types, cell division and markers 
of ISC’s were increased. This occurs concurrent with an increase in crypt cells displaying 
nuclear localised β-catenin and an increase in Wnt target gene expression. However, tumour 
formation was not induced in this tissue. It is possible that Apc2 loss alone is insufficient to 
induce a ‘just right’ level of Wnt signaling need for intestinal tumourigenesis. Indeed, APC2 
does display a reduced regulatory ability of Wnt signaling in comparison to APC (Nakagawa 
et al., 1998).  
 
Another possible explanation as to why Apc2 loss does not lead to intestinal tumourigenesis 
may lie with a lack of disruption of the cytoskeleton. Migration and polarity defects have 
been associated with tumourigenesis in both mice and humans with altered APC, and this 
most likely lays with APC’s ability to interact with microtubules. It is predicted that APC2  
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lacks domains that directly or indirectly interact with microtubules (reviewed in Allan & 
Nathke, 2001) so unlike APC, may have no influence on polarity or migration. However, as 
mentioned previously, it was shown by Shintani et al. (2009, 2012) that Apc2 does interact 
with the cytoskeleton within neural tissue, but this may be tissue specific. Also, Apc2 
deficient mice displayed increased intestinal epithelial migration. However, this is most 
likely compensatory for the noted increase in cell division as opposed to direct effects on 
the cytoskeleton. Together these findings might highlight disruption of polarity and 
migration as necessities for tumourigenesis within the intestine which are only disrupted 
following Apc loss. 
 
Apc2 loss was analysed in conjunction with targeted intestinal Apc deletion. This was done 
in an effort to elucidate any functional redundancies or co-operation between Apc proteins 
in intestinal epithelial homeostasis and delineate any role Apc2 may have in Wnt activated 
tumour progression. Additional Apc2 loss in the context of immediate intestinal 
homozygous Apc deletion surprisingly, reduced overall Wnt signaling and attenuated the 
phenotype in comparison to Apc deletion alone. The mechanisms behind this may be more 
effective Wnt repression and/or feedback loops which govern this repression. Indeed, the 
Wnt repressors Groucho and Dickkopf 2 were higher in intestines deficient for both Apc 
proteins. 
 
A further explanation may again fall with ‘just right’ levels of Wnt signaling.  Whereas 
moderate levels of Wnt activation incur a growth advantage (Lamlum et al., 1999; 
Albuquerque et al., 2002; Lucero et al., 2010; Chandra et al., 2012), higher levels induce cell 
death (Lazarova et al., 2004; Bordonaro et al., 2008). Whilst immediate intestinal Apc loss 
permits a suitable level of Wnt activation for manifestation of its phenotype, additional 
Apc2 loss may cause Wnt hyper-activation and selective death or terminal differentiation of 
some cells, such as ISC’s, and attenuate this phenotype. Given these cells usually display 
high levels of Wnt activation in both wild type and Apc deficient intestines, selective loss of 
these cells in intestines deficient for both Apc protein would account for a reduced overall 
Wnt signature in comparison to that of Apc loss alone. Indeed, additional Apc2 loss  
 
 
 198 
 
concomitant with intestinal Apc loss, increased cell death and reduced markers of intestinal 
stemness in comparison to Apc loss alone.  
 
From these findings, one would postulate that additional Apc2 loss would have an effect on 
intestinal tumourigenesis caused by heterozygous Apc mutation. However, this was found 
not to be the case. Additional Apc2 mutation did not alter tumour number, tumour grade or 
overall survival in the context of heterozygous Apc mutation. A likely explanation for this 
may lie with the nature of the ‘second hit’ (mutation of the normal remaining Apc allele) 
that initiates these tumours. For a ‘just right’ level of Wnt signaling needed for 
tumourigenesis, one would predict that the cells that form tumours in the intestines with 
additional Apc2 mutation will probably contain a second Apc mutation whereby Apc retains  
slightly more Wnt regulatory  ability than in intestines heterozygous for Apc alone.  
 
A further explanation for a lack of difference in tumourigenesis may lie with Wnt 
independent effects. For example, additional Apc2 mutation may increase Wnt activation 
however, cytoskeletal disruptions may be detrimental for tumourigenesis. A balance 
between these effects may be why no differences in tumourigenesis are apparent. 
How APC2 influences human cancer and how it affects tumours with other oncogenic 
mutations remains to be elucidated.  
 
Apc2 loss or targeted mammary epithelial Apc loss alone, failed to induce any overt 
phenotypes in the mammary gland.  No detectable differences were noticed in β-catenin 
subcellular location or Wnt target gene expression, no lesions were present in the glands 
after aging and overall lifespan displayed no differences from wild type mice. Together this 
indicates that either Apc or Apc2 alone is dispensable for mammary epithelial homeostasis 
and tumour suppression function. 
 
Beguilingly, combined loss of both Apc proteins led to severe mammary epithelial 
disruption, tumour formation and a reduction in survival. This again occurred in an Apc2  
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gene dose dependent manor, reiterating the importance of levels of Apc2. Together, these 
results imply that mammalian Apc proteins are functionally redundant in mammary gland 
homeostasis and tumour suppressor function. Given only subtle changes were noticed in 
Wnt signaling at an early time point in mammary epithelium deficient for both Apc proteins, 
whilst tumour cells were mostly Wnt activated, it is unclear if tumours arise from Wnt 
activation in certain cell types or cells acquire further genetic aberrations assisting in 
progression. Cytoskeletal defects were noticed in epithelium deficient for both Apc proteins 
and defects in spindle mechanics and mitosis may implement genomic instability which can 
assist this transformation. Also, it is important to note whilst disrupted functional 
redundancies between Apc proteins in Wnt regulation and/or cytoskeletal organisation may 
account for tumourigenesis, one cannot rule out the possibility that each protein plays a 
separate role, which combined loss of each is needed to induce tumourigenesis.  
 
At an early time point, mammary epithelium deficient for both Apc proteins displayed a 
phenotype reminiscent of human atypical ductal hyperplasia, a common premalignant 
lesion and precursor of invasive carcinoma (Arpino et al., 2005; Page et al., 1985). Given 
mice deficient for both Apc proteins also developed invasive carcinoma, this suggests that 
these mice show some parallels to progression of human disease and may pose as a useful 
animal model of breast cancer. This model could be used for a range of potential benefits 
ranging from detection of biomarkers through to screening of therapeutics. 
 
Within the liver, although Apc2 loss altered the subcellular location of β-catenin in some 
cells and altered overall Wnt target gene expression, it was dispensable for homeostasis and 
tumour suppression. This is in contrast to effects of acute loss of liver Apc, where cell 
division was increased and subsequent hepatomegaly became manifest. The differences 
noticed between loss of Apc or Apc2 in the liver, may again be due to the different affinities 
of β-catenin destruction between Apc proteins (Nakagawa et al., 1998). Whilst Apc loss 
activates Wnt signaling at a level that surpasses a threshold required to induce a liver 
phenotype, loss of Apc2 may not. However, it is not possible to rule out other reasons for 
differences in phenotype following loss of either Apc protein, such as different effects on 
the cytoskeleton.   
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Acute liver loss of Apc was achieved through the use of induced Ah-Cre+ Apcfl/fl mice. 
Although efficient liver recombination is apparent, mice died within 4-5 days due to 
recombination in other tissues. This hindered the used of these mice for long term studies. 
However, un-induced Apcfl/fl mice display reduced levels of Apc expression (Munemitsu et 
al., 1995) and these develop perturbations in liver physiology and HCC (Buchurt et al., 2010).  
 
As Apcfl/fl Apc2-/- were viable, it allowed us to directly test the significance of Apc2 in HCC 
development in mice with attenuated Apc expression. Surprisingly Additional loss of Apc 
prevented development of HCC. Although micro-adenomas were apparent in Apcfl/fl Apc2-/- 
livers at 400 days of age, these had failed to progress to HCC as in Apcfl/fl livers at the same 
time point. Given both Apc proteins have the ability to alter Wnt signaling, one could 
postulate that whilst attenuated Apc expression may lead to appropriate levels of Wnt for 
HCC formation, addition of an Apc2 mutation may alter these levels outside of that 
permissive for tumour progression. This again would be consistent with a ‘just right’ level of 
Wnt needed for tumourigenesis.  Given Apc2 is dispensable for normal liver function and its 
loss can attenuate HCC, it may be a potential therapeutic target. How Apc2 loss affects 
other models of HCC and how this may translate to human disease warrants further 
investigation. 
 
Upon combining the data, it is clear that the effects on tumourigenesis of Apc, Apc2 or 
combined loss are tissue specific (Figure 7.1). Although the extent of the contribution of 
Wnt independent effects is difficult to delineate, these results are consistent with a ‘just 
right’ level of Wnt activation that is optimal for tumour initiation and progression, and this 
optimal level may differ between tissues.  
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Figure 7.1 Effects of Additional Apc2 loss on tumourigenesis induced by altered levels of Apc are 
tissue specific. Within the intestines additional Apc2 loss has no overall effect. In the mammary 
gland, loss of both Apc proteins are required to induce tumourigenesis. However, within the liver, 
additional loss of Apc reduces tumourigenesis caused by reduced levels of Apc. This model proposes 
the ‘just right’ hypotheses (marked in red). Different tissues require different levels of Wnt 
activation to achieve this ‘just right’ level. 
 
 
To summarise, results from this thesis reveal that both mammalian Apc proteins are 
important in homeostasis and tumourigenesis. Although Apc2 is mostly dispensable, when 
combined with Apc loss, its effect is dependent upon the tissue. Additional Apc2 loss has no 
overall effect on tumourigenesis in the context of a heterozygous intestinal Apc mutation. In 
the mammary, loss of both Apc proteins synergise to promote tumourigenesis, whilst in the 
liver additional Apc2 loss attenuates tumour progression caused by reduced levels of Apc 
expression. 
 
The data presented here suggest that Apc proteins are functionally redundant in some 
contexts. Their roles include both Wnt dependent and Independent functions, which when 
disrupted can lead to perturbed tissue homeostasis and induction of tumourigenesis. This is 
the first study to demonstrate mammalian functional redundancies between the 
evolutionarily conserved Apc proteins ‘in vivo’. The implications of this finding are of 
importance in the understanding of both of Wnt signaling transduction and cancer biology.   
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